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ABSTRACT 
 
Objective: To assess the severity and predictors of fatigue in ANCA-associated vasculitis 
(AAV), and the contribution of peripheral and central mechanisms. 
Methods: Fatigue, anxiety/depression, sleep quality and pain were measured in 152 patients 
with AAV, 68 patients with CKD, and 71 healthy controls. Muscle mass, strength and 
endurance, cardio-respiratory fitness, perception of exertion, high-sensitivity C-reactive 
protein (hsCRP), and dehydroepiandrosterone (DHEA) were measured in 48 patients with 
AAV and 41 healthy controls. 
Results: Fatigue in AAV was more severe than in CKD (p=0.013) or controls (p<0.001), and 
correlated with anxiety/depression, sleep quality and pain (all p<0.001). There was no 
difference in muscle mass (p=0.979) or strength (p=0.315) between AAV and controls, but 
muscle endurance time was shorter in AAV (p=0.006), with greater muscle reserve (p=0.038) 
indicating central activation failure. Perception of exertion (p=0.006) and cardio-respiratory 
fitness (p=0.029) were worse in AAV than controls. Only perception of exertion 
independently predicted AAV fatigue (p=0.01). Sleep disturbance predicted altered 
perception of exertion (p=0.017). hsCRP was higher (p=0.011) and DHEAS levels were 
lower (p<0.001) in AAV than controls, but neither predicted fatigue. 
Conclusion: Fatigue in AAV is more severe than in CKD or health, is due to central 
mechanisms, and may be amenable to intervention. 
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1 INTRODUCTION AND LITERATURE REVIEW 
1.1 ANCA-Associated Vasculitis 
1.1.1 The Classification of Vasculitis 
Vasculitis comprises a group of diseases which are all characterised by necrotising 
inflammation of blood vessel walls, with the endothelium as the primary target. However, the 
diseases included under this umbrella term vary widely in immunopathogenic mechanisms, 
clinical presentation and pathology. In 1994, the ‘Chapel Hill Consensus Conference on the 
Nomenclature of Systemic Vasculitis’ (CHCC) (1) noted that different names were being 
used to describe the same disease, and that the same name was being used for different 
diseases. They attempted to standardise the diagnostic terms used to classify vasculitis;  their 
conclusions still form the basis of how vasculitis is described today, and their definitions 
were revised in 2012 and published the following year (2). They divided the vasculitides 
according to the smallest blood vessels affected into large, medium and small vessel 
vasculitis, and noted the clinical utility of subdividing the small vessel vasculitides into those 
associated with the presence of anti-neutrophil cytoplasmic antibody (ANCA), and those not. 
The different types of ANCA-associated vasculitis (AAV) which they described were: 
Wegener’s granulomatosis, which is now called ‘granulomatosis with polyangiitis’ (GPA); 
microscopic polyangiitis (MPA); and Churg-Strauss syndrome, which today is called 
‘eosinophilic granulomatosis with polyangiitis’ (EGPA). In 2007 the European Medicines 
Agency developed an algorithm designed to help in the classification of the different types of 
AAV, and although they used different definitions which they felt were more specific, they 
2 
kept the same names used by CHCC (3). A further refinement of the classification which 
includes ANCA specificity (described below) has been proposed more recently (4). 
1.1.2 What are ANCA? 
ANCA are IgG autoantibodies directed against specific lysosomal constituents of neutrophils, 
first identified as recently as 1982 in a group of patients with segmental necrotising 
glomerulonephritis (5). The investigators discovered what is now known as c-ANCA, that is, 
ANCA that results in diffuse cytoplasmic staining of ethanol-fixed neutrophils on indirect 
immunofluorescence. In 1988, Falk and Jennette identified that there were two different 
patterns of staining: in addition to c-ANCA, they described ANCA showing an artefactual 
perinuclear staining pattern now referred to as p-ANCA. Using the technique of enzyme-
linked immunosorbent assay (ELISA), they discovered that p-ANCA is usually directed 
against the antigen myeloperoxidase (MPO) (6). We now also know that c-ANCA is 
normally directed against proteinase 3 (PR3). 
MPO is a 150kDa chloride peroxidase, which in health is used by the neutrophil to kill 
phagocytosed bacteria; during the ‘respiratory burst’, it catalyses the formation of 
hypochlorous acid from hydrogen peroxide and chloride ions. PR3 is a 29kDa serine protease 
with a host of functions, including modulation of inflammatory mediators (for example, the 
cleavage of IL-8) (7). MPO and PR3 are both lysosomal enzymes, and are most abundant in 
the cytoplasmic primary granules of neutrophils and monocytes. Despite being present in the 
cytoplasm, MPO is not normally found on the cell membranes of resting neutrophils, but 
rather only on the membranes of neutrophils that have been ‘primed’, as will be discussed 
later. On the other hand, PR3 membrane expression is bimodal on resting neutrophils – i.e., 
resting neutrophils may be divided into subsets with either low or high membrane expression 
3 
even in healthy subjects. PR3 membrane expression patterns are stable for an individual, and 
twin studies suggest the level of membrane expression is genetically determined (8). 
The association between ANCA and AAV is strong, with antibodies against PR3 found in 
66% of patients with GPA, and antibodies against MPO being found in 58% of patients with 
MPA in one large study, where the specificity related to disease controls was 87% for anti-
PR3 and 91% for anti-MPO (9). However, around 10% of people with AAV will have no 
detectable ANCA in their sera by either indirect immunofluorescence or ELISA. Also, 
ANCA has been found in the sera of patients with other autoimmune diseases, inflammatory 
bowel disease, and infections such as tuberculosis, although in those diseases the ANCA is 
not usually directed against MPO or PR3. The positive and negative predictive values of 
ANCA results are very dependent on the clinical presentation, and must be interpreted as 
such by clinicians (10). 
1.1.3 Is AAV an Autoimmune Disease? 
Research done during the last two decades has provided fairly compelling evidence that AAV 
is an autoimmune disease, and that ANCA is pathogenic. The strongest direct evidence is the 
case report of the baby born of a mother with active AAV, who developed a pulmonary-renal 
syndrome 48 hours after delivery (11). The baby was found to have comparable levels of 
anti-MPO ANCA to its mother, presumably due to transplacental transfer, and recovered 
following treatment with steroids and plasma exchange. The other evidence may be divided 
into circumstantial evidence, evidence from in-vitro experiments, and that from animal 
models. 
1.1.3.1 Circumstantial Evidence 
There is an association between ANCA positivity and disease activity in humans – often a 
rise in anti-PR3 or anti-MPO ANCA titre may herald a flare in the disease. However, it must 
4 
be pointed out that some sufferers will demonstrate consistently high ANCA levels without 
clinically active disease, and conversely that some flares will occur without a rise in titre, and 
meta-analyses suggest that ANCA measurements during remission are of limited value in 
guiding treatment decisions (12).  Supportive evidence also comes from the MEPEX trial 
(13), which showed that patients with severe AAV had a lower risk of being dialysis-
dependent at 12 months if they were treated with plasma exchange instead of 
methylprednisolone - plasma exchange is a treatment that would be expected to remove 
circulating IgG from the blood, although of course it could have other effects such as altering 
cytokine levels. 
1.1.3.2 In-Vitro Evidence 
The first in-vitro evidence for the pathogenicity of ANCA was the demonstration that ANCA 
could induce respiratory burst and degranulation (14). ANCA activation of neutrophils can 
cause release of a number cytokines and chemokines, including IL-1, IL-8, and TNF-α (15), 
damage to endothelial cells (16), and accelerated and dysregulated neutrophil apoptosis in-
vitro (17). 
1.1.3.3 Animal Models 
The first convincing animal work was carried out on mice by Xiao and colleagues in 2002 
(18). They immunised MPO knockout mice with mouse MPO, inducing production of anti-
MPO antibodies. They then injected splenocytes from those mice into a mouse model known 
as Rag2 (-/-) which lacks functioning T- and B-lymphocytes. This introduced anti-MPO T- 
and B-lymphocytes, and caused a dose-dependent anti-MPO IgG ANCA production in the 
Rag-2 (-/-) mice. All mice that received splenocytes developed mild to moderate glomerular 
immune deposits, and those that received the highest doses developed a severe necrotizing 
and crescentic glomerulonephritis, as well as haemorrhagic pulmonary capillaritis and some 
granuloma formation. 
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They then tested the ability of ANCA alone to produce such effects, by injecting purified 
anti-MPO IgG ANCA into Rag2 (-/-) and wild-type mice. They found that both strains 
developed focal necrotising and crescentic glomerulonephritis without immune complex 
deposition. They concluded that anti-MPO IgG ANCA could produce a pauci-immune 
necrotising crescentic glomerulonephritis, both in the setting of absent lymphocytes, and in 
an intact immune system. 
A rat model of anti-MPO ANCA has been developed by Little and colleagues (19). They 
injected human MPO into Wistar/Kyoto (WKY) rats, which then produced anti-MPO 
antibodies that cross-reacted against rat neutrophils. The rats developed experimental 
autoimmune vasculitis (EAV), comprising pauci-immune crescentic glomerulonephritis and 
lung haemorrhage. They also used a technique known as intravital microscopy to demonstrate 
in-vivo that the ANCA conferred enhanced adhesion of neutrophils to the endothelial wall, as 
well as transmigration across the endothelium. Experiments by Nolan and colleagues on a 
mouse model also demonstrated evidence of enhanced leukocyte–endothelial cell interactions 
in the presence of anti-MPO IgG (20). 
1.1.4 Why do Patients Lose Tolerance to MPO and PR3? 
Existing evidence suggests this may be due to a combination of genetic and environmental 
factors. 
1.1.1.1  Genetic Factors 
A number of genetic factors are associated with an increased incidence of AAV. As 
mentioned previously, a variable proportion of human neutrophils express high levels of PR3 
on their surface membrane in the resting state. This has been shown to have a genetic basis, 
and an association has been demonstrated between higher levels of surface expression and the 
risk of AAV (21). 
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A genome-wide association study in the UK and Northern Europe recently found major 
histocompatibility complex (MHC) and non-MHC associations with AAV, and also found 
genetic distinctions between GPA and MPA (22). 
Studies by Kamesh and colleagues showed evidence that CTLA-4, a susceptibility locus for a 
number of common autoimmune diseases, may be involved in the development of AAV (23). 
Other pointers to genetic predisposition include the increased expression of C3F and C4A3 
complement gene polymorphisms in patients with AAV (24), and the markedly increased 
frequency of α1 antitrypsin defects in patients with GPA. Such defects confer a worse 
prognosis (25), which is perhaps unsurprising given that α1 antitrypsin normally inhibits 
PR3. 
1.1.4.1 Environmental Factors 
The most common environmental factor linked with the development of AAV is exposure to 
silica, which may cause production of ANCA through its potent stimulation of T- and B-
lymphocytes. Silica exposure can also cause release of PR3 and MPO, and accelerated 
apoptosis. It is theorised that disordered apoptosis, whether due to silica exposure or 
otherwise, could result in cross-presentation of self-antigens by dendritic cells (reviewed in 
(26)). 
Infection is also commonly suggested as a reason for loss of self-tolerance in AAV. There is 
some evidence that chronic nasal carriage of Staphylococcus aureus increases relapse rates in 
GPA (27), and that long-term co-trimoxazole therapy reduces relapse rates (28). One theory 
which might explain this link with infection was put forth by Pendergraft (29), who observed 
that many of their patients had antibodies not only to PR3, but also to a protein they termed 
‘complimentary PR3’ (cPR3), a peptide translated from the anti-sense strand of the DNA 
encoding PR3. They immunised mice with cPR3, and found that antibodies were produced 
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not only to cPR3, but also to PR3. Both Staphylococcus aureus and Entamoeba histolytica 
have been found to express proteins mimicking cPR3, thereby providing a potential stimulus 
for anti-PR3 ANCA production. 
Many drugs can cause the development of ANCA, most classically propylthiouracil. The 
clinical manifestations of drug-induced AAV are similar to those of idiopathic AAV, but with 
significant differences. For example, the ANCA found usually demonstrates multi-
antigenicity, and the diagnosis is made by excluding other medical conditions and linking the 
temporal onset of disease to use of the offending drug. Treatment also differs: removal of the 
drug is most important, rather than immunosuppression (reviewed in (30)). 
1.1.5 Pathogenesis of AAV 
Current evidence suggests that there are four basic steps in the immunopathogenesis of AAV: 
1. Both the neutrophil and the endothelium must be ‘primed’ in order for the process to 
begin; 
2. The primed neutrophil adheres to the endothelium; 
3. ANCA interacts with the adhered neutrophil, leading to neutrophil activation; 
4. Neutrophil activation results in damage to the endothelium. 
This is an over-simplification of the situation as it is in-vivo, but it provides us with a 
framework for looking at the process, as illustrated in Figure 1.1. 
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Figure 1.1: The interaction of cytokines, neutrophils, ANCA and endothelium. 
(a) In the resting state of a neutrophil, most PR3 and MPO is found in the primary granules, and resting 
endothelium does not support neutrophil adhesion. (b) An inflammatory stimulus, such as infection, causes the 
release of pro-inflammatory cytokines, including TNF-α. These induce neutrophils to display PR3 and MPO on 
their surface, and also cause the expression of P- and E-selectins on the endothelium. (c) Selectin on the 
endothelium engages with the ligands on the neutrophil cell surface, allowing the neutrophil to roll on the 
endothelial surface. (d) Once the neutrophil is rolling, ANCA acts on PR3/MPO on the cell surface, activating 
the neutrophil. (e) ANCA brings about a change in neutrophil surface molecules, allowing it to adhere firmly 
and transmigrate through into surrounding tissues. (f) The activated neutrophils undergo degranulation and 
respiratory burst, resulting in endothelial injury. 
 
1.1.1.1  Neutrophil Priming 
As described previously, there is normally no MPO on the surface of neutrophils, and the 
surface expression of PR3 varies considerably between individuals (8, 31). In order therefore 
for effective interaction to occur between ANCA and antigen, the neutrophils must be 
‘primed’ in such a way that they are induced to carry PR3 or MPO on their cell surface. It is 
believed that this is brought about by the action of cytokines, particularly tumour necrosis 
factor-α (TNF-α) interleukin-1(IL-1), and interleukin-8 (IL-8) (31). In-vitro and animal 
experiments suggest that TNF-α is central to neutrophil priming, and in some animal models 
it has been shown that anti-TNF-α therapy will arrest glomerular crescent formation and 
pulmonary haemorrhage (32).  
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1.1.5.1 Activation of the Endothelium, and Neutrophil Adhesion 
There is in-vitro evidence that adherence to the endothelium is a prerequisite for neutrophil 
activation (33). However, without stimulation by cytokines, glomerular endothelium does not 
support neutrophil adhesion because it does not normally express VCAM-1, P- or E- selectin 
on its surface. Once expression of these molecules have been induced by cytokines such as 
IL-1, IL-4, TNF-α and IFN-γ (34), the neutrophil begins to roll on the surface of the 
endothelium. A second signal, such as ANCA, causes a conformational change in β2-integrin 
on the neutrophil surface. This allows the neutrophil to stop rolling and to adhere firmly to, 
and even transmigrate through, the endothelium. 
1.1.5.2 ANCA activation of the Neutrophil 
Once neutrophils have been primed by cytokines, they are ‘activated’ by binding with 
ANCA, then undergo several changes, including the increased expression and altered 
conformation of β2-integrins. This has been demonstrated in-vitro, where neutrophils flowing 
over an endothelial monolayer are induced by incubation with ANCA to stop rolling and 
adhere firmly to the monolayer, resulting in a ten-fold increase in neutrophil transmigration 
(35); intravital microscopy has also demonstrated this phenomenon in-vivo (19). ANCA also 
induces polymerisation of the actin cytoskeleton within the neutrophil, making the cell more 
rigid. This could lead to sequestration within capillary beds, explaining why AAV tends to 
mainly affect regions with major capillary beds, such as the kidneys and lungs (36). 
Activated neutrophils secrete further cytokines including TNF-α and IL-1, the chemokine 
interleukin-8, monocyte chemoattractant protein 1 and leukotrine-B4 (15, 37). These 
substances act as chemoattractants to other neutrophils, monocytes and lymphocytes, 
resulting in perpetuation of unregulated inflammation and damage (38). Additionally, 
apoptosis is dysfunctional in neutrophils that have been activated by ANCA, with a delay in 
the expression of apoptotic surface molecules required for effective phagocytosis by 
10 
macrophages. This delays their removal from the tissues, resulting in secondary necrosis, the 
release of damaging intracellular contents, and yet more spiralling inflammation (26). 
1.1.5.3 Damage to the Endothelium Results in the Classical Histopathology of AAV 
When primed neutrophils are incubated together in-vitro with ANCA and endothelial cells, 
endothelial damage can be demonstrated (16, 39). This occurs by two main mechanisms: 
once neutrophils are firmly adhered to endothelium and activated by ANCA they undergo 
‘respiratory burst’ to produce superoxide and other reactive oxygen species, and they also 
degranulate to release MPO, PR3, and the other proteolytic constituents of their primary 
granules into the microenvironment (14, 40). Once internalised by endothelial cells, PR3 can 
induce apoptosis (programmed cell death) (41); likewise, MPO may be internalised and then 
damage the endothelial cells by intracellular generation of active oxygen species (42). 
As the process spirals out of control, detachment of the endothelium from its basement 
membrane occurs; the exposed basement membrane initiates thrombosis in the capillary 
lumen, and when that occurs in the kidney it results in segmental necrosis of the glomerulus. 
If the segmental necrosis causes vessel rupture, bleeding into Bowman’s space causes 
epithelial cells and monocytes to form a characteristic crescentic scar, leading to the classical 
histopathology seen on renal biopsy of ‘pauci-immune, focal and segmental, necrotising and 
crescentic glomerulonephritis’. If on the other hand, such vessel rupture occurs in the lungs, it 
may cause pulmonary haemorrhage. 
1.1.6 The Complement Cascade in AAV 
Traditionally it has been thought that the complement system is not involved in AAV, for two 
reasons: because the histology is ‘pauci-immune’, and because serum complement levels are 
normal despite active disease. However, both of these arguments are flawed. 
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Firstly, IgG is also rarely found on biopsy in AAV, even though it is central to the whole 
disease process. Also, several pathology studies in AAV have shown a degree of immune 
complex deposition, both in skin biopsies (43) and also in early renal biopsies (44). C3, and 
to a lesser extent C1q have both been shown. Secondly, hypocomplementaemia is a very 
insensitive way of measuring complement consumption; anti-GBM disease, for example, 
features extensive complement deposition but normal serum complement levels.  
Positive evidence of complement involvement in AAV has been found in both in-vitro and 
in-vivo experiments. In-vitro experiments have suggested that the oxygen radicals, MPO and 
various proteases released by ANCA-activated neutrophils are all capable of activating the 
complement system. Mouse studies have shown that the alternative pathway of the 
complement system appears to be critical to the model of anti-MPO ANCA-induced 
crescentic glomerulonephritis. Finally, in humans it has been found that there is skewed 
expression of certain gene polymorphisms: increased C3F expression was found among 
people who were PR3-ANCA positive, and increased expression of C4A3 was found in AAV 
as a whole, although the clinical relevance is not clear (reviewed in (45)). 
1.1.7 What is the Role of Lymphocytes? 
The role of B-lymphocytes and plasma cells in AAV is obviously critical, since there is now 
convincing evidence that the ANCA which they produce is central to the disease 
immunopathogenesis. This has been illustrated in recent years by the success of rituximab in 
controlling resistant disease. Rituximab is a chimeric antibody directed against the CD20 
antigen on B cells, and it has been shown to induce remission in disease which is refractory to 
corticosteroid and cyclophosphamide therapy (46).  
Culton and colleagues (47) have demonstrated that the surface expression of CD19 in AAV is 
20% lower than on the B-cells of healthy controls. This antigen is involved in signal 
12 
transduction, and the authors propose that the lower CD19 expression results in lower levels 
of signal transduction, perhaps allowing autoreactive B-cells to avoid being selected out. 
T-lymphocytes probably have a significant role to play as well. Since ANCA are high-
affinity, class-switched antibodies, it is likely that CD4+ T-cell help is required. Further 
evidence of their involvement comes from the high numbers of T cells found in renal biopsy 
specimens; they are a major feature of the interstitial infiltrate, and their numbers correlate 
with the number of crescentic glomeruli and the serum creatinine level (48). 
There are many changes within the circulating T-cell populations in AAV. Often up to 20% 
are found to be activated, even during remission (49). Lymphopenia and markedly low 
numbers of CD4+ T-cells have been found even in untreated patients, suggesting that it is 
secondary to the disease itself rather than to therapy  (50). There is skewing towards effector 
memory cells, which could be a reason for the common relapsing remitting course, and could 
be a target for new therapies (reviewed in (51). 
1.1.8 Monocytes in AAV 
In the same way that neutrophils do, monocytes from the peripheral blood of patients with 
AAV express MPO and PR3 on their surface during periods of active disease. In-vitro, 
ANCA has been shown to activate monocytes, causing the release of interleukin-8 (52), a 
potent attractor for neutrophils, and monocyte chemoattractant protein-1 (53). It even causes 
monocytes to release reactive oxygen species (54). 
As discussed previously, macrophages are responsible for removing apoptotic neutrophils, 
but the process of neutrophil apoptosis is disturbed by ANCA activation. When these 
activated neutrophils are eventually ingested, the ingesting macrophages display enhanced 
phagocytotic activity and TNF-α release (55). 
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1.1.9 Epidemiology 
Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Eosinophilic 
granulomatosis with polyangiitis (EGPA) are all uncommon diseases; the incidence and 
prevalence of each disease in the UK is shown in Table 1.1. 
 GPA MPA EGPA 
Incidence 10.2 5.8 4.2 
Prevalence 109 28 38 
Table 1.1: Incidence and prevalence of AAV in the UK, expressed per million population. 
Data from ref (56) 
 
 
AAV can affect any age group, but peak onset is between 65 and 74 years. Unlike many other 
auto-immune diseases there is a slight male preponderance. Across the Western Hemisphere 
it is a disease which affects Caucasians much more commonly: for example, a recent study in 
France reported that the prevalence was twice as high in those individuals who were of 
European compared to non-European descent (57). Within Europe, GPA seems to be more 
common in colder Northern European countries than in the Mediterranean countries, whereas 
MPA seems to have the opposite trend; in Japan up to 90% of AAV seems to be MPO-
positive and to show clinical characteristics in keeping with MPA (56). 
1.1.10 Clinical Presentation 
The clinical presentation of AAV can be extremely variable, and a high index of suspicion 
must be maintained so as not to miss the diagnosis. Many symptoms such as fever, malaise, 
arthralgia, myalgia, anorexia and weight loss are common in all types of AAV, sometimes 
described as a preceding ‘flu-like illness’, and a purpuric skin rash is a common clinical sign.  
Each disease does have a characteristic pattern of organ involvement, as detailed below, but 
these classical presentations are not always seen. 
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1.1.1.1  Microscopic Polyangiitis 
The kidneys are the organ most commonly involved in MPA (90% of cases) with evidence of 
necrotising crescentic glomerulonephritis. Manifestations can range in severity from a rapidly 
progressive glomerulonephritis (RPGN) which may result in complete renal failure, to 
microscopic haematuria and proteinuria at the other end of the spectrum. The vessels of the 
lower respiratory tract are involved in around 50% of cases, resulting in shortness of breath, 
cough and haemoptysis. Unlike the other forms of AAV, granuloma formation does not 
occur, and upper respiratory tract involvement is rare (58). 
1.1.1.2  Granulomatosis with Polyangiitis 
In addition to necrotising vasculitis (as seen in MPA), GPA is characterised by the presence 
of necrotising granulomatous lesions of the upper and lower respiratory tract. Granulomas are 
microscopic collections of macrophages, which in the lung may form large cavitating masses. 
The classical triad of organ involvement seen in GPA is upper respiratory tract (90% of 
cases), lower respiratory tract (90%), and kidneys (80%). Ear nose and throat (ENT) 
symptoms are often prominent, and GPA may even be ENT-limited. Although MPA may 
involve the same organs, the presence of granulomas is required for some clinical 
manifestations such as saddle nose deformity, which therefore do not occur in MPA. 
1.1.10.1 Eosinophilic Granulomatosis with Polyangiitis 
EGPA is also characterised by both necrotising vasculitis and necrotising granulomas, but 
there are a number of differences between it and GPA. It is associated with eosinophils in the 
blood and in areas of inflammation, and clinical features of asthma may also be seen. 
Although the neurological system may be involved in any form of AAV, it is most often seen 
in EGPA (70% of cases). 
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1.1.11 Prognosis and Relapse 
Without immunosuppressive treatment AAV has a very poor prognosis of around 7% 
survival at two years (59), but with modern treatments survival is good at 80% at 5 years 
(60). A recent Dutch study showed that two-year survival was only 61.8% for the period 
1979-1989 and 59.2% for the period 1990-2000, but had improved to 84.8% between 2001 
and 2009 (61); the authors postulated this was due to increased awareness, earlier diagnosis, 
and improvement in treatment strategies. Factors which are known to correlate with poorer 
outcomes in AAV are older age (62), pulmonary haemorrhage, renal impairment at 
presentation, and above all, dialysis-dependant renal failure (63). patients with AAV with 
active urinary sediment but normal function have more than twice the risk of death than those 
with no renal involvement, and those with impaired renal function at diagnosis have more 
than five times the risk of death (64). For patients who have renal involvement, the renal 
biopsy is also of significance: patients who have predominantly sclerotic glomeruli on biopsy 
have the worst prognosis in terms of renal recovery (65), and by extension would be expected 
to have worst survival. 
AAV remains an incurable disease, and treatment advances have turned it from a rapidly fatal 
disease into one with a chronic relapsing-remitting course. Around 40-50% of patients will 
relapse during the first five years (58), and with each relapse there is a risk of accruing 
irreversible damage to vital organs such as the kidneys and lungs, so close monitoring is 
essential. Hogan et al (66) identified anti-PR3 seropositivity (hazard ratio 1.87 [confidence 
interval (CI) 1.11 to 3.14]), lung involvement (hazard ratio 1.71 [CI 1.04 to 2.81]), and upper 
respiratory tract involvement (hazard ratio 1.73 [CI 1.04 to 2.88]) as carrying increased risk 
of relapse; patients with all three of these risk factors had a 3.7-fold increased risk of relapse 
(CI 1.4 to 9.7). Walsh et al (67) looked at 535 patients enrolled across four RCTs, and again 
identified anti-PR3 antibodies as a risk factor for relapse (subhazard ratio (sHR) 1.62 [CI 
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1.39–1.89]), but in their cohort did not find a significant association with lung or ENT 
involvement, instead finding that cardiovascular involvement carried an increased risk of 
relapse (sHR 1.59 [CI 1.07–2.37]). Between 18% and 40% of patients with GPA will relapse 
in the first two years after diagnosis, compared with only 8% at two years for MPA (68), 
which is unsurprising given the strong association between GPA and PR3 positivity. 
1.1.12 Treatment 
Treatment of AAV is divided into three phases: aggressive initial treatment with the aim of 
halting active inflammation (‘induction of remission’), followed by less toxic treatment in the 
longer term with the aim of preventing inflammation from recurring (‘maintenance of 
remission’), and finally treatment of any subsequent relapses. 
1.1.1.1  Induction Therapy 
Modern induction therapy for AAV usually consists of corticosteroids and 
cyclophosphamide. The precise dosage schedules used vary somewhat from unit to unit, but 
are often based on regimens used in the large multi-centre randomised control trials (RCTs) 
which have provided the evidence-base for modern strategies. 
Corticosteroids achieve immunosuppression through many mechanisms, including 
lymphopenia and monocytopenia, as well as suppression of cytokine production (including 
IL-1, IL-2 and TNF-α). Although they cause a neutrophilia, they impair neutrophil 
chemotaxis and adhesion. The main corticosteroid used is prednisolone, at an initial dose of 
1mg/kg which is tapered over time.  Corticosteroid therapy is also commonly delivered as 
intravenous pulses of methylprednisolone, at doses varying from 500mg to 1g for three 
consecutive days at the start of therapy. There is little direct evidence for the use of 
methylprednisolone, as the only trial it was tested in (MEPEX) showed it to be less 
efficacious than plasma exchange in induction of remission (69); however it does have a 
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more rapid immunosuppressive effect than oral prednisolone, and is therefore a common part 
of induction therapy. Corticosteroids have many side-effects, both short- and long-term, 
including infection risk, hypertension, diabetes, hyperlipidaemia, peptic ulcer disease, 
osteoporosis, weight gain and psychiatric disturbances. 
Cyclophosphamide is a nitrogen mustard alkylating agent which interferes with DNA 
replication within cells by forming intrastrand and interstrand DNA crosslinks. Its effects are 
dose dependent, and it must be given at high doses in order to cause the immunosuppressive 
effects employed in the treatment of autoimmune diseases. Cyclophosphamide provides a 
significant benefit when added to corticosteroid therapy, improving remission rate from 56% 
to 85% and reducing the risk of relapse three-fold (70).  There is still some debate about the 
best regimen for cyclophosphamide delivery; the CYCLOPS trial (71, 72) compared daily 
oral with pulse IV regimens, and found that the pulse IV regimen allowed administration of 
half the cumulative cyclophosphamide dose of the daily oral regimen, but long term follow-
up showed that the cost of this was almost twice as many relapses. However despite the 
higher relapse rate, survival and renal function were no different between the two groups at 
the end of the study, and this coupled with the significantly lower cyclophosphamide 
exposure is a convincing argument in favour of a pulse IV regimen. Cyclophosphamide is 
toxic, associated with potentially life-threatening side-effects, including leukopenia 
(associated with infection and death (73)), increased cancer risk (particularly transitional cell 
carcinoma of the bladder and acute myeloid leukaemia), haemorrhagic cystitis, and 
temporary or permanent sterility. There is an increasing body of evidence that the cumulative 
cyclophosphamide dose is important in determining toxicity risk (74).  
Plasma exchange is a treatment in which a proportion of the patient’s plasma is removed by 
either plasma filtration or centrifugation, and the same volume is then replaced with another 
fluid, usually 5% human albumin solution. It is sometimes used in AAV to remove ANCA 
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from the circulation, but compared to other therapies there is relatively little evidence to 
support its role in this disease. The main evidence base for its use in AAV comes from the 
MEPEX trial, in which patients underwent seven plasma exchanges within fourteen days, on 
each occasion exchanging a volume of 60ml per kg of body weight(69). The trial showed that 
when patients with AAV presented with severe acute kidney injury (creatinine >500µmol/l), 
the addition of plasma exchange to cyclophosphamide and prednisolone resulted in a higher 
rate of renal recovery than did the addition of IV methylprednisolone. Side-effects of plasma 
exchange include transfusion reactions, complications related to the central venous catheters 
which are required to deliver the treatment, sepsis, bleeding, and electrolyte abnormalities. 
Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen on B cells. 
Because of the convincing evidence that ANCA are pathogenic, there has been great interest 
in intravenous rituximab both as an induction agent and as a maintenance agent. Two RCTs 
recently reported on the use of rituximab for induction. The RITUXIVAS trial (75) compared 
a regimen of rituximab combined with only two doses of IV pulse cyclophosphamide to a 
conventional ten dose regimen of IV pulse cyclophosphamide and found that rates of 
remission and adverse events were similar in both groups. RAVE (76) compared rituximab to 
oral cyclophosphamide, and again found no significant difference in rates of remission, 
adverse events, or rates of relapse. However due to the relatively unknown long-term efficacy 
and safety of rituximab, as well as its comparative cost, cyclophosphamide remains first line 
therapy. The Kidney Disease: Improving Global Outcomes (KDIGO) international guidelines 
currently recommend that rituximab should be used in conjunction with steroids as an 
alternative induction treatment for those patients “without severe disease or in whom 
cyclophosphamide is contraindicated” (77). They also recommend the use of rituximab in 
ANCA-positive glomerulonephritis resistant to induction therapy with cyclophosphamide and 
corticosteroids. 
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1.1.12.1 Maintenance Therapy 
It is conventional to move to a maintenance regime following disease remission. Such 
regimens typically include a much lower dose of prednisolone (e.g. 5mg/day) and either 
azathioprine or mycophenolate. 
Azathioprine is a purine analogue which works by blocking purine synthesis, thereby 
inhibiting DNA synthesis and the proliferation of cells in the body, particularly affecting 
lymphocytes (other cells are less affected due to salvage pathways which lymphocytes lack). 
Azathioprine has the best evidence of the available remission agents, with RCT evidence that 
introducing azathioprine after only three to six months of cyclophosphamide therapy resulted 
in similar relapse rates after eighteen months as when cyclophosphamide was continued for 
twelve months (78). 
Mycophenolate also inhibits purine synthesis, and it has therefore been suggested as an 
alternative maintenance agent. However there is RCT evidence that relapse rates with 
mycophenolate are significantly higher than with azathioprine. It is therefore only 
recommended as maintenance therapy in those patients who are allergic to or intolerant of 
azathioprine (77). 
Methotrexate is sometimes used for remission in patients without renal involvement. An RCT 
appeared to show no difference in efficacy between methotrexate and azathioprine (79). It 
must be used with caution in renal impairment, but is recommended by some authors for 
ENT-limited disease (80) 
Trimethoprim-sulfamethoxazole is a combination sulfonamide antibiotic used in the 
treatment of a variety of bacterial infections. Interest in the use of this antibiotic in the 
treatment of AAV arose from the association between chronic nasal carriage of 
Staphylococcus aureus and increased relapse rates in GPA (27). Long-term use of this drug 
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can reduce the rate of upper respiratory tract relapses in GPA, although it has not been shown 
to reduce relapse rates in other organ systems (28). 
As yet, no large scale RCTs have looked at the use of rituximab as a long-term maintenance 
agent, but there is significant interest in using the drug in this way, particularly for patients 
with refractory disease in whom the immunosuppressive burden is highest. An English study 
of 73 patients showed that routine re-treatment with rituximab at fixed intervals reduced the 
rates of relapse in such patients from 75% to 22% at 24 months, as wells as reducing the 
percentage of patients requiring other immunosuppressive drugs such as azathioprine and 
allowing corticosteroid withdrawal in 40% (81). Similarly encouraging results were reported 
by American retrospective studies (82, 83). The ongoing RITAZAREM trial is examining 
whether maintenance rituximab is more effective than azathioprine for the prevention of 
relapse after rituximab induction for relapsing AAV, as well as relapse rates following 
withdrawal of these therapies (84). 
1.1.12.2 Treatment of Relapses 
Relapse is defined as the occurrence of increased disease activity after a period of partial or 
complete remission. Treatment depends on the severity of the relapse: a severe relapse that 
threatens life or an organ should be treated according to the same guidelines as for induction 
therapy, whereas a milder relapse may be treated by restarting or increasing 
immunosuppressive therapy with agents other than cyclophosphamide (77). 
1.2 What is Fatigue? 
Fatigue is a common symptom in the healthy general population (85-88), as well as in a host 
of physical (89-96) and psychological (97-99) illnesses, but despite this there remains no 
universally accepted definition of exactly what fatigue is. A common medical definition of 
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fatigue is “that state, following a period of mental or bodily activity, characterised by a 
lessened capacity for work and reduced efficiency of accomplishment, usually accompanied 
by a feeling of weariness, sleepiness or irritability” (100), but although this is a reasonable 
definition of fatigue in normal healthy life, it does not match the experiences of patients in a 
number of ways that will be explored in this chapter. Efforts by researchers to arrive at a 
more satisfactory definition of fatigue have been hampered by three main issues: 1) fatigue is 
a very subjective experience, and descriptions sometimes vary greatly between individuals; 2) 
it has proven very difficult to separate fatigue reliably from other every-day symptoms such 
as drowsiness, tiredness or weariness; 3) the impact of fatigue has only truly been recognised 
in the last two decades, and compared to many other symptoms fatigue research is still in its 
relative infancy. 
In 2008, Mills and Young (101) developed what they hoped would be a unifying definition of 
fatigue. They interviewed a UK cohort of multiple sclerosis (MS) patients, then administered 
a questionnaire survey based on the qualitative data gained. They arrived at a definition of 
fatigue as a “reversible, motor and cognitive impairment with reduced motivation and desire 
to rest, either appearing spontaneously or brought on by mental or physical activity, humidity, 
acute infection and food ingestion. It is relieved by daytime sleep or rest without sleep. It can 
occur at any time but is usually worse in the afternoon.” Although much more 
comprehensive, this definition is still contradicted in parts by qualitative studies in other 
diseases. 
Hewlett et al conducted qualitative research looking at the nature and impact of fatigue in 
rheumatoid arthritis (RA) (102); their findings were similar to other studies in RA (103, 104) 
and fibromyalgia syndrome (FMS) (105) and might be applicable to many of the long-term 
conditions associated with fatigue. Their patients reported that the fatigue associated with 
their RA was fundamentally different from the fatigue they had experienced in health in a 
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number of ways: it was much more severe and overwhelming; there was often no obvious 
physical or mental trigger, making it feel ‘unearned’, unfair and unpredictable to patients; it 
was only partly or not at all relieved by rest.  Two main descriptions of the nature of fatigue 
in RA emerged: firstly that it was akin to carrying a weight around with you, so that everyday 
tasks became very much harder than they had previously been, and secondly that some 
people experienced it as sudden waves of extreme exhaustion that left them unable to carry 
on, termed ‘wipe-out’ by Hewlett. The reported duration of fatigue episodes in those patients 
varied from minutes to days, and for some it was constant. It had significant mental and 
emotional components, with a reported loss of ‘mental energy’, motivation and concentration, 
and a tendency to make some people feel very tearful. The study found that fatigue had an 
impact on every sphere of life, with effects on work, leisure and activities of daily living 
(ADLs), as well as a profound effect on inter-personal relationships. Patients felt uncertain 
about how best to manage their fatigue, employing a whole range of coping techniques with 
varying levels of success, and invariably felt that their fatigue was either ignored or dismissed 
by health-care professionals. 
Another qualitative study in 2003 instead looked at how healthy working adults describe 
fatigue (88). They interviewed 40 healthy adults between the ages of 30 and 60 about their 
experiences of fatigue, and defined fatigue in healthy adults as “an acute, subjective, 
sometimes overwhelming, but temporary state (with physical, emotional mental and 
behavioural manifestations) caused by stress and overwork in one’s life roles, which disrupts 
activity and alerts the person to take restorative measures such as rest, sleep, or reordering of 
activities and goals”. Whilst some parts of this definition are not dissimilar to the definitions 
of Mills (101) and Hewlett (106), the acute and temporary nature, the direct relation to 
physical or mental stressors, and the restorative power of rest and sleep all confirm the 
assertion of Hewlett’s patients that fatigue in health and fatigue in illness are quite different 
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entities. Previous reports have suggested that the prevalence of chronic fatigue lasting more 
than six months is as high as 1-3% among healthy adults in the community (107), seemingly 
contradicting the notion that fatigue in healthy people is transient, but other studies suggest 
that these contradictory findings might be explained by undiagnosed illnesses such as 
Chronic Fatigue Syndrome (CFS - see Section 1.7) or depression. One such study found 
evidence of undiagnosed hypothyroidism, psychiatric illness, and CFS (108). In another, 
18.3% of primary care patients described significant fatigue for six months or longer, but a 
strong correlation was found between chronic fatigue and psychological symptoms (86). 
1.3 How is Fatigue Measured? 
Quantifying fatigue is difficult because the symptom is subjective and heterogeneous. Some 
physical and physiological aspects of fatigue may be measured: for example if we measure 
how long a person is able to continue a physical task such as lifting a known weight this 
could be seen as an objective measure of their fatigability, but this would only capture one 
aspect of fatigue and in isolation would be of very limited use. Common sense suggests that 
subjective fatigue, regardless of cause, would lead inevitably to a reduction in objectively 
measurable activity, so that pedometers and other similar devices could be used to obtain an 
objective surrogate measure of fatigue, but although a good correlation was found between 
such measurements and subjective fatigue for patients with CFS, this was not the case for 
patients with MS (109). 
In view of these difficulties, the only way to reproducibly and reliably measure the subjective 
experience of fatigue is through the use of self-rating questionnaires. As the importance of 
fatigue has been increasingly recognised in the last few decades, so the number of fatigue 
tools has proliferated – there are now more than thirty different scales designed specifically to 
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measure fatigue, and many more such as the Medical Outcomes Study Short Form-36 (SF-
36) which include fatigue as one dimension of a broader health outcome (110). One study of 
fatigue instruments identified 252 different ways in which fatigue had been measured, of 
which 150 had only ever been used once (111)! Although in theory all of these scales assess 
the same symptom, in reality the questions asked and therefore the information derived can 
vary considerably based on the scale author’s own concept of fatigue. When researchers are 
deciding which scale to use, they must consider which tool is best suited to answer the 
questions they want answered in the target population they wish to study and within the 
practical constraints of their study. 
The first question to consider is whether to use a unidimensional scale or a multidimensional 
scale. Unidimensional scales are designed to sum up all the aspects of fatigue into a single 
summary score; they are usually short and easy to administer, and equally easy to score and 
interpret with minimal training. At its most basic a unidimensional scale might only consist 
of a single visual analogue scale, but the best known and most widely cited unidimensional 
fatigue scale is the Fatigue Severity Scale (FSS). This is a tool which was first developed for 
patients with chronic medical illnesses including MS and systemic lupus erythematosus 
(SLE), and consists of nine items each scored on a 7-point Likert scale (where 1 = ‘strongly 
disagree’ and 7 = ‘strongly agree’), with statements including “I am easily fatigued” and 
“Fatigue is among my most disabling symptoms”. It has been used across a wide range of 
illnesses including MS, Parkinson’s disease (PD), CFS, cancer and sleep disorders, and has 
been shown to have good internal consistency (Cronbach’s α=0.88 - i.e., there is good 
correlation between different items on the scale), good test-retest reliability (0.84), and high 
sensitivity to changes in symptoms with time (112). 
Multidimensional scales are generally longer and more time-consuming to complete, as well 
as being more complex to score and interpret. However, the advantage of multidimensional 
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scales is that they provide more detailed quantitative and qualitative data, thereby allowing a 
more meaningful assessment of the nature of fatigue in the disease being studied, and also 
potentially allowing researchers to gain insights into the mechanisms underlying the different 
aspects or ‘dimensions’ of fatigue. A good example of a multidimensional fatigue scale is the 
Multidimensional Fatigue Inventory (MFI-20). This tool consists of 5 subscales, each 
purporting to represent a different dimension of fatigue, the last two of which are sometimes 
considered to be outcomes of fatigue: General Fatigue, Physical Fatigue, Mental Fatigue, 
Reduced Activity, and Reduced Motivation. All five subscales have been shown to have good 
internal consistency across a variety of illness and in health, as well as good test-retest 
reliability results (113). It was developed in cancer patients, but has since been used across a 
multitude of illnesses including AAV (114, 115), cancer (116-122), CFS (123-127), CKD 
(128-131), Primary Sjögren’s syndrome (132, 133), Ankylosing Spondylitis (AS) (134, 135), 
RA (132, 135, 136), inflammatory bowel disease (137-139), MS (139-142) as well as in 
health (143, 144). There were initial concerns regarding the ability of the scale to distinguish 
between healthy people and those with illnesses (113), but the scale was further developed 
following the initial study, and other studies seem to have allayed those initial fears (145, 
146). 
Once a decision has been made to use either a unidimensional or multidimensional scale, the 
next step is to decide which scale most closely matches the aspects of fatigue the study is 
interested in measuring. The names of the scales can often be misleading: for example the 
Fatigue Severity Scale is not actually a measure of the severity of fatigue per se, but rather a 
measure of the impact of fatigue, with eight of the nine statements describing the effect of 
fatigue on motivation, social life etc. Finally, it is important to check whether the scale of 
interest has been used before and preferably validated in the disease group to be studied, 
although this might not be the case for any scales if studying a rare disease. 
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1.4 Classifying the Determinants of Fatigue 
When considering fatigue, as for any symptom, it is helpful to create models which categorise 
or group the possible causes, helping researchers to more easily understand the symptom and 
create hypotheses which may then be tested. Leading on from the qualitative research 
discussed earlier, Hewlett’s group developed one such conceptual model of fatigue in RA 
(106), separating the causes of fatigue into three interacting groups:  
 Disease factors, which Hewlett proposed for RA might include deconditioning, 
muscle atrophy, joint damage, anaemia, medications, pain, poor sleep, and abnormal 
cortisol responses due to ongoing inflammation (147); 
 Cognitive and behavioural factors. This aspect of the model is based on a recognised 
pre-existing model (148). Such factors might include illness beliefs such as low self-
efficacy, feelings such as anxiety and depression, and behaviours such as over- and 
under-activity. 
 Personal life issues, including role responsibilities, standard of housing, a lack of 
social support, and comorbid illnesses. 
Hewlett proposed that any of these factors might predispose to fatigue, precipitate fatigue 
episodes, or help perpetuate fatigue which had been caused by other factors, and that the 
relative importance of different factors varied from one individual to another. This model 
could easily be applied to AAV or to any other disease or fatigued state; the ‘disease factors’ 
might differ depending on the illness being looked at, for example in cancer they might 
include the administration of chemotherapy (149), but the same over-riding themes apply. 
Another useful way to consider the determinants of fatigue is by classifying the possible 
causes into ‘peripheral fatigue’ and ‘central fatigue’, although it is important to note that 
peripheral and central fatigue may coexist within the same individual. ‘Peripheral fatigue’ 
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describes fatigue which is either due to: a) cardio-respiratory problems such as 
deconditioning, which results in normal tasks being carried out at a higher percentage of the 
maximum possible heart rate (150); or b) neuromuscular problems outside of the central 
nervous system such as muscle atrophy, impaired muscular contractility, or impaired 
neurotransmission in peripheral nerves. A loss of muscle mass due to protein breakdown is 
common in many acute and chronic illnesses (151, 152), particularly when inflammation is a 
major component, and because this would result in a reduction in strength and endurance 
capacity it is likely to be a relatively common cause of peripheral fatigue in long-term 
illnesses (153). Central fatigue describes abnormalities in perception, motivation or central 
motor activation, which are probably caused by alterations in neurotransmitter pathways 
within the brain. It has been proposed previously that central fatigue is more important than 
peripheral fatigue in patients with chronic illnesses, “although the absolute contribution of 
peripheral and central fatigue… may vary significantly between different diseases” (154). 
1.4.1 Peripheral Fatigue in Health and Disease 
In young healthy people, peripheral fatigue is most significant during high intensity exercise 
such as running up a flight of stairs. This is because energy utilization in the form of ATP 
breakdown is happening at a faster rate than the rate at which new ATP can be generated by 
oxidative metabolism or glycolysis (155). Even in the fittest athlete the blood supply and the 
ability of the muscle to take up and utilise the oxygen in the blood are too slow to meet the 
demands of a high-intensity activity. 
In disease states, metabolic abnormalities within skeletal muscle could result in peripheral 
fatigue through acceleration of the same processes described in health, but such abnormalities 
are very rare and are therefore not a common cause of peripheral fatigue (156).  Peripheral 
fatigue is often assumed to be significant only in those diseases (primarily rheumatological, 
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such as RA) which are characterised by either muscle atrophy, where increased demand is 
placed on the remaining muscle, or by joint deformities, where there is alteration of the angle 
of torsion of the muscles acting on the joint. However the contribution of peripheral fatigue in 
other diseases might actually be more important than commonly thought, because most of the 
diseases associated with fatigue become more common with increasing age, and as a result a 
significant number of patients might also be affected by sarcopenia. Sarcopenia is the loss of 
muscle mass, strength and endurance associated with ageing that occurs through mechanisms 
including reduced protein synthesis, mitochondrial dysfunction, malnutrition and altered 
levels of anabolic hormones including dehydroepiandrosterone (DHEA – see Section 1.6.2) 
(157). It is estimated that around 5% of muscle mass is lost per decade from the fourth decade 
onwards (158, 159), and although loss of muscle mass occurs in all individuals to an extent, it 
is accelerated by inactivity, poor nutrition and chronic illness (157). The prevalence of 
sarcopenia (as defined by muscle mass of more than two standard deviations below the sex-
specific young-normal mean) has been reported as up to 15% amongst over 65 year-olds in 
the community (160), and numerous studies have shown that these changes are associated 
with reduction in functional measurements such as gait speed and stair-climbing speed 
(reviewed in (157)). 
1.4.1.1 Skeletal Muscle Contraction and Fatigue 
The three major muscle types are cardiac, smooth, and skeletal muscle; this section will 
discuss the basic structure and function of skeletal muscle, with regard to its role in peripheral 
fatigue in health and disease. 
Skeletal muscle is found in muscles which are attached to the skeleton, are under voluntary 
control, and are used to provide movement to the body; a typical example is the biceps 
muscle, which is used to flex the arm around the elbow joint. Skeletal muscle cells, 
commonly referred to as muscle fibres, may range from 10 to 80 micrometres in diameter and 
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often extend for the entire length of whichever muscle they form part of. Each individual 
fibre is generally innervated by only a single efferent nerve known as a motor neuron, which 
runs from its origin in the spinal cord to an interface at the surface of the muscle fibre known 
as the neuromuscular junction. Each motor neuron innervates anywhere between a few and 
almost two thousand skeletal muscle fibres (161), all of which will therefore be stimulated 
together. Collectively a motor neuron and all of the muscle fibres that it innervates are known 
as a ‘motor unit’; groups of motor units often work together to control the overall function of 
a single muscle, and the greater the number of activated motor units the greater the force of 
the overall muscle contraction (162). 
Contraction of a muscle fibre is initiated when an action potential travels along the length of 
the motor neuron to the neuromuscular junction, causing the release of the neurotransmitter 
‘acetylcholine’. Acetylcholine diffuses across the neuromuscular junction and binds to 
receptors on the muscle fibre cell membrane, causing ion channels in the cell membrane to 
open; this allows an influx of sodium ions, depolarising the muscle fibre membrane and 
starting a cascade of events which culminate in the contraction of that fibre (162). 
There are a variety of skeletal muscle fibre types, and they may be classified in a number of 
different ways based on either histochemical staining or function. Although in reality muscle 
fibres may not fall as neatly into discrete subtypes as was previously believed (161), when 
discussing fatigue it is still very useful to classify fibres by function, into ‘fast-twitch’ and 
‘slow-twitch’ fibres: 
 Fast-twitch fibres are about twice as large in diameter compared with slow-twitch 
fibres. They contain a high density of glycogen, and display high activity levels for 
the enzymes involved in rapid energy release through anaerobic pathways (the 
‘phosphagen’ and ‘glycogen-lactic acid’ metabolic systems). These features allow 
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fast-twitch fibres to provide short bursts of explosive force, but only for eight to ten 
seconds at maximal power and up to two minutes at sub-maximal power. 
 Slow-twitch fibres, in contrast, have features which make them more suitable for 
prolonged endurance at lower intensity. They have a higher concentration of 
mitochondria and myoglobin, as well as a higher capillary density, and the enzymes 
involved in the aerobic generation of energy from glucose, amino acids and fatty acids 
are much more active than in fast-twitch fibres. Though not capable of the same 
explosive power as fast-twitch fibres, the effective use of aerobic metabolism allows 
these fibres to sustain low-intensity exercise for a few hours or more in trained 
athletes. 
Individual muscles are usually a mix of both of these types of fibre, although the proportions 
are known to vary from muscle-to-muscle and from person-to-person. All of the fibres in any 
individual motor unit will usually be of the same type (162), and so whole motor units are 
often described as being fast- or slow-twitch. 
Although there are known to be exceptions to the rule, according to ‘Henneman’s size 
principle’, we understand that when the body carries out a movement there is normally an 
orderly recruitment of motor units from smallest to largest potential force; in other words, the 
least powerful units will be recruited first, usually comprising slow-twitch muscle fibres, and 
the more powerful units of fast-twitch fibres will only be recruited when greater force is 
required (163). When healthy subjects become fatigued quickly during high-intensity 
exercise such as running a 100m race, this is largely due to the aforementioned limitations of 
anaerobic energy production within the more powerful fast-twitch motor units. However, as 
will be discussed later, people with chronic disease often complain of fatigue after very low-
level exertion, or even in the absence of overt physical exertion. This might suggest that there 
is something different about their muscles, for example that there has been a shift in the ratio 
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of slow-twitch to fast-twitch fibres, or a reduction in the density of mitochondria within the 
slow-twitch fibres. Alternatively, perhaps they are experiencing central rather than peripheral 
fatigue. 
1.4.2 Central Fatigue in Health – Interoception and the Central Governor Theory 
During less intensive exercise (e.g. when running at around 5 m/sec), the generation of ATP 
can keep up with the energy demands of the muscles, and in theory a subject could continue 
exercising until their body’s supply of carbohydrate was exhausted. This would normally take 
between one and three hours, depending on whether the subject had eaten a large 
carbohydrate meal recently and increased his or her muscle glycogen stores. If the speed were 
further reduced to running at about 2-3 m/sec, the metabolism of fat could also provide 
sufficient energy and, again in theory, exercise could continue for tens of hours since there 
are large quantities of fat in the body (164-166). However although elite athletes can do this, 
the average person finds it difficult to exercise for more than about 30-40 minutes at 60-70% 
maximum HR. Why should this be? There is little evidence of peripheral muscle failure or 
that cardiac output has reached a limit in such instances, so the conclusion is that there has 
been some failure of motivation, desire, or ‘drive’ of the subjects to continue to exercise; this 
loss of central drive to use muscles to their full potential is sometimes referred to as ‘central 
activation failure’ (CAF) (167, 168), and is one manifestation of what was referred to earlier 
as ‘central fatigue’. 
The mechanisms within the brain that lead to exercise-induced central fatigue have been the 
subject of research for the last 30 years without a definitive answer. One thing we know is 
that central fatigue during prolonged exercise is sensitive to high body temperature (169) and 
that exercise can be prolonged by ’precooling’ (170). It has been suggested that when body 
temperature during exercise begins to rise to dangerously high levels (~40oC) there is a 
32 
protective reflex that comes into play which reduces the level of exercise and hence prevents 
a further rise in body temperature. This type of evidence has given rise to the ‘central 
governor’ theory of fatigue ((171), critiqued in (172)) which says that exercise intensity and 
duration is regulated subconsciously to maintain homeostasis. According to this theory the 
brain has a subconscious image of ‘self’ which defines the safe limits of activity, and it 
monitors multiple physiological processes and regulates exercise intensity to keep the body 
working within safe limits – for example by preventing a dangerously high temperature.  In 
these circumstances the subject’s feelings of fatigue are their conscious perception of the 
subconscious workings of the brain pathways involved in these protective reflexes.  Body 
temperature may be one factor that the brain monitors but there are many other consequences 
of physical activity: increased heart rate, ventilation, high forces in muscles, tendons and in 
joints as well as the stimulation of chemo- and mechanical receptors in muscle. There will 
also be changes in blood metabolite and hormone levels and circulating cytokines. 
This subconscious monitoring of the internal physiological state of the body is known as 
‘interoception’ (173), and the sensitivity of these pathways may vary between people and 
with the state of training; in one individual a very sensitive pathway may shut down exercise 
very rapidly with a large safety margin, whereas other people may operate closer to the 
limits. Thus an untrained person may be very sensitive to dyspnoea, body temperature or 
pains in his or her muscles when running, but with training their interoception becomes less 
sensitive and there is increased tolerance of these sensations (174).  
1.4.3 Central Fatigue in Ill Health 
What is it that prevents patients with chronic illnesses from exercising to a similar extent as 
healthy people? Patients with orthopaedic, cardiac or respiratory disease have obvious 
‘peripheral’ reasons to stop exercising prematurely, but in the absence of such problems most 
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patients should have enough muscle glycogen to support low intensity exercise for at least an 
hour or so. Quite possibly if the reward was high enough, or the danger threatening enough, 
they could do it, but it would be a constant mental battle to keep going despite an 
overwhelming urge to stop, and afterwards they would feel completely exhausted for hours or 
even days. If we consider this in terms of interoception and the Central Governor theory, then 
chronic illness seems to cause interoception to become much more sensitive, so that afferent 
signals from working muscles or joints that in health would be unexceptional now become 
unpleasant and inhibiting, and the brain’s subconscious image of self becomes altered to a 
much lower level. In this way, the central fatigue associated with chronic illness is 
remarkably similar to what is known in the setting of acute illness as ‘sickness behaviour’ 
(175). 
1.5 Sickness Behaviour 
Everyone who has had a significant viral or bacterial infection has experienced sickness 
behaviour at first hand: when sick, we all exhibit traits of fatigue, anorexia, disinterest in 
surroundings and activities, and depressed and irritable mood. Although I have introduced it 
in the context of physical exercise, it also encompass other aspects including mental activity, 
social interaction, depression and anxiety, in much the same way as the chronic fatigue 
associated with long term illness was described by the qualitative studies outlined earlier in 
this chapter (Section1.2). 
Sickness behaviour is clearly an evolutionarily advantageous behaviour pattern: by reducing 
activity and interaction it protects a wounded animal from danger at times of physical 
vulnerability, and once an acute illness has resolved the person or animal would then be 
expected to resume normal behaviour. But what are the biological mechanisms underlying 
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sickness behaviour, and why in chronic illnesses such as AAV or RA do these patterns of 
behaviour seem to persist even after a severe acute flare has settled? There is circumstantial, 
experimental and clinical evidence to suggest that sickness behaviour in acute illness and 
chronic fatigue in the setting of long-term illness are both caused by actions of the immune 
system on the brain – and in particular the actions of pro-inflammatory cytokines. 
1.5.1 Circumstantial Evidence 
During the early stages of an acute illness such as a bacterial or viral infection, the body’s 
immune response is coordinated through a massive release of pro-inflammatory cytokines, 
and this is also the time when fatigue and the other symptoms of sickness behaviour are at 
their worst. When infections and other brief illnesses resolve, cytokine synthesis settles down 
to very low baseline levels, and with this settling of the inflammatory response there is a 
corresponding return to normal behaviour patterns. In contrast, it is known that in many long-
term illnesses such as RA (176, 177), SLE (176, 178), MS (179), chronic liver disease (180) 
and AAV (our own data, unpublished) cytokine levels never return to the very low levels 
seen in health, and all of these diseases are characterised by fatigue which is chronic rather 
than acute in nature. Some studies have shown direct correlation between the concentration of 
pro-inflammatory cytokines and disease activity (176, 178), but as will be discussed later, the 
evidence of a direct correlation between cytokine concentrations and the severity of fatigue 
itself is tenuous. 
1.5.2 Experimental / Clinical Evidence 
Injection of IL-1β or TNF-α into rats and mice has been shown to directly induce not only 
fever but also sickness behaviour, and further experiments suggested that the resultant 
sickness behaviour was mediated primarily by central actions of IL-1β on receptors within 
the CNS (181-184). Similarly, injection of IL-6 in humans induced anorexia and fatigue 
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(185) (both hallmarks of sickness behaviour), and when Interferon has been used 
therapeutically one of the major side-effects was fatigue (186). Injection of IL-6 was further 
shown in mice to induce increased concentrations of serotonin within the brain (187), and 
with this in mind it is interesting that a study of patients with CFS found evidence suggestive 
of the up-regulation of hypothalamic serotonin receptors (188). There is even some evidence 
that fluoxetine (a selective serotonin reuptake inhibitor, SSRI) can treat fatigue in patients 
with fibromyalgia (189); however this finding was not replicated in CFS (190) and the 
beneficial effect could possibly be explained by improved depression rather than any direct 
effect on central fatigue pathways. 
1.5.3 How Could Systemic Inflammation Influence the Brain? 
Despite all the evidence discussed, until the last decade it was difficult to conceive of any 
mechanisms by which peripheral inflammation could exert influence on the brain to cause 
sickness behaviour. The brain was considered to be an ‘immune-privileged’ organ because, in 
the absence of an intrinsic CNS injury or illness, inflammatory cells and cytokines are unable 
to cross the blood-brain barrier (BBB) (191).  However we now know that not only does the 
immune-protection offered by the BBB vary with age and brain region (192), but also that the 
meninges and parts of the brain parenchyma actually contain their own immune cells such as 
macrophages (known in the brain parenchyma as microglial cells) and dendritic cells (193). 
Researchers have now identified four ways in which peripheral inflammation can be 
monitored by the brain, which probably act in parallel to result in the changes we see in 
sickness behaviour: 
 Synthesis and release of cytokines within the CNS. Observational work on patients 
with RA demonstrated that concentrations of IL-1β within the cerebrospinal fluid 
(CSF) of patients were markedly elevated compared with serum concentrations in 
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those same patients, and also compared to the CSF cytokine concentrations of healthy 
controls, and  that there was a good correlation between CSF IL-1β concentration and 
subjective fatigue (r=0.55, p<0.05). Follow-on work in mice with ‘serum-transferred 
arthritis’ showed that IL-1β mRNA and TNF mRNA levels within the spinal cord 
were increased at the peak of peripheral arthritic disease activity (194). This work 
along with other studies demonstrates that cytokines can be synthesised within the 
CNS itself (195-197). 
It has subsequently been shown that at the BBB there are IL-1 receptors on 
perivascular macrophages and the endothelial cells of brain venules (198-200); when 
stimulated by IL-1 these cells synthesise and release prostaglandin E2 into the CSF 
(reviewed in (201)), and this prostaglandin then acts as a stimulant for cytokine 
production by microglial cells within the brain parenchyma (194). 
 Direct transport of cytokines across the BBB. Transport mechanisms have been 
identified for IL-1β, IL-6, and TNF-α (202). It has been suggested that these receptors 
have too low a capacity to be a significant mechanism in the acute phase of illness 
(201), but they can transport quantities of cytokines that are comparable to the 
passage of therapeutic doses of morphine across the BBB (202), and could be an 
important mechanism in long-term illnesses where there is low-level grumbling 
inflammation. 
 Passage of cytokines via the circumventricular organs. Circumventricular organs are 
structures in the brain that are characterized by their extensive vasculature and lack of 
a normal blood brain barrier (BBB) (203). The lack of a BBB allows cytokines to 
enter the brain by volume diffusion (204) at these points. 
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 Signalling to the brain through the activation of peripheral nerves. Sensory neurones 
of the vagus nerve express receptors for IL-1β and are thus activated by IV injection 
of IL-1β (205). Following on from this, it has been found that sickness behaviour 
secondary to intraperitoneal or visceral inflammation can be blocked or reduced by 
resection of the vagus nerve without compromising the peripheral immune response 
(206-208). Cytokines are similarly capable of activating the trigeminal nerve during 
oro-lingual infections (209). It is believed that these afferent nerve signals may 
sensitise target brain structures for the production and action of cytokines (210).  
The pathways which subsequently translate these cytokine and afferent nerve signals within 
the brain into the observed aspects of sickness behaviour remain elusive (193), and are the 
focus of ongoing research. 
1.6 Hormones Implicated in Central Fatigue 
Cytokines are not the only chemicals in the body which have been implicated in central 
mechanisms of fatigue; a number of hormones have also been the subject of investigation, 
and perhaps the two hormones of most interest are corticotrophin-releasing hormone and 
dehydroepiandrosterone. 
1.6.1 Corticotrophin-Releasing Hormone (CRH) 
CRH is a peptide hormone secreted by the paraventricular nucleus of the hypothalamus in 
response to stress, and with its effector the pituitary-adrenal axis and the sympathetic and 
autonomic nervous systems it is one of the central pillars of the body’s stress response system 
(211). The best-known function of CRH is to stimulate release of ACTH by the anterior lobe 
of the pituitary gland, which in turn stimulates production of other hormones in the pituitary 
gland including cortisol and dehydroepiandrosterone. However this is not its only role: CRH-
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containing nerve fibres extend from the hypothalamus into brainstem autonomic nuclei and 
many other parts of the brain, and CRH has been localised within a number of these areas 
including limbic and autonomic structures; it is therefore thought that CRH is involved in not 
only the hormonal responses to stress, but also the behavioural and autonomic responses 
(212, 213). 
There is evidence of abnormal synthesis and release of CRH in some of the human diseases 
in which chronic fatigue is a prominent symptom. The most direct evidence comes from 
studies in CFS, which have repeatedly shown abnormalities of the hypothalamic-pituitary-
adrenal axis, and in particular reduced CRH secretion by the hypothalamus (214, 215). 
Indirect evidence of reduced CRH synthesis and / or release has also been shown in SLE 
(216), RA (217), MS (218) and primary biliary cirrhosis (PBC) (154). Experimental evidence 
in rats suggests that the effect of chronic stress on CRH production and release might depend 
on what the stressor is: whereas various physical and psychological stressors have all been 
shown to induce an up-regulation of CRH in the hypothalamus (219-221), animal models of 
immune-mediated arthritis (222), SLE (223), MS (224) and cholestatic liver disease (225) all 
suggest that if that stressor is inflammation then there is instead a reduction in CRH synthesis 
and secretion. In reviewing this evidence, Swain (154) suggested that fatigue in these chronic 
inflammatory diseases may be due in part to defective CRH release. 
1.6.2 Dehydroepiandrosterone (DHEA) 
In humans DHEA is synthesised from cholesterol primarily in the adrenal glands, with 
smaller quantities produced in the gonads and in the brain. Most DHEA in the blood is not 
found in its free form, but rather as the sulphate ester dehydroepiandrosterone sulphate 
(DHEAS), with serum levels of DHEAS around 300 times greater than free DHEA; 
conversion between the two forms is reversible, and occurs in the adrenals, liver, small 
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intestine and many other peripheral tissues. DHEAS is often measured in preference to 
DHEA not only because it is more abundant, but also because DHEA concentrations ebb and 
flow in a diurnal variation, whereas DHEAS concentrations do not.  It is known that 
endogenous DHEA production increases in response to exercise in humans (226, 227) and 
calorie restriction in primates (228). DHEA levels decline slowly with age – a process which, 
coupled with the relative glucocorticoid excess that often occurs in older people, is referred to 
as ‘adrenopause’ (229). 
The main function of DHEA is probably as a precursor to androgens and oestrogens, but over 
the last couple of decades it has been discovered not to be inert, but rather to have roles in 
obesity, aging, stress and immune responses amongst other effects (230). There is evidence 
for example in older individuals (229, 231, 232) that adrenopause is important in many of the 
changes associated with aging, including cognitive impairment, ischaemic heart disease, 
immunodeficiency, malignancies and osteoporosis. It is extremely difficult to prove to what 
extent these effects are caused by DHEA itself or whether they are entirely effects of its 
metabolites, but for example DHEA is known to be a full agonist in its own right of the ERβ 
oestrogen receptor, and because the normal physiological concentrations of DHEA in the 
human body are fairly high it probably acts as an important endogenous oestrogen (233). It 
also has a low affinity to the androgen receptor, but this is so much weaker than testosterone 
as to be insignificant (234). It does not bind to the glucocorticoid or mineralocorticoid 
receptors, and in fact it has an anti-glucocorticoid action, partly though effects on the enzyme 
11β-HSD1 which is essential for the synthesis of glucocorticoids such as cortisol (230). 
Studies in many patient populations including CFS, SLE, MS and PSS (235-242) have shown 
that DHEA levels are often reduced. This is unsurprising, since chronic inflammation results 
in reduction of DHEA and DHEAS levels, with IL-6 and TNF playing an important role 
(243). Compounding the effects of inflammation, treatment of such illnesses usually includes 
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the use of corticosteroids, which have also been shown to suppress DHEA and DHEAS levels 
as a result of the suppression of pituitary ACTH secretion (244). Some studies have shown 
that low DHEA levels are associated with fatigue (235, 240), and low levels of androgen 
steroids (synthesised from DHEA) have also been associated with fatigue in AAV (114), but 
other studies have not shown a correlation between lower DHEA levels and greater fatigue 
(236, 238). Similarly, although some interventional studies of DHEA replacement have 
shown improvements in wellbeing, psychological symptoms and fatigue (245-247), others 
have been negative (237, 241, 248, 249). 
1.7 Chronic Fatigue Syndrome (CFS) 
CFS is an acquired illness which is primarily characterised by severe, debilitating fatigue 
which is aggravated by physical or mental exertion and is not relieved by rest (250) – in other 
words, fatigue which is very much the same as that associated with sickness behaviour, and 
with AAV and many other chronic illnesses. What is fundamentally different between CFS 
and sickness behaviour or the fatigue of chronic illness is that in CFS there is no known 
specific cause, and there is no diagnostic test; indeed the name was chosen in 1988 
specifically because it included no statement of aetiology (251). The diagnosis is instead 
made on the basis of exclusion of other illnesses, subjective clinical assessment and patient 
self-report (252). The fatigue found in CFS is often extremely severe, with a profound impact 
on function in personal, social and professional life and resultant economic consequences for 
sufferers and society (253, 254). 
Because there is no diagnostic test, clinicians and researchers must diagnose CFS on the basis 
of ‘case definitions’, in other words “an approved criterion of disease specific signs and 
symptoms, which is used to determine the presence of a disease or health complaint” (255). 
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Unfortunately there has not been agreement on how best to diagnose the disease, resulting in 
there being at least six commonly used case definitions (250). This is not merely an 
inconvenience for clinicians and researchers - it has been estimated that the prevalence of 
CFS in the adult population can vary between 0.007% and 2.8% depending on which case 
definition is used (256). The 1994 US Centres for Disease Control and Prevention (CDC) 
Case Definition (257), which is the most common case definition used, lists the following 
diagnostic criteria: 
 The fatigue must have been persistent or relapsing for at least six months; 
 There should be significant reductions in previous levels of occupational, educational, 
social and personal activities; 
 The fatigue cannot be explained by medical or psychiatric conditions; 
 It must be accompanied by at least 4 of 8 self-reported symptoms: sore throat; tender 
lymph nodes; muscle pain; arthralgia without joint swelling or redness; new 
headaches; unrefreshing sleep; post-exertional malaise lasting more than 24 hours; 
cognitive dysfunction (impaired short-term memory or concentration). These 
symptoms must also have been present for >6 months and must not have predated the 
fatigue. 
CFS affects all ages including children, and although it affects people of both genders, and 
across all ethnicities and socioeconomic strata, it has been shown that it is twice as common 
in women, and that healthcare workers have a higher prevalence than those in any other 
occupation (258). The cause of CFS is unknown; suggested causes include neuroendocrine 
abnormalities (giving rise to the alternative name of ‘myalgic encephalomyelitis’ or ME 
which is preferred by many patient groups), Epstein Bar Virus infection (post-viral fatigue 
syndrome), immunological abnormalities (chronic fatigue immune dysfunction syndrome), 
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genetic predisposition and psychological trauma, but no one of these factors can be attributed 
to more than a small percentage of all the cases of CFS. Various models have been proposed 
to explain CFS, but as with sickness behaviour and the chronic fatigue associated with 
illnesses such as RA or MS, the best explanation is probably that of an altered representation 
of self and an increase in the sensitivity of interoception. According to this theory an 
increased sensitivity to afferent pain signals would be expected and this has been described in 
a limited number of studies. 
Because the cause of CFS is unknown, the treatments used are the same as those used in the 
fatigue of chronic illness where there is no identifiable reversible factor, as described in 
Section 1.11. The prognosis of the illness is not good: a systematic review of 14 studies 
showed that the median full recovery rate was only 5% (range 0-31%), and the median 
proportion of patients who improved during follow-up was 39.5% (range 8-63%). Good 
prognostic factors were less severe fatigue at baseline, a sense of control over symptoms, and 
not attributing the illness to a physical cause; return to work was only measured in three 
studies, and ranged from 8-30% (259). 
1.8 Fatigue in Autoimmune Disease 
Fatigue is a common symptom of virtually all known autoimmune diseases, and because 
some of these other autoimmune diseases are significantly more common than AAV, there is 
a correspondingly larger body of existing fatigue literature. For example RA has a prevalence 
in the UK of around 0.8% (260), and up to 80% of patients with RA describe fatigue (261). 
Repeated studies have shown that fatigue is at least as prevalent and severe a symptom of RA 
as is pain (262, 263) and that most patients consider fatigue to be both more important and 
more difficult to deal with (136, 264, 265). This has led to the RA research community 
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showing increasing interest in fatigue over the last decade, with an international consensus in 
2006 that it should be measured in all subsequent clinical trials (266). Studies have shown it 
to be no less of a problem in other autoimmune diseases – for example the prevalence of 
fatigue is 90% in SLE (267), 68% in primary Sjögren’s syndrome (PSS) (268) and 78% in 
MS (269). 
1.8.1 Fatigue, Disease Activity and Inflammation 
Despite numerous studies across different diseases, controversy remains over whether disease 
activity is a predictor of fatigue in autoimmune disease. One early study found that in a 
cohort of 59 SLE patients with severe fatigue there was a significant correlation between 
fatigue and the physician’s clinical rating of disease activity (270), another study found that 
although disease activity, depression and helplessness all correlated with each other and with 
fatigue, only disease activity was a predictor of future fatigue three months later (271), and a 
number of other studies in SLE have also shown evidence of significant correlation between 
fatigue and disease activity (272-275). However, most of the studies in SLE which have 
shown a correlation with disease activity utilised a disease activity tool known as Systemic 
Lupus Activity Measure, which actually includes perceptions such as fatigue as component 
scores. Studies in SLE which have used other instruments to assess activity (276), and most 
studies in RA, have found no significant correlation between fatigue and disease activity 
(262, 277), and nor did a study of 88 patients with primary biliary cirrhosis (PBC, an 
autoimmune liver disease) (278). There is similarly conflicting evidence on whether fatigue 
worsens with disease duration: whilst some studies have shown higher levels of fatigue 
amongst those who have had RA for a longer time (279, 280), others have found greater 
fatigue amongst those patients with a more recent diagnosis (281), and there was no 
association found between disease duration and fatigue in PBC (278). 
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As described in Section 1.5, pro-inflammatory cytokines probably have an important role in 
inducing sickness behaviour, and therefore could be at least partly responsible for central 
mechanisms of fatigue. There is also a great deal of evidence for a link between inflammation 
and depression (reviewed in (282)). It is puzzling therefore that although some clinical 
studies have shown a correlation between higher circulating cytokine levels and greater 
fatigue (283), many have not (133, 284, 285), but there are a number of very plausible 
explanations. Firstly, perhaps the wrong fluid is being sampled: clinical studies of fatigue 
have almost invariably measured serum cytokine levels, but a study by Lampa et al in RA 
patients showed that CSF concentrations of IL-1 were much higher than those in the serum, 
perhaps reflecting local production within the CNS (194); if this is true then only CSF levels 
would be expected to correlate with fatigue, as indeed they did in that study. Alternatively it 
could be a technical issue, as cytokines are relatively difficult to store and test without 
degradation of samples. It could be an issue of timing: cytokines concentrations appear to 
have a circadian rhythm, perhaps explaining why many symptoms of inflammatory diseases 
have a rhythmical pattern of severity; the ‘perfect’ time for sampling probably does not exist, 
as it has been shown that the peak concentrations of different cytokines occur at different 
times in the 24hr cycle, and that the cycle is altered in RA depending on severity of disease, 
but undoubtedly all study participants should have samples taken at approximately the same 
time of day (147). Finally, most studies that have attempted to look at the relationship are 
relatively small, and since there are so many other factors influencing fatigue levels 
(particularly the psychosocial influences discussed below) it may be that the influence of 
cytokines is not strong enough to show statistical significance in small studies. 
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1.8.2 The Interplay between Psychiatric Disease, Psychosocial Factors and Fatigue 
In primary care fatigue is strongly correlated with depression (286), and this finding has been 
replicated in autoimmune disease. Higher levels of fatigue in RA are predicted by ‘trait 
anxiety’ (287) (a tendency to respond with anxiety in anticipation of threatening situations), 
current depressive or anxiety symptoms (277) and also by a lifetime history of mood disorder 
(288). Longitudinal fluctuations in mood appear to affect fatigue also: patients with RA 
reported higher levels of fatigue during the same annual assessments at which they also 
reported lower mood, a finding most marked in those individuals with less aggregate 
depressive symptoms (288); and patients with SLE who reported the greatest increases in 
anxiety and depression over the first nine months of a study subsequently reported greater 
fatigue at the fifteen month time-point (289). There appears to be a similarly strong 
correlation between fatigue and depression in PBC (278). An early study by Krupp (290) in 
patients with MS found no association between fatigue and depression, but this was a small 
study and such findings are in the minority. 
Several studies appear to demonstrate a link between pain and fatigue in inflammatory 
disease. For example, on days when patients with RA reported increased pain they also 
reported increased fatigue (291), and the association is replicated in other RA studies (277) as 
well as studies of juvenile rheumatic disease (292, 293). Pollard et al found that pain and 
depression were the two characteristics that most strongly correlated with fatigue in RA 
(261). 
Sleep also seems to be an important predictor of fatigue. Patients with RA who reported poor 
sleep in one study also had higher levels of pain and fatigue (294), and in a study of 1488 
patients with rheumatic disease (a mixture of patients with RA, osteoarthritis and FMS were 
studied), 90% of fatigue was explained by pain, sleep disturbance and depression (262).  A 
number of SLE studies have shown that patients with poor sleep have higher levels of fatigue 
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(273, 295-297), and in PBC, sleep and depression were the two strongest predictors of fatigue 
(278). 
Other psychosocial factors may also be important determinants of fatigue. In RA, for 
example, those patients who perceived themselves to have less help at home experienced 
greater fatigue (287), as did those with a higher level of functional disability (287, 298). 
There is a suggestion that the coping mechanisms used to deal with fatigue might be 
important, with an association found between avoidant coping and greater fatigue (299). 
1.9 Fatigue in Cancer 
Cancer-related fatigue (CRF) is almost universal among cancer patients (300), and has the 
same wide-ranging effects on all aspects of patients’ lives that are seen in autoimmune 
disease; it is also similarly disproportionate to the patient’s level of exertion and is not 
relieved by rest or sleep (301). Most commonly fatigue in cancer is associated with 
radiotherapy and chemotherapy treatments; whilst a positive aspect of this is that patients 
may find it more predictable, there is some evidence that the onset of fatigue outside of 
therapy courses can cause fear of disease progression for patients (302). Fatigue often begins 
before the diagnosis of cancer is made (303), and may continue for a considerable amount of 
time beyond the end of treatment (304, 305). The MFI-20 has shown that fatigue continues to 
affect patients after the start of treatment across all five dimensions (306, 307). Although it 
has been suggested that research into CRF lags behind research into cancer-related pain, 
nausea and vomiting (308, 309), it has still received more attention than fatigue has done in 
most other diseases due to the sheer number of people who suffer from cancer and CRF. 
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1.9.1 Prevalence and Impact 
The prevalence of CRF is influenced by patient characteristics, primary malignancy, and the 
type and intensity of treatment, but has been variably reported in 60-99% of cancer patients 
who undergo treatment with chemotherapy, radiotherapy or both (310-314). Indeed it is so 
prevalent and severe that CRF is now a distinct diagnosis in the International Classification of 
Diseases 10th Revision (ICD-10). The prevalence and impact of CRF during and after 
chemotherapy was assessed in a large telephone interview study of 379 patients (315), 62% 
of whom had breast cancer. When patients were asked to identify the side-effect which had 
affected them most during chemotherapy, 18% reported fatigue (second only to nausea, 
34%), and fatigue was the symptom with the greatest impact during the period after 
completion of treatment (25%). 76% reported that they had suffered from fatigue on at least a 
few days each month during their most recent chemotherapy, with 30% experiencing fatigue 
every day. Patient characteristics associated with fatigue included female gender and age 
>55years, as well as depression and pain (p<0.05 for all). Patients reported reduced physical 
activity across a variety of measures, and also reported the need for an average of 2.8 
additional hours of sleep per day; 88% stated that they had to alter their daily routine due to 
fatigue, and on average they reported only being able to complete 55% of the activities they 
would normally have performed. It also had a profound psychosocial impact, with effects on 
motivation, mood and cognition. Of the 177 patients who had been employed prior to cancer 
diagnosis, 75% changed their employment status as a direct result of fatigue, with 28% 
leaving work altogether. 
1.9.2 Aetiology 
Many of the determinants of fatigue in cancer are poorly understood, but a review of the 
causes by Wagner and Cella (91) listed them under the following construct: 
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1. Direct effects of cancer and tumour burden; 
2. Treatment side-effects – chemotherapy, radiotherapy, surgery and medication; 
3. Psychosocial factors – coping with chronic illness, anxiety and depression; 
4. Exacerbating comorbid symptoms – chronic pain, sleep disturbances, deconditioning; 
5. Comorbid medical conditions – Anaemia, malnutrition, thyroid dysfunction, infection. 
The first point on this list is obviously unique to cancer, but otherwise the list is practically 
identical to the causes of fatigue in autoimmune disease (e.g. Hewlett’s construct in RA 
(106)). Reviews of CRF have implicated cytokines, serotonin and the hypothalamic-pituitary 
axis in the pathogenesis of the symptom (309), and a study by Bower et al suggested that 
CRF may be associated with a T-cell mediated inflammatory process (316), all of which are 
theories which have been discussed in this chapter in the context of autoimmune disease.  
In summary the prevalence, impact and proposed causes of CRF are all remarkably similar to 
those in auto-immune disease, suggesting that fatigue in chronic disease may have much 
more to do with the biological and psychosocial processes that are common to all long-term 
illnesses than anything which is unique to a particular disease. 
1.10 Fatigue in AAV 
Compared to diseases such as cancer, RA and CFS, there has been little fatigue research 
conducted in AAV, perhaps because the monitoring of patients with AAV has traditionally 
been focused on what doctors thought was important rather than patients’ priorities. The tools 
used to assess the disease, such as the Birmingham Vasculitis Activity Score (BVAS) (317, 
318) and the Vasculitis Disease Index (VDI) (319) were designed without any patient input, 
and their purpose is to help doctors to know if there is any active inflammation, or any 
damage to specific target organs, rather than how the patient is feeling subjectively. This 
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might be due to the relatively recent improvements in patient mortality – issues of quality of 
life for patients with AAV have only come to the fore in the last few decades in parallel with 
improving survival. 
In the late 1990s awareness began to grow of the huge impact AAV was having on health-
related quality of life (HRQOL), as the disease became a chronic relapsing-remitting disease 
for many patients rather than a fatal one. In 1998, the first study to attempt to use patient-
reported outcome measures (PROMs) in AAV was a questionnaire study of 60 patients by 
Hoffman et al (320) which investigated the patient-perceived effects of GPA on health, 
function, income and relationships. 80% of the patients surveyed said that their activities of 
daily living were compromised, and the effect on employment and income was also huge: 
57% of patients had to take sick-leave for more than six consecutive months, 51% had to 
reduce their work hours, 31% had to completely leave work on disability benefits, and the 
average income one year after diagnosis had dropped by 26%. 
That study stimulated interest in PROMs in AAV, and three significant studies were all 
reported in 2002. One of those studies had a similar focus to Hoffman’s study, this time 
administering a questionnaire to 60 patients with GPA who were under the age of 40 at 
diagnosis (321). The researchers found that 27% of those who were employed at time of 
diagnosis had left work and gone onto work disability benefit within 39 months, and that the 
risk of this was three-fold greater for women than for men. Those who were unemployed 
suffered a considerable reduction in HRQOL compared with those who were employed, 
independent of disease factors. Another questionnaire study of 701 GPA patients also 
reported significant effects of the disease on disability and employment, although they found 
that the impact was less in patients who were diagnosed in the 1990’s than those diagnosed in 
previous decades (322). A questionnaire study by Boomsma et al looked at 79 patients with 
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GPA and 114 patients with SLE, and found that both diseases had profound effects on levels 
of disability, employment, mood and personal relationships (323). 
Although those earlier studies helped to increase awareness of the socioeconomic, 
psychological and inter-personal effects of AAV, the first study to comprehensively address 
patients’ subjective experiences and priorities in AAV was only published as recently as 
2010. Herlyn et al (324) conducted a questionnaire study of 264 patients with AAV across 
three countries (USA, Germany and the UK) which, in addition to questions about 
demographics and disease activity, also asked the patients to rate to what extent 40 different 
symptoms related to AAV had impacted upon their lives. Of the symptoms that more than 
50% of patients reported having experienced, the five most severe were: ‘Tiredness/Fatigue’ 
(reported by 95% of patients, mean rating 3.5 / 5); ‘Loss of Energy’ (reported by 93%, mean 
rating 3.4); Weight gain (76%, mean 3.1); Joint pain (83%, mean 2.9); Sinusitis (70%, mean 
3.0); severe organ manifestations such as seizures, CKD and oxygen dependency were all 
rated lower by patients. In a free text section where patients were asked to list the five most 
important aspects of the disease in their daily life, fatigue/energy loss (75%), pain (31%) and 
musculoskeletal symptoms (24%) were listed most frequently. Herlyn’s study was the first to 
illustrate this startling difference between what health care professionals thought was 
important in AAV and the priorities of patients. It brought the problem of fatigue in AAV to 
the fore as a major cause of reduced HRQOL, highlighted the fact that none of the disease-
monitoring tools currently being used clinically or in AAV research included fatigue in their 
scoring schemes, and gave a compelling argument for the inclusion of measures of PROMs in 
all future studies in AAV. 
The underlying cause of fatigue in patients with AAV is not understood. The inflammatory 
nature of the disease might be critical, because even during disease remission patients with 
AAV have evidence of inflammation with elevated circulating pro-inflammatory cytokines 
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such as IL-1, IL-6 and TNF-α (our unpublished data and (325)); however it has already been 
shown that data in other autoimmune diseases has not shown a consistent link between either 
disease activity or inflammation and fatigue. Another possible cause could be end-organ 
damage – for example, it is known that many patients with AAV have renal involvement and 
are left with degrees of renal impairment varying from mild CKD to dialysis-dependence 
(326). Previous studies have shown that the prevalence of fatigue in haemodialysis patients is 
around 70%, and that the correlates of fatigue in CKD are virtually the same as those in 
cancer, including: comorbidity, raised body mass index (BMI), inflammation, lack of 
physical exercise, poor mental health, pain and sleep problems (92, 93). These possible 
causes can be most easily explored by dividing them again into causes of peripheral fatigue 
and causes of central fatigue. 
1.10.1 Potential Causes of Peripheral Fatigue in AAV 
In a previous study by our group patients with AAV cited muscle fatigue rather than 
breathlessness as a reason for exercise termination, and peripheral muscle weakness was 
significantly correlated with reduced exercise tolerance (327). No studies have previously 
systematically examined whether peripheral muscular problems contribute to fatigue in AAV, 
but there are a number of reasons why this might be the case: 
1. Loss of Muscle Mass or Contractility: As with other chronic inflammatory illnesses, 
we might expect significant muscle atrophy in AAV, leading to fatigue due to 
muscular weakness as described previously (153, 328, 329). Reduced muscle strength 
may also be due to impaired peripheral nerve conductivity due to inflammation-
induced epineural endothelial damage (330, 331). Alternatively, pro-inflammatory 
cytokines may affect muscle contractility by reducing the resting membrane potential 
of muscle and nerve (332, 333). In elderly patients, serum TNF-α concentration was 
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associated with reduced muscle endurance (334), although it might be argued that this 
finding could be due to a central mechanism. In addition to the direct effects of 
inflammation on muscle, corticosteroids and cyclophosphamide, the mainstay of 
treatment in AAV, are known to reduce myofibrillar mass and may also alter aerobic 
metabolism via reductions in mitochondria (335-337). Corticosteroids may induce the 
development of the metabolic syndrome, including insulin resistance. Insulin 
resistance results in impaired amino acid uptake into the muscle fibre, reduced protein 
synthesis, and increased protein degradation resulting in a progressive loss of muscle 
mass (338, 339). 
2. Blood supply and oxygen delivery to the muscles: Microangiopathy resulting in 
reduced oxygen delivery to muscle cells has been suggested as an important cause of 
lowered exercise capacity and increased fatigue (340) in SLE, and similar 
pathological changes could occur in AAV.  In health, various studies have shown a 
40-50% increase in the number of perfused muscle capillaries, and up to a 100% 
increase in capillary blood volume, in response to physiological increases in insulin, 
and even larger increases are seen during exercise (341, 342). TNF-α, has been shown 
to block insulin-mediated microvascular recruitment (341, 343). This blunting of the 
haemodynamic effects of insulin and exercise by TNF-α may reduce glucose and 
oxygen transport to muscles, possibly leading to premature fatigue (344). 
3. Uraemia: CKD in many patients with AAV may cause selective muscle weakness, as 
uraemia affects fast twitch fibres more than slow twitch (345).  
4. Deconditioning of Skeletal Muscle: The effects of reduced muscle strength are often 
compounded by "deconditioning", which lowers muscle mitochondrial content, 
resulting in enhanced glycogen breakdown, glycolysis and acidosis, stimulating 
muscle afferents leading to an exaggerated cardiovascular response to exercise (346). 
53 
5. Reduced Cardiac Output: Maximal sustained muscle power output is partly 
determined by cardiac output, which in turn is determined by stroke volume. Stroke 
volume decreases with age, inactivity, or inflammation (all of which are features of 
AAV), as a result of which normal activities are carried out at a higher percentage of 
maximum aerobic capacity than would otherwise be the case, and at a higher heart 
rate (347). Additionally, as explained above, the increased metabolic demand of 
deconditioned muscles with a low oxidative capacity results in an exaggerated 
stimulation of the muscle heart reflex (346, 348). Collectively these mechanisms can 
cause normal physical activities to be more readily experienced as exhausting. 
6. Ischaemic Heart Disease: Systemic inflammation is an independent risk factor for 
ischaemic heart disease (349, 350). 
1.10.2 Central Fatigue in AAV 
The literature reviewed in the previous sections suggests that fatigue in many chronic 
illnesses might be primarily central in origin, and there is some evidence that this might also 
be the case in AAV. 
One Danish study of 68 GPA patients in 2010 found no association between HRQOL and any 
measures of disease extent or severity, although it did not look at whether fatigue or any other 
psycho-social factors might have explained the reduced quality of life in that cohort (351). A 
questionnaire study by Basu et al, also in 2010 (352), attempted to identify which factors in 
AAV contributed to reduced HRQOL: patients were twice as likely as healthy controls to 
suffer from mild/moderate fatigue (OR 2.0; 95% CI 1.1-3.8) or severe fatigue (OR 2.5; 95% 
CI 1.4- 4.5), and fatigue appeared to be a major determinant of HRQOL. As in the 
aforementioned Danish study, fatigue did not correlate with disease activity or damage. A US 
study of 55 patients with GPA found no association between fatigue and disease duration, 
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damage or activity, or with steroid use; rather, significant correlations were found between 
fatigue and FMS, sleep disorder and depression (353). Another British questionnaire study of 
51 patients with AAV found that patients who experienced moderate-to-severe pain had 
significantly reduced HRQOL as well as significantly greater fatigue, depression and sleep 
disturbance than those who reported little or no pain. The authors hypothesised that pain was 
a major determinant of HRQOL, but acknowledged that longitudinal work would help to 
establish causal pathways (354). 
No studies thus far have attempted to identify the mechanisms linking these psychosocial 
factors with fatigue, and no studies have attempted to study the treatment of fatigue in AAV 
either. 
1.11 Treatment of Fatigue 
Studies have shown that patients believe health professionals dismiss their fatigue (102), 
forming a significant barrier to treatment. Numerous treatment strategies exist however, and 
although the evidence of efficacy is variable, the widely held view among patients and 
physicians that fatigue is unmanageable is probably not justified. The first step in managing 
chronic fatigue in any patient must be to look for easily correctable causes such as anaemia, 
hypothyroidism, electrolyte imbalances, or culprit medications, as highlighted by the 
National Comprehensive Cancer Network (NCCN) guidelines for cancer-related fatigue 
(300); the second step, which will be the focus of this section, is the pharmacological and 
non-pharmacological management of fatigue that either occurs in the absence of, or persists 
following the treatment of such correctable causes. 
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1.11.1 Pharmacological Treatments 
A number of pharmacological treatments might help treat fatigue in patients with AAV, 
particularly for individuals who have a readily reversible cause of fatigue. For example, 
treating anaemia (which might be due to an associated CKD) with erythropoiesis-stimulating 
agents would be expected to help, as might treating a co-incidental co-morbidity such as 
hypothyroidism, or withdrawing drugs known to cause fatigue such as benzodiazepines or 
beta-blockers. Depression was shown earlier to be an important predictor of fatigue, and 
antidepressants have shown some promise in reducing fatigue in FMS (355); therefore 
depression and anxiety should be actively looked for and treated in any patients with chronic 
fatigue regardless of which long term condition they have. 
In RA, several studies have shown improvements in HRQOL (of which fatigue is a 
component) with the administration of drugs that are designed to reduce inflammation, 
including the biological agent infliximab (an anti-TNF-α antibody that was previously used to 
treat AAV but has not been shown to be effective). The largest RCT looking at the use of 
infliximab in RA was ATTRACT, in which 428 patients received infliximab or placebo in 
addition to methotrexate (356). In ATTRACT, all groups achieved statistically significant 
and clinically meaningful improvements in HRQOL as measured by the physical component 
score (PCS) of the SF-36 quality of life questionnaire, but whereas the ‘methotrexate plus 
placebo’ group achieved a median score improvement of only 2.8 at two years, the 
‘infliximab plus methotrexate’ groups achieved an overall improvement of 6.4 (p=0.011 for 
the lowest dose, and p<0.001 for higher doses). A smaller RCT also showed that infliximab 
improved HRQOL more than methylprednisolone in patients with active RA (357). It should 
be noted that although the PCS of the SF-36 does include a measure of fatigue (‘vitality’), 
both of these trials found greater improvements in some of the other subscales which 
contribute to the PCS, particularly ‘bodily pain’, and that observational work by Pollard et al 
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found that most of the improvement in fatigue scores with anti-TNF therapy could be 
explained by improvements in pain (261). However, since pain has been shown to predict 
fatigue as already discussed, these RCT findings remain fairly encouraging. 
Some promising results have also been demonstrated for rituximab in RA: in REFLEX, an 
RCT that recruited 520 patients with active RA, patients treated with rituximab plus 
methotrexate achieved statistically significant and clinically meaningful improvements in 
both the PCS and mental component score (MCS) of the SF-36 compared to those treated 
with methotrexate plus placebo (358). 
1.11.2 Non-Pharmacological Treatments 
There have been a large number of studies looking at the non-pharmacological management 
of fatigue in various illnesses, and whilst the studies have mainly been small and of variable 
quality, they have provided some evidence of benefit from exercise and / or psychological 
therapies. The role of these therapies remains very controversial for many patient groups, 
particularly CFS patient groups, who have highlighted negative reports from some of their 
members (359). There is an assumption that the use of such therapies implies that the 
pathogenesis of the symptom is entirely psychological, a view which many patients find 
unpalatable (360). Nonetheless, therapies such as graded exercise therapy and cognitive 
behavioural therapy are probably the best evidence-based therapies available to treat fatigue 
at the moment. Some beneficial effects have been reported in small studies which looked at 
homeopathy, osteopathy and massage therapy, but none of these studies were of good quality 
(reviewed in (361)). 
1.11.2.1 Graded Exercise Therapy (GET) 
Graded exercise programmes have been assessed across a number of illnesses associated with 
fatigue with mixed but mainly positive results. One of the problems in comparing the results 
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of GET studies is the heterogeneity of the programmes being tested: they are of varying 
intensity and duration; they are variably aerobic-only, strength-only, or a mixture of both; 
perhaps most importantly they may be exercise only, or exercise combined with a non-
exercise component such as cognitive behavioural therapy. The exercise component of any 
such programmes might be expected to work through a number of mechanisms: 
 There is some evidence that aerobic and strength training may improve depression 
(362, 363), and as previously discussed there is evidence that depression is a strong 
predictor of fatigue; 
 Exercise has been shown to help sleep complaints (364, 365), another known 
predictor of fatigue; 
 Improvements in cardio-respiratory fitness would be expected to improve maximal 
aerobic capacity, thereby reducing the percentage of maximal aerobic capacity at 
which normal ADLs are carried out. 
In a study of 93 patients with SLE, one RCT compared a twelve week programme of GET 
with relaxation sessions to no intervention, and found a significant improvement in fatigue in 
the exercise group (as measured by the Vitality subscale of the SF-36 and the Chalder Fatigue 
Scale) which was maintained at follow-up after three months but only in those individuals 
who continued to exercise (366). Dalgas et al (142) enrolled 38 patients with MS into either a 
twelve week progressive resistance training group or a control group, and measured fatigue 
(with both the FSS and the MFI-20), mood and quality of life (with the MOS SF-36). At 
baseline all these parameters were comparable between the two groups, but by the end of 12 
weeks the intervention groups reported statistically significant improvements in fatigue (on 
the FSS score and the General Fatigue scale of the MFI-20, but not the other MFI-20 
dimensions), mood and quality of life (on the SF-36 Physical but not Mental Component 
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Score) when compared to the control group, and all of these improvements were maintained 
after a further 12 week follow-up period. A larger American RCT included 347 patients with 
varying types of arthritic illnesses, 25% of whom had RA, and found a statistically significant 
improvement in fatigue at both completion of the eight week programme, and at six months 
follow-up (367). 
A recent large RCT in patients with CFS challenged the view of patients’ organisations that 
GET and cognitive behavioural therapy (CBT – see Section 1.11.2.3 below) can be harmful 
by randomising 641 patients to one of four groups: specialist medical care (SMC) alone; 
SMC plus GET; SMC plus CBT; or SMC plus adaptive pacing therapy. After one year of 
follow-up they found that mean fatigue scores and mean physical function scores were 
significantly better in the groups who received GET or CBT compared with SMC alone, but 
that adaptive pacing therapy (favoured by some patients’ groups) conferred no benefit over 
just SMC, and that there was no difference in the incidence of serious adverse reactions 
(359). A prospective RCT of fluoxetine therapy with and without GET, also in patients with 
CFS, found that fluoxetine on its own only helped depression, but exercise significantly 
improved health perception and fatigue at 28 weeks (190). Two other RCTs that looked at 
GET in CFS also found a statistically significant improvement in fatigue and other measures 
(368), as did six separate studies of cancer patients (369-374) 
On the other hand, an RCT which recruited patients with both SLE and RA found less 
impressive results with a ‘minimally supervised’ home exercise programme: although there 
were improvements in fatigue in both exercise groups, especially in the RA patients, the 
results did not reach statistical significance (375).  A Cochrane review of RCTs of GET in 
FMS was also fairly disappointing; although some studies showed evidence of improvements 
in fatigue from exercise (376-378), those were trials of exercise combined with education, 
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and studies without education showed no benefit. They concluded that “it is not known 
whether exercise training… improves other symptoms such as fatigue.” 
It is unclear why these studies have yielded such variable results, but common themes 
amongst the studies which have yielded the most promising improvements in fatigue seem to 
be that the exercise program was well supervised rather than self-directed or ‘minimally 
supervised’, that the GET was of lower intensity or aerobic in nature, and also that combining 
an element of education seems to be beneficial. 
1.11.2.2 Taught Self-Management Strategies 
Qualitative studies have found that in the general absence of clinician-led treatment for their 
fatigue, patients have developed varying self-management strategies. Hewlett (379) described 
some such strategies: 
 Behavioural – resting for periods, pacing overall activity level so as to maximise 
productivity without provoking exhaustion, planning ahead and adjusting other 
activities accordingly to ‘conserve energy’ for crucial tasks, using appliances which 
minimise energy expenditure; 
 Cognitive – distraction, re-normalising life; 
 Social – Seeking emotional and practical support. 
Occasionally such strategies can be maladaptive – for example in Hewlett’s own study (102) 
patients reported that they were sacrificing social activities in order to conserve energy for 
mundane tasks which they perceived to be more essential, undoubtedly reducing their quality 
of life in the process. Counselling from health professionals is important to help patients to 
use self-management strategies effectively, and a careful balance must be struck – although 
strategies such as pacing are frequently reported as helpful by patients (360), it has been 
shown that excessive rest worsens fatigue in cancer (380), and as previously discussed a large 
60 
RCT of patients with CFS found no benefit from adaptive pacing therapy (359). Nonetheless 
many patients claim benefit from such strategies, and they are recommended in the NCCN 
guidelines for the management of CRF (300). This recommendation is based on evidence 
from studies such as that by Barsevick et al, which showed that cancer patients undergoing 
chemotherapy or radiotherapy experienced significantly less fatigue if they were randomised 
to an energy conservation and activity management intervention than to a control group that 
was similar in terms of time and attention (381). 
Evidence supporting the efficacy of taught self-management strategies can be found in a large 
RCT in UK primary care which studied 544 patients with a diagnosis of arthritis (37% RA, 
52% OA, 11% ‘other’), comparing a treatment group that was enrolled into the Arthritis Self-
Management Programme (ASMP) to a control group that was placed on a waiting list for the 
same programme (382). The ASMP is a community-based programme delivered by lay 
people who have arthritis themselves, which aims to enhance perceived ability to control 
various aspects of the disease through four main strategies: ‘skills mastery’, which involves 
participants learning and practicing new behaviours such as cognitive symptom management 
techniques (e.g. distraction, visualisation, and ‘contracting’, a technique based on setting 
realistic goals to be achieved in the coming week); ‘modelling’, where the course leaders act 
as positive role models; persuasive communication; reinterpretation of physiological 
symptoms, which helps participants to distinguish disease symptoms from similar symptoms 
that can arise for example from exercise. In addition to significant improvements in 
perception of control and health behaviours, the treatment group achieved a significant 
reduction in fatigue (measured by the VAS, p=0.02), depression and anxiety (measured by 
the Hospital Anxiety and Depression Scale (HADS), <0.0005 and 0.014 respectively) at four 
months, and not only were these differences even more pronounced at a twelve month 
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follow-up, but visits to general practitioners regarding arthritis were also significantly 
reduced (p<0.0005). 
1.11.2.3 Cognitive Behavioural Therapy  
Cognitive behavioural therapy (CBT) is the collective term for therapies that address patients’ 
thoughts and beliefs about their symptoms (cognition) as well as how they cope with those 
symptoms (behaviour) through the setting and achievement of individualised goals. For 
example if the aim was to help a patient to cope with anxiety, CBT might include sessions to 
identify maladaptive thinking patterns that lead to increased stress and anxiety, as well as any 
dysfunctional coping strategies the patient might use, and then setting a ‘homework’ goal of 
practicing newly taught techniques by talking to a stranger before the next session. Typical 
CBT programs consist of anywhere between six and eighteen face-to-face sessions of around 
an hour each with a trained therapist, with a gap of 1–3 weeks between sessions. This initial 
programme might be followed by some booster sessions, for instance after one month and 
three months, although this is not always the case. Sometimes other techniques are combined 
with CBT – for example a study by Greco et al in SLE patients used 6 sessions of CBT which 
were re-enforced by auditory electromyographic biofeedback from the trapezius area as an 
indicator of muscle relaxation (383). 
CBT for fatigue reduction has probably been used most in CFS, where it has achieved both 
significant improvements in fatigue (359, 384-386) and also some more disappointing results 
(387-389), but it has also been used increasingly in other illnesses such as autoimmune 
disease (390). Given et al conducted an RCT of 237 patients with a variety of different solid 
organ and haematological cancers, and found that a 20 week CBT program produced a 
significant improvement in fatigue levels among patients who had moderate or severe fatigue 
at baseline. An RCT of 64 patients with RA of less than 8 years duration, all of whom 
achieved high scores on a psychosocial risk profile, compared treatment with or without 
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tailor-made CBT treatment in addition to standard medical therapy. The study showed that 
those in the CBT group achieved significantly lower levels of fatigue and depression post-
treatment which were maintained at six months follow-up (391). A study of SLE patients 
found that although CBT did have a marginal effect on levels of fatigue, this effect was no 
greater than two control groups who either underwent a 6-session ‘symptom-monitoring 
support programme’ where a therapist’s role was to listen empathetically but avoid giving 
advice or teaching any new skills, or else only had ‘usual care’ but completed follow-up 
evaluations in the same manner as the other groups (383). It should be noted, however, that 
fatigue was not one of the primary symptoms studied, and this may have been reflected in the 
CBT provided. A study of CBT combined with education and exercise in patients with FMS 
demonstrated an improvement in fatigue at four months (change in Fibromyalgia Impact 
Questionnaire fatigue score of -0.61 vs +0.09, p=0.02), but this effect was lost at 8 months. 
1.11.2.4 Expressive Writing 
Although CBT is the main psychological intervention which has been studied in fatigue, it is 
not the only one to have shown some benefit. Expressive writing has shown some promise in 
the treatment of fatigue, as it has also in the treatment of depression. In a study by Broderick 
et al, 92 patients with FMS were randomised to either ‘written emotional disclosure’ (ED), 
‘neutral’ (purely factual) writing, or usual care. ED describes a technique where subjects are 
asked to speak or write about a traumatic event not only factually but also with deep 
emotional expression and cognitive reflection, and the technique has been described in 
physical illnesses as long ago as 1997 (392), when it was shown to result in better 
psychological and physical functioning in RA; since then it has been tested in a variety of 
illnesses including asthma (393), prostate cancer (394), renal cell carcinoma (395) and breast 
cancer (396). Broderick’s study found that the ED group had improvements in fatigue, pain 
and psychological well-being at four months compared to the control groups (change in SF-
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36 vitality score of -13.7 for ED vs -3.7 for controls, p=0.05), although this was lost by 10 
months follow-up. Another study in patients with RA or SLE found that two different types 
of expressive writing both improved fatigue levels compared to factual writing at three month 
follow-up (397). 
1.11.2.5 Mindfulness 
‘Mindfulness-based interventions (MBIs)’ are being increasingly proposed as a way of 
helping those with chronic physical or psychiatric illness to cope with pain and other 
symptoms (398), including fatigue (399), anxiety and depression (400-402), sleep disturbance 
(403) and stress (404). Mindfulness is a form of meditation which was historically associated 
with Buddhism, but many of its modern applications are not inherently spiritual or religious. 
Most therapeutic programmes are based on ‘mindfulness-based stress reduction’ (MBSR), 
which was developed in Massachusetts (USA) by Jon Kabat-Zinn, who defines mindfulness 
as ‘the effort to intentionally pay attention, non-judgmentally, to present-moment experience 
and sustain this attention over time’ (405). MBSR is an eight-week group workshop which 
teaches a number of techniques including: mindfulness meditation; ‘body scanning’, where 
the subject is to lie on their back and focus their attention fully on one part of the body at a 
time, moving from the toes up to the head; and gentle yoga (406). Another programme based 
on many of the same principles is ‘mindfulness-based cognitive therapy’ (MBCT), which 
combines elements of MBSR with CBT. It was initially developed to prevent relapses of 
depression, and encourages participants to ‘change their relationship to thoughts and 
feelings… to discover that these are fleeting events in the mind and the body that they can 
choose to engage with – or not’ (400). To date there have been no studies of the use of MBIs 
in patients with AAV, but the literature available for cancer, rheumatoid arthritis and a great 
many other chronic illnesses suggest it may have a potential role in relieving fatigue and 
other psychological symptoms. 
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In the first study of MBIs in cancer, 90 patients with a variety of different cancers were 
randomised to either MBSR or ‘waiting list’ (i.e., a control group which received no 
psychological intervention), and found that the intervention group benefitted from significant 
improvements in a variety of psychological symptoms including anxiety and depression 
(p<0.001). However the results for fatigue were mixed: they used the POMS questionnaire 
which includes subscales for both ‘vigour’ and ‘fatigue’, and although there was a significant 
improvement in the ‘vigour’ subscale (p<0.05), the improvement in the ‘fatigue’ subscale did 
not reach significance (p value not supplied) (407). Another study by the same group looked 
at sleep disturbance and cancer-related fatigue in 63 patients; again the participants had a 
variety of cancer types and stages, and were randomised to MBSR or waiting list, but this 
cohort of patients experienced a significant improvement in sleep quality (p<0.001) as well as 
much more marked improvements in fatigue as measured by the POMS fatigue (p<0.001) 
and vigour (p=0.016) subscales (408). The benefits of MBIs for sleep and fatigue were 
further supported by the findings of a smaller qualitative study (409). A small study of 24 
patients with breast cancer in Iran found that a MBSR programme significantly reduced 
fatigue compared to no intervention (p<0.001) (410), but a similar study in the UK found a 
less impressive improvement in fatigue severity which was not statistically significant 
(p=0.62) (411). 
Rimes and Wingrove investigated whether mindfulness would be of use in patients with CFS 
who had failed to respond to CBT. They conducted a small pilot study in England comparing 
MBCT to ‘waiting list’ in patients who were still excessively fatigued despite CBT, and 
found that the MBCT group reported significantly lower levels of fatigue after therapy than 
the control group (p=0.014), and that this improvement was sustained at six months (399). It 
is worth pointing out that this study did not directly compare the two therapy types, so 
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although the findings strongly suggest a possible role for MBCT in patients who have failed 
to benefit from CBT, it cannot be concluded that MBCT was superior.  
Many studies have shown that MBIs are beneficial for patients with chronic pain (406), and 
therefore one disease of particular interest is fibromyalgia. Numerous studies have shown 
MBSR to be a useful intervention in fibromyalgia, with improvements in common symptoms 
including pain, fatigue and depression (412-414). However it has not shown additional 
benefit compared with other psychological interventions, and has yet to be compared with 
CBT (406). 
In RA, an observational questionnaire study of 201 patients found that greater mindfulness, 
as assessed by the Freiburg Mindfulness Inventory-short-form, was associated with lower 
levels of psychological distress at baseline and at twelve-months follow-up (415). Zangi et al 
conducted an RCT of 73 patients with inflammatory joint diseases including RA and AS, 
comparing their own MBI to a control group that received routine care plus access to a CD 
with mindfulness-based home exercises. They found that the formal group intervention 
resulted in significantly greater improvements in psychological distress, fatigue and overall 
wellbeing (416). Another RCT of 63 patients with RA again randomised patients to MBSR or 
‘waiting list’; although there were no significant differences between groups after the eight-
week course, follow-up after a further four-month maintenance programme showed improved 
psychological distress (p=0.04) and well-being (p=0.03) (417). 
1.12 Conclusion / Rationale for this Study 
Based on clinical observations and the evidence presented in this chapter, there is good 
reason to believe that a high proportion of patients with AAV who are treated and stable 
nevertheless complain of excessive fatigue.  Furthermore, anecdotal evidence suggests that 
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this fatigue has a major effect on their quality of life.  However, fatigue is a complex 
multidimensional phenomenon and, to date, there have been no studies of the nature of the 
problem in AAV, whether, for instance, it is more the physical or the cognitive and 
psychological aspects of fatigue that affect the patients.  Likewise the extent to which the 
symptoms of fatigue degrade the quality of life to the patients has not been quantified.   
It is unlikely that any successful treatment for fatigue in AAV can be devised without 
understanding more about the underlying mechanisms, and there are many possibilities.  
Through mechanisms outlined previously, there might be atrophy or weakness of skeletal 
muscle, meaning that the patient would be making a greater effort to achieve the same 
outcome during the activities of daily living. Alternatively, or in addition, patients might have 
lower levels of cardio-respiratory fitness, meaning that the activities of daily living are 
carried out at a higher percentage of maximum aerobic capacity.  These changes might be 
described as “peripheral” causes of fatigue, but inflammatory disorders give rise to sickness 
behaviour which in some patients can lead to depression.  Although fatigue and depression 
are not the same condition, there are close associations between the two and it is possible that 
the long lasting fatigue could be due to persistent systemic inflammation or to some central 
adaptation as a result of the stress of the disease.  
The aim of the work presented in this thesis was to obtain a better understanding of the 
fatigue experienced by patients with AAV, and to identify possible causes or mechanisms 
that may then be amenable to pharmacological, nutritional or lifestyle interventions.   
To these ends, the objectives of this study were to: 
1. Determine the prevalence, nature and severity of fatigue in patients with AAV in 
comparison with patients with CKD and healthy controls, and to assess the impact of 
fatigue on their quality of life. 
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2. Determine whether fatigue in AAV is associated with depression, anxiety or other 
psycho-social variables. 
3. Measure the strength and fatiguability of skeletal muscle in patients with AAV 
compared with matched healthy controls. 
4. Determine the cardiorespiratory fitness of patients compared with matched controls. 
5. Investigate whether any deficiencies observed in skeletal muscle function or 
cardiorespiratory fitness might be contributing to subjective fatigue. 
6. Determine the extent of any central mechanisms of fatigue, including altered 
perception of exertion and reduced central motor drive. 
7. Determine whether there is any reduction in global cognitive function in patients with 
AAV, and whether any reduction is associated with fatigue. 
8. Determine whether patients with AAV who are in sustained remission have 
measurably increased levels of systemic inflammation compared with healthy 
controls, and whether any inflammation is related to their symptoms of fatigue. 
Objectives 1 & 2 were assessed by questionnaire, objectives 3 - 7 were achieved with 
laboratory-based studies, and blood samples were taken for objective 8.  
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2 MATERIALS AND METHODS 
2.1 Study Structure 
The study was conducted as two cross-sectional sub-studies which ran in parallel: a large 
questionnaire study which examined the prevalence, nature, severity, impact and predictors of 
fatigue in AAV compared to disease and healthy controls, and a laboratory-based study 
which examined the mechanisms resulting in fatigue. Throughout the original ethical and 
R&D applications, as well as in the information and consent forms, the questionnaire study 
was referred to as ‘Part 1’ of the study, and the mechanistic study as ‘Part 2’. 
2.2 Questionnaire Study 
2.2.1 Subjects 
Three groups of participants were recruited to the questionnaire study: 
 Patients with AAV. This group comprised adult patients meeting the European 
Medicines Agency (EMA) vasculitis classification algorithm (3) for AAV, all of 
whom were in sustained remission.  The majority of patients recruited to this group 
were regular attenders at the University Hospitals Birmingham NHS Foundation Trust 
(UHBNFT) vasculitis clinic; patients were pre-screened to ensure that they met the 
inclusion criteria and did not meet any of the exclusion criteria (as detailed below), 
and all patients who were eligible were then approached at their next scheduled 
outpatient visit. Additionally, there were pro-active approaches by some patients who 
did not attend clinic at UHBNFT, but who had heard about the study through various 
69 
patient support groups (Vasculitis UK, previously known as The Stuart Strange 
Vasculitis Trust, and Vasculitis Support Group West Midlands (VSGWM)); these 
patients were screened prior to recruitment using the same inclusion and exclusion 
criteria as local patients, using information supplied by the patient. 
 Patients with CKD. This group was utilised as a disease control group, because CKD 
is a common consequence of AAV and is itself independently associated with fatigue. 
Patients were only recruited to this group if their CKD was not secondary to a 
systemic inflammatory disease, and were pre-screened and recruited consecutively 
from the UHBNFT CKD clinics. 
 Healthy controls. The majority of healthy controls were recruited through a ‘buddy 
system’, whereby each recruited AAV patient was asked to identify a partner, relative 
or friend who was of a similar age. Additional healthy volunteers were recruited using 
the following strategies: 
o Outreach research clinics using the ‘Health Research Bus’ of the Wellcome 
Trust Clinical Research Facility (Birmingham). The bus spent time parked in 
prominent Birmingham city centre locations, and recruited members of the 
public who had no link to UHBNFT outpatient clinics; 
o Recruitment of healthy volunteers from the Staff at the University of 
Birmingham (UoB) and UHBNFT. 
2.2.2 Sample Size and Statistical Analysis 
Over the course of the year during which the study was designed, there had been around 170-
180 patients attending the vasculitis clinic at UHBNFT. We therefore aimed to recruit 150 
patients with AAV into the questionnaire study, and to match this by recruiting 150 
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participants into each of the CKD and healthy control groups. A priori power calculations 
were not carried out during the design of this part of the study.  
In fact, although 152 participants were eventually recruited to the AAV group, only 68 were 
recruited to the CKD group and 71 to the Healthy Control group; when it is also taken into 
account that some of the questionnaires were not fully completed (see Table 3.1), there was 
enough data to generate a General Fatigue score for 145 patients with AAV, 67 patients with 
CKD, and 66 Healthy Controls. Post-hoc power calculations were carried out and showed 
that, taking a conventional alpha of 0.05 into account, this study had 61.8% power to detect 
an effect size of 0.4 between the AAV and CKD groups, 61.3% power to detect an effect size 
of 0.4 between the AAV and Healthy Control groups, and 46.1% power to detect an effect 
size of 0.4 between the CKD and Healthy Control groups in analyses of variance. 
Statistical analysis was carried out using IBM SPSS Statistics 21.0. Categorical data was 
summarised with percentages, and quantitative data was summarised with mean and standard 
error (SEM), or with median and interquartile range (IQR) according to normality of 
distribution. Comparisons of results between the groups were assessed using χ2 tests for 
categorical data and Mann-Whitney tests for quantitative data, and Spearman’s rank order 
correlation was used to assess the strength of associations between variables. Unless stated all 
correlations include both patients with AAV and healthy controls. Multivariable analysis was 
carried out using linear regression, having first confirmed that the distribution of the 
standardised residuals was normal. 
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2.2.3 Inclusion and Exclusion Criteria 
2.2.3.1 Inclusion Criteria 
 Patients with AAV: Adult patients with biopsy-proven disease, meeting the 
European Medicines Agency (EMA) vasculitis classification algorithm (3) for AAV. 
All recruited patients were in sustained remission (Birmingham Vasculitis Activity 
Score =0 for >6 months) at time of recruitment. Those patients with a recent diagnosis 
were required to have been diagnosed at least 9 months prior to entry into the study, 
and to have had an uncomplicated treatment course with remission within three 
months of diagnosis. 
 Patients with CKD: Adult patients with a diagnosis of CKD due to any cause other 
than systemic inflammatory disease, and with disease no more advanced than CKD 
stage IV (i.e., estimated glomerular filtration rate ≥15ml/min/1.73m2). 
 Healthy Controls: People not known to suffer from AAV, CKD or from any other 
major organ disease on screening. Minor illnesses such as osteoporosis, hypertension 
or hyperlipidaemia were permissible, provided that there was no known damage to 
any major organ, and that the illness had not been previously associated with fatigue 
in the literature. 
 For all three groups, written informed consent was a pre-requisite for inclusion. 
 Age ≥ 16 years. There was no upper age limit for inclusion. 
2.2.3.2 Exclusion Criteria 
 Symptoms, signs or investigation results in keeping with sepsis within the six weeks 
prior to enrolment. 
 Any known active malignancy, or still on active treatment for previous malignancy. 
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 Patients with AAV were excluded if they had received high dose steroids (>30mg 
prednisolone daily) within the previous 6 months, as this was interpreted to represent 
significant clinical suspicion of a relapse. 
 Patients with CKD and healthy controls were excluded if there was any evidence to 
suggest the presence of a systemic inflammatory disease. 
2.2.4 Data Collection and Baseline Bloods 
A data sheet was completed for all subjects who entered the study, comprising the following 
information which was gained from interview with the participant, as well as their medical 
notes (where available): 
 Gender, date of birth, height and weight; 
 Presence or absence of comorbidities including CKD, SLE, RA, other inflammatory 
arthritis, asthma/COPD, bronchiectasis, inflammatory bowel disease (Crohn’s disease 
or ulcerative colitis, irritable bowel syndrome, thyroid disease; 
 List of medications; 
 For the patients with AAV– diagnosis, date of diagnosis, organ involvement, relapses, 
and pharmacological treatments given. 
Baseline blood samples were taken on entry to the study and tested for full blood count 
(FBC), urea & electrolytes (U&E), albumin and C-reactive protein (CRP). 
2.2.5 Questionnaire 
The questionnaire was divided into ten ‘sections’, each of which gathered a different sub-set 
of information. ‘Section 1’ of the questionnaire collected the following information:  
 Age, gender, ethnicity, marital status, education and employment status; 
 Smoking history; 
73 
 Caffeine and alcohol intake;
 Habitual physical activity – participants were asked how many hours per week they
had spent engaging in various physical activities such as walking, swimming and
gardening during the previous year.
The other sections of the questionnaire included a number of pre-existing and widely used 
symptom-rating tools, as follows: 
2.2.5.1 Section 2 - The Short Form (36) Health Survey 
The Short Form (36) Health Survey, more commonly known as the ‘SF-36’, remains the most 
commonly used and well validated tool for the assessment of HRQOL. It was constructed 
following the Medical Outcomes Study (MOS) (418), a two-year American study in which 
22,462 patients with chronic illnesses including diabetes, hypertension, ischaemic heart 
disease and depression were studied to determine whether variations in patient outcomes 
were explained by differences in system of care, and to develop more practical tools for the 
routine monitoring of patient related outcomes in medical practice. From the forty physical 
and mental health concepts included in the original MOS, the eight which were seen as most 
important were subsequently selected for inclusion in the SF-36 (419). 
The SF-36 was designed to be as brief as possible without sacrificing measurement precision, 
and to be self-administered. It includes 36 statements which the respondent is asked to score 
using a Likert scale (420); these 36 items contribute towards eight subscale scores, each of 
which assesses a different domain of HRQOL (421). Raw scores are transformed into a 1-100 
scale for each domain, where higher scores indicate better HRQOL: 
 Physical functioning – 10 items on the SF-36 contribute towards this variable. Low
scores indicate great limitation in all physical activities due to health problems;
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 Role-Physical – Four items contribute towards this measure of problems with work or 
other daily activities as a result of physical health. Lower scores indicate more 
significant problems;  
 Bodily Pain – Two items contribute to this score, where low scores indicate severe 
and very limiting pain; 
 General Health – Five items contribute to this measure of the patient’s own perception 
of his or her health. Low scores indicate that the individual perceives their health to be 
poor and likely to get worse;  
 Vitality – Four items contribute towards this measure which is often considered to be 
the inverse of fatigue. Low scores indicate that the individual feels tired and ‘worn 
out’ all of the time; 
 Social Functioning – Two items contribute to this measure of the ability of the 
individual to engage in normal social activities. Low scores indicate that the 
individual encounters extreme and frequent interference with normal activities due to 
either physical or emotional problems; 
 Role-Emotional – Three items contribute to this scale. Similarly to the Role-Physical 
scale, this measures the impact of emotional problems on work and other daily 
activities, where lower scores indicate greater impact; 
 Mental Health – Five items contribute to this score, which is a measure of how 
nervous or depressed the individual is. Lower scores indicate poor mental health. 
In addition to the 35 items which contribute to the eight primary scales listed above, there is 
also one item used to derive an outcome known as Reported Health Transition.  
A recent enhancement of the scale has been the development of summary scores, whereby 
pooling of the eight  primary scale scores allows researchers to calculate a Physical 
Component Score (PCS) and a Mental Component Score (MCS) (422). The SF-36 is the 
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mostly widely used HRQOL measure in AAV, including in UK populations, and as such is 
well validated for our study population (354, 423). 
2.2.5.2 Section 4 - The Multi-Dimensional Fatigue Inventory (MFI-20) 
As described in Chapter 1, the MFI-20 is one of the most commonly used multi-dimensional 
fatigue scales (110), and is well validated across healthy (113, 143, 144) and disease 
populations (116-142, 146) including AAV (114, 115). It allows assessment not only of the 
severity of fatigue, but also of the nature and impact of the symptom. Participants are asked 
to rate the truth of twenty statements using a Likert scale, and the responses generate five 
scores, each representing a different ‘dimension’ or aspect of fatigue: ‘General Fatigue’, 
‘Physical Fatigue’, ‘Mental Fatigue’, ‘Reduced Activity’ and ‘Reduced Motivation’; Reduced 
activity and Reduced Motivation are sometimes regarded as measures of the impact of 
fatigue. The score for each item ranges from 1-3, and therefore the score for each dimension 
ranges from 4 (no fatigue) to 20 (maximal fatigue). There is no overall or total score, and the 
author’s recommendation is that the ‘General Fatigue’ score should be used in place of a 
summary score when comparing between studies (113, 118). 
There is no ‘upper limit of normal’ reported for the MFI-20, i.e. there is no accepted cut-off 
above which a person would be considered to suffer from fatigue and below which they 
would not. It was decided, therefore, that we would define patients with AAV and CKD as 
having ‘severe fatigue’ if their MFI-20 ‘General Fatigue’ scores were above the 95% 
confidence limits of our matched healthy controls. 
2.2.5.3 Section 5 - The Revised Piper Fatigue Scale 
Part of the Revised Piper Fatigue Scale (PFS) was included in order to assess the direct 
impact of fatigue on role impairment (424). Questions 2-6 of the Behavioural/Severity 
subscale were used, supplemented by an additional question relating to the impact of fatigue 
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on activities of daily living (ADLs); it was not necessary to include the whole scale since the 
other sections did not add to the information already provided by the MFI-20. 
2.2.5.4 Section 6 - The Hospital Anxiety and Depression Scale (HADS) 
The HADS is a short but comprehensive instrument designed to identify people suffering 
from anxiety and / or depression (425). The HADS was chosen above other such measures 
because its authors purposely excluded somatic symptoms, thereby enabling it to more 
accurately define psychological illness in people who are also suffering from physical illness 
(426, 427), and also because it has previously been shown to be acceptable and discriminative 
in AAV (354). 
The scale consists of 14 items which are scored from 0-3 on a Likert scale to generate two 
summary scores: an ‘Anxiety Score’ ranging from 0 (no anxiety) to 21 (maximal anxiety), 
and a ‘Depression Score’ which also ranges from 0 to 21 (425). In addition to analysing the 
raw scores, it is common to categorise the scores into ‘Normal’ (scores of 0-7), ‘Borderline 
Abnormal’ (scores of 8-10), and ‘Abnormal’ (11-21); there is good evidence that such score 
cut-offs are useful for predicting psychiatric morbidity (427). 
2.2.5.5 Section 9 - The Pittsburgh Sleep Quality Index (PSQI) 
The PSQI (428) is a self-rated questionnaire which assesses sleep quality and disturbance 
over the previous month. The questionnaire consists of nineteen items, each scored on a 
Likert scale from 0-3; these nineteen scores are used to derive seven component scores 
(subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, use of sleeping medications, and daytime dysfunction), and the seven 
component scores are further summed to yield a global PSQI score ranging from 0 (best 
possible sleep quality) to 21 (worst possible sleep quality). The tool has been used across a 
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wide spectrum of illnesses as well as in healthy populations to assess sleep quality and 
disturbance, and has been appropriately validated as such (429). 
2.2.5.6 Section 11 - Brief COPE 
As discussed in Chapter 1, associations have been seen between the severity and impact of 
fatigue and the coping mechanisms employed by patients. The ‘Brief COPE’ is a 30 item 
scale which assesses fourteen dimensions of generalised coping relevant to chronic diseases 
(430). These dimensions comprise: dysfunctional coping (denial, self-distraction, self-blame, 
substance use, venting, and behavioural disengagement); emotion-focused coping 
(acceptance, use of emotional support, humour, positive reframing, and religion); and 
problem-focused coping (instrumental support, planning, and active coping) (431). Each item 
is scored on a four point ordinal scale ranging from 1 ‘I don’t do this at all’ to 4 ‘I have been 
doing this a lot’. 
2.2.5.7 Questionnaire Sections Not Used In This Study 
Four additional sections of the questionnaire were not used in this study, but were included as 
part of a collaborative study. These were: 
 Section 3 - The Chalder Fatigue Scale (CFS) 
 Section 7 - The Sino-Nasal Outcome Test-25 (SNOT-25) 
 Section 8 - The EQ-5D-3L 
 Section 10 - Assessment of Chronic Widespread Pain 
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2.3 Mechanistic Study 
2.3.1 Subjects 
Initially it was planned that patients from all three groups would also be enrolled into the 
mechanistic study. However, initial results of the questionnaire study indicated that there 
were unlikely to be major differences between the fatigue experienced by patients with AAV 
and that experienced by patients with CKD. In view of this, and in order to optimise the use 
of available testing time, the CKD disease control group was not included in the mechanistic 
study. All participants from the AAV and Healthy Control groups who completed the 
questionnaire study were screened for eligibility for the mechanistic study, and if they 
fulfilled inclusion criteria and were not excluded by the additional exclusion criteria (see 
below) they were given the relevant information leaflets to take away and read for a 
minimum of 24 hours, following which they were contacted and offered the opportunity to 
participate. 
2.3.2 Sample Size 
The aim for the mechanistic study was to recruit 50 participants to each of the AAV and 
healthy groups. This sample size was determined on the basis of power analyses (G-power, 
v3.01), imputing moderate to large effect sizes (r=0.40 - 0.60). The projected effect size was 
based on prior research using comparable methods (327), on clinical relevance (i.e., weak 
associations between fatigue markers and clinical characteristics are unlikely to inform 
effective interventions), and on the basis of the existing literature on fatigue in other 
inflammatory conditions (94, 432). On the basis of published data (324), it was anticipated 
that approximately 80% of patients with AAV would report fatigue compared to 20% in the 
healthy population. With the intended sample size of 50 participants per group, and taking a 
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conventional α of 0.05 into account, an effect size of 0.40 would give 97% power to detect an 
effect between groups in analyses of variance and 97% power to detect an effect between 
groups in multiple regression analyses. 
2.3.3 Inclusion and Exclusion Criteria 
Because all of the participants in the mechanistic study comprised a sub-population of those 
in the questionnaire study, all of the same inclusion and exclusion criteria applied. However 
in view of the nature of the tests included in the mechanistic study, the following additional 
exclusion criteria were applied: 
 Any proven or suspected acute coronary syndrome within the last six months, defined 
by the American College of Cardiology and American Heart Association (433) as 
either: 
o Unstable angina – angina commencing when the patient is at rest, or of new-
onset (less than 2 months), or of increasing intensity, duration, and/or 
frequency; 
o Non-ST Elevation Myocardial Infarction; 
o ST Elevation Myocardial Infarction. 
This exclusion was necessary to reduce the risk of adverse events, particularly during 
exercise testing. 
 Known moderate or severe aortic stenosis (AS), as defined by the American College 
of Cardiology (valvular cross-sectional area of less than 1.5cm2, mean trans-valvular 
gradient greater than 25 mm Hg, or jet velocity greater than 3.0m/s) (434). This 
exclusion was necessary both because of the risk of adverse events during exercise, 
and also because of the association between significant AS and fatigue. Screening for 
AS was done by clinical assessment and by examination of the medical notes at the 
80 
time of recruitment; routine pre-study echocardiograms were not deemed necessary 
because in the absence of symptoms and signs it is unlikely that a patient would have 
AS in the moderate or severe categories.  
 Pregnancy, which would have been a contra-indication for the radiation involved in 
DEXA-scanning. 
 Severe musculoskeletal problems or levels of general debility that were deemed likely 
to impede participation in any of the investigations. 
 Severe deafness, which would have made participation in the Paced Auditory Serial 
Attention Test impossible. 
 Stage V CKD, whether on dialysis or pre-dialysis, because this would have been a 
major confounding factor in interpreting the results of many of the tests. This was felt 
to be particularly important once the decision was made no longer to recruit patients 
with CKD to the mechanistic study. 
2.3.4 Physiological Investigations 
Subjects underwent a series of tests of muscular and cardiovascular function. All of the tests 
conducted were volitional, so that each allowed assessment of both peripheral and central 
mechanisms. 
2.3.4.1 Muscle Strength and Voluntary Activation 
Muscle function was assessed by the participants performing a series of maximal isometric 
voluntary contractions (MVC) of the quadriceps on their dominant side, utilising the twitch 
interpolation technique (168, 435) to assess the extent of voluntary activation and theoretical 
maximal strength. 
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Figure 2.1: Participant in position for muscle testing. 
Participant has adopted the position described in the text, the self-adhesive carbon-rubber electrodes have been 
applied to the dominant leg quadriceps muscle, and the strain gauge attached to the ipsilateral ankle. 
 
Participants sat upright, firmly strapped into an isometric testing chair (436) with hip and 
knee at 90° flexion. Self-adhesive carbon-rubber electrodes (American IMEX, USA, 4x7 
inches) were affixed to the skin over the mid and proximal regions of the quadriceps, and a 
strain gauge attached to the ankle (see Figure 2.1). The force was recorded digitally by a 
Micro1401-3 data acquisition unit (Cambridge Electronic Design (CED), UK). 
In preparation for testing, the maximum tolerated electrical stimulation (ES) was then 
determined at rest using square wave doublet pulses, each of 50µs duration with a 10-ms 
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inter-stimulus gap, delivered via the electrodes by an electrical stimulator (168) (Digitimer 
DS7AH High Voltage Constant Current Electrical Stimulator, UK) and the force response 
measured.  The amplitude of the stimulus was increased in 50mA increments (starting at 
150mA) until either no additional force was generated or the subject’s tolerance was reached. 
This final current, the ‘maximal intensity doublet’, was used for electrical stimulation during 
subsequent testing.  
A minimum of 3 MVCs were performed (up to a maximum of five if required for 
consistency), separated by one-minute rest periods.  The electrical stimulation was delivered 
first at rest, and then super-imposed on the MVC three seconds after the start of the 
contraction. Participants could see the force record and received strong verbal encouragement 
to make a maximal effort. Spike2 software (CED, UK) was used for data analysis. 
As illustrated in Figure 2.2, four measurements were made from the force records: 
1. The force generated by electrical stimulation at rest (Ti); 
2. The greatest voluntary force exerted before the superimposed stimulus (F0, 
designated the MVC force); 
3. The voluntary force measured immediately prior to the super-imposed stimulation 
(F1); 
4. The additional force, i.e. the force above F1, generated by the superimposed electrical 
stimulus (Ts). 
83 
 
Figure 2.2: A typical MVC with twitch interpolation. 
Ti = response from a resting electrical stimulation; Ts = response from electrical stimulation super-imposed on a 
MVC; F0 = maximal voluntary contraction force; F1 = voluntary power just prior to superimposed stimulation. 
 
These direct measurements were then used to calculate the two primary outcome variables: 
1. ‘Voluntary Muscle Activation’. This is a measure of how fully the individual activates 
their muscle of their own volition, derived from the ratio of response to stimulation 
super-imposed on the voluntary contraction to that in the resting condition, expressed 
as a percentage: 
Voluntary Muscle Activation = [1-(Ts/Ti)] x 100 
 
2. ‘Theoretical Maximal Contraction (TMC)’, derived from the percentage voluntary 
muscle activation and the measured voluntary strength.  
Theoretical Maximal Contraction = [F1 / voluntary muscle activation] x 100. 
 
Ti 
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Voluntary Activation = [1-(Ts/Ti)] x 100 
TMC = [F1 / voluntary activation] x 100 
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2.3.4.2 Muscle Endurance 
A large variety of different techniques have been used to assess peripheral muscle fatigue or 
endurance, but they may be roughly divided into those studies which have examined a 
sustained sub-maximal contraction (437), those which have used repeated maximal strength 
contractions (438), and those which have used a combination of both (140, 439). As 
described in Chapter 1, the fatigue of chronic disease is often reported at rest or after 
extremely low levels of physical exertion, and it is not effectively relieved by a period of rest. 
It therefore seems unlikely that fatigue in AAV is related to the use of high-power fast-twitch 
motor units, and so for this study it was decided to investigate prolonged sub-maximal 
exertion in an attempt to more closely replicate real-life scenarios. 
Participants were asked to maintain a single sustained quadriceps contraction at 50% of their 
MVC force for as long as possible, using the same limb tested for strength and voluntary 
activation.  Participants matched the force trace to a ‘50% target’ on the computer screen and 
received strong verbal encouragement to continue.  The end point was either volitional 
fatigue or when the force fell more than 5% below the target for three seconds.  The muscles 
were electrically stimulated as described above every 10s during the contraction to monitor 
the level of voluntary activation. The outcome measures for this test were: 
1. Endurance Time - the time for which the participants were able to maintain a 50% 
MVC; 
2. Muscular Reserve - The ratio of the response to the last superimposed ES before task 
failure compared with the response to the resting stimulation. This ratio indicates the 
proportion of muscle that is able to contract in addition to that being used to achieve 
the 50% target.  If, at the point of task failure the superimposed stimulus evoked no 
additional force the muscle reserve would also be zero and the fatigue would be 
considered of entirely peripheral origin.  If the superimposed stimulus was a quarter 
85 
of the resting doublet then the muscle reserve would be 25%, indicating a substantial 
failure of central activation.  The greater the muscular reserve at the point of task 
failure, the greater the extent of central fatigue. 
2.3.4.3 Body Composition 
Body Composition was measured by dual energy x-ray absorptiometry (DEXA; Hologic 
Discovery A QDR Bone Densitometer, Massachusetts, USA) (440, 441).  Bone, lean and fat 
mass were calculated for the whole body and for each limb. 
2.3.4.4 Incremental Submaximal Exercise Test 
Participants undertook a 10 minute incremental exercise protocol on a cycle ergometer (Lode, 
Groningen, the Netherlands), beginning with a 1 minute warm-up at a workload of 10W, 
followed by 3 minute periods at 25W, 50W and 75W. Oxygen uptake (V̇O2) was recorded 
continuously with an on-line gas analysis system (MOXUS, AEI Technologies, USA). Heart 
rate was monitored continuously with a Polar T31 Coded Transmitter (see Figure 2.3). 
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Figure 2.3: Participant performing a submaximal exercise test. 
Participants were asked to rate their perception of exertion (RPE) during the last 30 seconds of each exercise 
stage, i.e. just before the transition to the next work load, using the Borg 6-20 RPE scale (442, 443). 
 
The outcome measures for this test were: 
 Cardio-respiratory fitness, which was assessed using two variables: 
o The Oxygen Pulse (O2 Pulse). This was determined as the slope of the linear 
regression of V̇O2 against heart rate using the data points at the end of each 
exercise period (444).  To allow for differences in body size of the 
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participants, the O2 Pulse was divided by lean body mass since, in healthy 
control subjects, O2 Pulse varies in a linear fashion with lean body mass; 
o Estimated maximum oxygen uptake (estimated V̇O2max). This was also 
estimated by extrapolating oxygen uptake as a function of heart rate, assuming 
it to be linear (445), to an estimated maximum heart rate calculated as [205.8 – 
(0.685x age)]. 
 Perception of exertion. This was also assessed in two ways: 
o The RPE at the end of the highest workload completed by the participant. 
o RPEindex. The Borg RPE scale was constructed based on the physiology and 
psychology of young healthy individuals, whose resting and maximum heart 
rates were assumed to be approximately 60bpm and 200bpm respectively. 
Many studies have shown that in such individuals there is a strong correlation 
(0.8-0.9) between heart rate and Borg RPE ratings at a ratio of ten to one - e.g. 
exertion sufficient to cause a heart rate of 170bpm would be rated as 17 on the 
RPE scale (446). However this relationship is not precise, and is influenced by 
many variables including age. Because the average age of the participants in 
this study was expected to be 60-70 years, many would be expected to have a 
maximum heart rate significantly below 200bpm, but a rating of ’20’ on the 
Borg RPE scale would still be expected to equate to an individual’s maximum 
heart rate in the absence of abnormally high central fatigue. Therefore, if the 
relationship between HR and RPE remains linear across all age groups, the 
following equation should always be true: 
 
𝐻𝑅 𝑎𝑡 𝐸𝑥ℎ𝑎𝑢𝑠𝑡𝑖𝑜𝑛 𝑜𝑟 𝐸𝑛𝑑 𝑜𝑓 𝐸𝑥𝑒𝑟𝑐𝑖𝑠𝑒
𝐴𝑔𝑒 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 max 𝐻𝑅
=
𝑅𝑃𝐸 𝑎𝑡 𝐸𝑥ℎ𝑎𝑢𝑠𝑡𝑖𝑜𝑛 𝑜𝑟 𝐸𝑛𝑑 𝑜𝑓 𝐸𝑥𝑒𝑟𝑐𝑖𝑠𝑒
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑅𝑃𝐸 (𝑖. 𝑒. 20)
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Rearranging these variables: 
 𝑅𝑃𝐸𝑖𝑛𝑑𝑒𝑥 =
𝑅𝑃𝐸 𝑎𝑡 𝐸𝑥ℎ𝑎𝑢𝑠𝑡𝑖𝑜𝑛 𝑜𝑟 𝐸𝑛𝑑 𝑜𝑓 𝐸𝑥𝑒𝑟𝑐𝑖𝑠𝑒 ×  𝐴𝑔𝑒 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑚𝑎𝑥 𝐻𝑅
𝐻𝑅 𝑎𝑡 𝐸𝑥ℎ𝑎𝑢𝑠𝑡𝑖𝑜𝑛 𝑜𝑟 𝐸𝑛𝑑 𝑜𝑓 𝐸𝑥𝑒𝑟𝑐𝑖𝑠𝑒 ×  20
 
 
2.3.5 Cognitive Performance 
A common complaint of individuals reporting chronic fatigue is the perceived inability to 
adequately perform cognitive tasks. In order to investigate whether this perceived problem 
was objectively measurable, subjects in the mechanistic study undertook a prolonged 
cognitive task which primarily tests attention, concentration, short-term recall, and executive 
function (Paced Auditory Serial Addition Test; PASAT). The test was performed at 4 speeds, 
using inter-digit intervals of 2.4s, 2.0s, 1.6s, and 1.2s and the number of correct responses 
was recorded. 
2.3.6 Laboratory analysis 
Serum samples were collected from participants at four time-points: a fasting morning sample 
was taken at rest between 9am and 10am, and non-fasting samples were taken at the end of 
the exercise, and at 1 hour and 2 hours post-exercise. These samples were allowed to sit 
undisturbed for between 30 minutes and one hour to allow the blood to clot, and the clot was 
then removed by centrifuging at 5,000rpm for ten minutes in a refrigerated centrifuge. The 
resultant serum was then apportioned into 500µl aliquots and stored at -800C for batch 
processing after all samples had been collected. 
2.3.6.1 Cytokine Analysis 
Samples from each of the four time-points were subsequently used to measure serum 
interleukin (IL)-1b, IL-1RA, IL-6, IL-8, IL-10 and TNF-α by multiplex luminex assay 
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according to the manufacturer’s instructions (Bio-Rad, UK). This process was carried out by 
colleagues in the Clinical Immunology Service at the University of Birmingham. Precise 
instructions for duplicating the process they followed are available from bio-rad at: 
http://www.bio-rad.com/webroot/web/pdf/lsr/literature/10044282.pdf 
2.3.6.2 Hormone Analysis 
Serum concentrations of cortisol, DHEA and DHEAS were also measured (in the fasting 
baseline samples only) using liquid chromatography/tandem mass spectrometry (447, 448). 
This technique is superior to radioimmunoassay because it avoids antibody cross-reactivity 
and allows the simultaneous measurement of multiple steroids with a high degree of accuracy 
(449). The analysis was carried out by colleagues in the Centre for Endocrinology, Diabetes 
and Metabolism (CEDAM) at the University of Birmingham, where methods and assays have 
been validated as described by Honour (450) so that the sensitivity of the system to each 
steroid, the accuracy, reproducibility, and extraction efficiency are known. 
The first step in the process was the extraction of steroids from the serum samples, a process 
which is different for cortisol/DHEA compared with that for DHEAS: 
 For cortisol/DHEA, 200μL of serum was pipetted into a silanized glass thin layer 
chromatography tube, and 20μL of internal standard solution was added. The tube 
was vortexed, 1ml of MTBE is added, and the tube vortexed again. After freezing for 
>30 minutes, the top layer was pipetted into a 96 well plate then evaporated to 
dryness under nitrogen at 55oC. The sample was then reconstituted in 125μL of 50/50 
methanol/water and centrifuged at 3000rpm for 10 minutes. The sample was then 
stored at -20oC until analysis. 
 To prepare for DHEA analysis, the above sample was then evaporated to dryness 
under nitrogen, and 100μL of hydroxylamine in pyridine (0.16g/8mL of pyridine) was 
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added. The plate was vortexed for 10 minutes, then centrifuged at 3000rpm for 10 
minutes, heated for 1.5hrs at 60oC, then centrifuged at 3000rpm for another 10 
minutes. The sample was evaporated to dryness under nitrogen, reconstituted in 
125μL of 50/50 Methanol/water, then centrifuged at 3000rpm for 10min. The sample 
was then stored at -20oC until analysis. 
 For DHEAS, 20μL of serum was pipetted into a low volume 96 well plate, followed 
by 20μL of internal standard, 20μL of zinc sulphate solution (0.1mmol/L) and 100μL 
of acetonitrile. The plate was placed for 10 minutes on a plate shaker, and then 
centrifuged at 3000rpm for a further 10 minutes. 100μL of supernatant was transferred 
into another plate, evaporated to dryness under nitrogen at 55oC, reconstituted in 
125μL of 50/50 methanol/water, then stored at -20oC until analysis. 
The samples then underwent liquid chromatography/tandem mass spectrometry in an 
automated process using a Waters Xevo (triple quadrupole) mass spectrometer. 
2.3.7 Statistical Analysis 
As with the questionnaire study, all analysis was carried out using IBM SPSS Statistics 21.0. 
Categorical data was summarised with percentages, and quantitative data was summarised 
with mean and standard error (SEM), or with median and interquartile range (IQR) according 
to normality of distribution. Comparisons of results between the groups were assessed using 
χ2 tests for categorical data and Mann-Whitney tests for quantitative data, and Spearman’s 
rank order correlation was used to assess the strength of associations between variables. 
Unless stated all correlations include both patients with AAV and healthy controls. 
Multivariable analysis was carried out using linear regression, having first confirmed that the 
distribution of the standardised residuals was normal. 
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3 RESULTS CHAPTER 1: WHICH PATIENT 
CHARACTERISTICS AND SYMPTOMS ARE 
PREDICTORS OF FATIGUE? 
3.1 Introduction 
One hundred and fifty two patients with AAV, sixty eight patients with CKD and seventy one 
healthy controls completed a questionnaire which consisted of a ‘Participant Characteristics’ 
section and several symptom-rating tools as outlined in Chapter 2. The questionnaire was 
designed with two purposes: firstly to assess the differences in severity and nature of fatigue 
and other symptoms between the three groups, and secondly to determine which 
characteristics and symptoms within the patient group were associated with greater or lesser 
severity of fatigue. 
Based on the experience of the investigating team it was predicted that the questionnaire 
would take around half an hour to complete, and in order to minimise inconvenience to the 
participants it was completed at home unsupervised. 
Data collection was almost 100% for simple sections where only a single response by the 
participant was required to generate data – for example only four participants did not give 
valid data on marital status (completion rate was 98.6% for all participants, 98.0% for 
patients with AAV, 100% for CKD patients, and 98.6% for healthy controls). For more 
complex sections the completion rates were lower, e.g. only 82.8% of participants provided 
enough responses for us to be sure about whether they participated in sport (84.9% of patients 
with AAV, 80.9% of participants with CKD, and 80.3% of healthy controls), but 
92 
encouragingly the completion rates were very similar across the three groups and this is 
therefore unlikely to have significantly influenced results. 
The completion rates for some of the important summary scores are shown in Table 3.1. The 
lowest completion rates obtained were for the summary scores which require the greatest 
number of valid responses in order to be calculated: for example, calculation of the Physical 
Component Score (PCS) of the MOS SF-36 requires valid responses to all 36 items on the 
scale, whereas calculation of General Fatigue on the MFI-20 requires only four valid 
responses. 
 All 
Participants 
AAV CKD Healthy 
General Fatigue 95.5 95.4 98.5 93.0 
Physical Fatigue 95.2 95.4 97.1 93.0 
Mental Fatigue 95.9 96.1 98.5 93.0 
Reduced Activity 94.5 95.4 95.6 91.5 
Reduced 
Motivation 
95.9 96.1 98.5 93.0 
Anxiety 96.2 96.1 100 93.0 
Depression 96.6 96.1 100 94.4 
Physical Component 
Score (PCS) 
77.7 80.3 70.6 78.9 
Mental Component 
Score (MCS) 
77.7 80.3 70.6 78.9 
Global PSQI Score 86.9 86.8 85.3 88.7 
Table 3.1: Completion rates for the symptom-rating scales in the questionnaire. 
Percentage of participants giving enough valid answers to generate summary scores for the main symptom-
rating tools included in the questionnaire. Results are expressed as percentage of all participants in the study and 
of all participants in each group. General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Activity and 
Reduced Motivation – Multi-dimensional Fatigue Inventory (MFI-20); Anxiety and Depression – Hospital 
Anxiety and Depression Scale (HADS); PCS and MCS – MOS SF-36; Global PSQI Score – Pittsburgh Sleep 
Quality Index. 
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3.2 Participant Characteristics 
As shown in Table 3.2, there were no significant differences between any of the groups for 
age, gender or ethnicity, and nor was there any difference in the proportion of subjects across 
the groups who had a living partner. 
 AAV CKD Healthy Significance 
n 152 68 71 - 
Age (yrs) 
63.1 (49.8-
71.5) 
64.4 (47.8-75.2) 61.9 (49.8-67.0) 0.355 
Male Gender 73 (48.0%) 39 (57.4%) 35 (49.3%) 0.429 
White Ethnicity 141 (92.8%) 61 (89.7%) 66 (93.0%) 0.530 
Living Partner 102 (67.5%) 48 (70.6%) 56 (78.9%) 0.221 
Age Left 
Education (yrs) 
16 (15-18) 16 (15-18) 18 (16-22) <0.001 
Obtained a 
University Degree 
18 (12.1%) 8 (11.8%) 27 (39.7%) <0.001 
Currently 
Working/Studying 
51 (34.2%) 27 (39.7%) 33 (48.5%) 0.133 
Current Smoker 14 (9.3%) 10 (14.7%) 3 (4.3%) 0.109 
Caffeine Intake 
(g/Wk) 
1.8 (0.9-2.5) 1.6 (0.9-2.4) 1.8 (1.2-2.4) 0.592 
Alcohol Intake 
(Units/Wk) 
1.5 (0-9.0) 1.8 (0-9.8) 4.8 (0-16.4) 0.035 
Involved in 
Exercise or Sport 
62 (48.1%) 21 (38.2%) 40 (70.2%) 0.002 
Hb (g/l) 132 (125-140) 127.5 (117-138) 139 (131-149) <0.001 
eGFR 
(ml/min/1.73m2) 
61.0 (37.0-
75.5) 
38.8 (27.0-56.0) 79.0 (71.0-90.0) <0.001 
Disease duration 
(months) 
68 (29-120) - - - 
VDI 4 (3-6) - - - 
Table 3.2: Characteristics of the study participants by group.  
‘Male Gender’, ‘White Ethnicity’, ‘Living Partner’, ‘Obtained a University Degree’, ‘Currently 
Working/Studying’, ‘Current Smoker’ and ‘Involved in Exercise or Sport’ are expressed as number of 
participants and as percentage of valid responses; other results expressed as median with IQR. eGFR = 
estimated GFR, calculated using Modification of Diet in Renal Disease (MDRD) formula; VDI = Vasculitis 
Damage Index. Significant differences across the three groups are highlighted in bold. 
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Table 3.3 shows the most important disease-specific characteristics of the AAV group. As 
shown, the vast majority (86.2%) of participants had a documented diagnosis of either GPA 
or MPA; 7.2% had a biopsy-proven diagnosis of AAV but no precise phenotypic diagnosis 
given by the clinical team. 88 participants had renal involvement, of who 17 remained 
dialysis-dependent, and 65 had lung involvement. Table 3.4 (on the next page) details the 
demographic characteristics of the patients with AAV who had a documented diagnosis of 
either GPA or MPA. 
 Number and Percentage of Participants 
GPA 89 (58.6%) 
MPA 42 (27.6%) 
eGPA 6 (3.9%) 
Renal-Limited AAV 4 (2.6%) 
Other or Uncertain Diagnosis 11 (7.2%) 
Renal Involvement 88 (57.9%) 
Dialysis-Dependent 17 (11.2%) 
Lung Involvement 65 (42.8%) 
ENT Involvement 70 (46.1%) 
Joint Involvement 37 (24.3%) 
Peripheral Nerve Involvement 28 (18.4%) 
Previous Exposure to Cyclophosphamide 108 (71.1%) 
Currently on Prednisolone 
131 (86.2%) 
(Median dose 5mg, IQR 2.5-5) 
Table 3.3: Disease-specific characteristics of the AAV group 
Results are expressed as absolute number, with percentage of all patients with AAV in brackets. ‘Other or 
Uncertain Diagnosis’ includes three participants who were felt to have drug-induced AAV, and the rest had a 
documented diagnosis of AAV but without a specific phenotypic diagnosis. 
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 GPA MPA Significance 
n 89 42 - 
Age (yrs) 58.1 (46.5-67.7) 68.9 (61.2-76.2) <0.001 
Male Gender 46 (51.7%) 14 (33.3%) 0.049 
White Ethnicity 84 (94.4%) 39 (92.9%) 0.734 
Living Partner 62 (70.5%) 29 (69%) 0.870 
Age Left Education 
(yrs) 
16 (15-18) 16 (15-17) 0.240 
Obtained a 
University Degree 
10 (11.4%) 3 (7.5%) 0.502 
Currently 
Working/Studying 
33 (37.9%) 11 (26.8%) 0.217 
Current Smoker 10 (11.4%) 1 (2.4%) 0.085 
Caffeine Intake 
(g/Wk) 
1.8 (0.7-2.1) 1.8 (1.2-2.8) 0.124 
Alcohol Intake 
(Units/Wk) 
1.5 (0-9.0) 1.5 (0-5.0) 0.289 
Involved in Exercise 
or Sport 
42 (52.5%) 11 (36.7%) 0.139 
Hb (g/l) 135 (126-142) 127 (119-134) 0.008 
eGFR 
(ml/min/1.73m2) 
63.0 (47.5-75.5) 41.5 (26.0-69.0) 0.004 
Disease duration 
(months) 
76 (38-126) 74.5 (24.5-115) 0.527 
VDI 4 (3-7) 5 (3-6) 0.997 
Table 3.4: Characteristics of the patient group with AAV by phenotypic diagnosis.  
‘Male Gender’, ‘White Ethnicity’, ‘Living Partner’, ‘Obtained a University Degree’, ‘Currently 
Working/Studying’, ‘Current Smoker’ and ‘Involved in Exercise or Sport’ are expressed as number of 
participants and as percentage of valid responses; other results expressed as median with IQR. eGFR = 
estimated GFR, calculated using Modification of Diet in Renal Disease (MDRD) formula; VDI = Vasculitis 
Damage Index. Significant differences are highlighted in bold. 
 
As shown, patients with GPA were significantly younger and more likely to be male than 
those with MPA. They also had significantly better Hb and eGFR, but any other differences 
were not significant – in particular they were not significantly more likely to be involved in 
exercise. 
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3.2.1 Education and Employment 
Better education, which has previously been associated with lower levels of fatigue (451), 
was assessed in our questionnaire by the participants’ age of leaving the education system 
and by the percentage of participants who had attained formal qualifications. There was no 
difference in school-leaving age between the AAV and CKD disease groups (p=0.225), but 
mean school-leaving age in the healthy group was significantly higher (p<0.001) than in 
either disease group. Likewise, there was no difference in the proportion of patients with 
university degrees between the two disease groups (p=0.571), but healthy controls were 
significantly more likely to have obtained a university degree (p<0.001) compared with either 
of the other groups. Disease duration could not have accounted for this difference, as most 
patients were not affected by the disease in childhood or early adulthood, and the difference 
is probably largely due to the recruitment of hospital and university employees into the 
healthy control group. Studies have also previously found that educational attainment has an 
influence on enrolment in research (452). 
Although there was no overall significant association between study group and the likelihood 
of currently being in employment or education (as shown in Table 3.2), direct comparison 
between the AAV and healthy groups showed that patients with AAV were less likely to be 
currently working or studying (p=0.045); this could be important, as there have been links in 
previous studies between employment status and fatigue (85, 453). 
3.2.2 Lifestyle 
Smoking status was asked for because it has been associated with fatigue previously (454, 
455), perhaps due to carbon monoxide hampering the delivery of oxygen to muscle 
mitochondria (456). Overall in this study there was no significant difference in smoking 
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status between the groups, although sub-analysis showed that those in the CKD group were 
significantly more likely to be current smokers than those in the healthy group (p=0.034). 
Questionnaire participants were asked to estimate their intake of both caffeine and alcohol. 
There is evidence that antagonism of adenosine receptors in the brain by caffeine can reduce 
fatigue, particularly in the setting of exercise (457), and it is widely used in Western society 
as a way of reducing tiredness. It exhibits a U-shaped dose-response curve, with generally 
positive effects on attention and concentration at lower doses but decreases in performance 
and higher levels of anxiety with higher dose, and there is evidence of greater effects in 
fatigued than non-fatigued individuals (458). Participants were asked how many cups of 
coffee and tea they consumed in a typical week, with weekly caffeine intake calculated by 
assuming the average caffeine content of a cup of coffee or tea to be 100mg and 50mg 
respectively; as shown in Table 3.2 no differences in intake were seen between the groups. 
Self-reported alcohol intake in units per week was also calculated, with the alcohol content of 
drinks assumed to be 1.5 units for a small glass of wine (125ml), 1 unit for a measure of 
fortified wine (50ml), 2.5 units for a pint of beer or cider, and 1 unit for a 25ml measure of 
spirits or a 50ml measure of liqueur. A significant association was found between participant 
group and alcohol intake, with the healthy control group admitting to around three times the 
alcohol consumption of the CKD and AAV groups (p=0.01 for AAV vs healthy group, 
p=0.077 for CKD vs healthy group). The explanation for this might be that the patients had 
been told by their doctors that they must not drink excessive amounts of alcohol due to the 
medications they were on, or that the patients themselves perceived that to be the case – for 
example those on prednisolone might have been concerned about the increased risk of 
gastritis or peptic ulcers caused by the combination of alcohol and oral steroids. They might 
even have thought that simply having AAV or CKD means they should drink less alcohol. 
However the effects of alcohol are in many respects similar to those of fatigue, particularly 
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with regards to the reduction they cause in attention and concentration (459), so perhaps 
patients were avoiding excessive intake so as not to make their fatigue symptoms worse. 
Activity levels were much lower than had been anticipated when the questionnaire was 
designed, so responses to questions 21-28 in Section 1 were dichotomised to ‘not involved’ 
(participant answered ‘Never’) or ‘involved’ (participant gave any of the other possible 
answers). The responses to involvement in jogging or running, swimming, cycling, and 
exercise or dance classes (and ‘other’ if appropriate) were then analysed together as 
‘involvement in exercise or sport’; as shown, the CKD group were found to be the most 
sedentary and the healthy control group were the most active (p=0.005 for AAV vs healthy 
and p=0.001 for CKD vs healthy). It may be that patients were more sedentary than healthy 
controls because the severity of their baseline fatigue made them feel disinclined to engage in 
sport and exercise. Alternatively, perhaps they were actively avoiding exercise because their 
previous experience told them that they could avoid developing significant fatigue if they did 
so. An alternative explanation might be the variability of knowledge about and attitudes 
towards fatigue amongst physicians and other health care workers. In clinic, physicians are 
frequently asked by fatigued patients for advice on how best to manage the symptom, and it 
would not be surprising if some had been advising their patients that they should conserve 
energy by not exerting themselves excessively.  
3.2.3 Biological Factors 
Anaemia and renal impairment are causes of fatigue, and in the present study Hb and eGFR 
in the AAV group were both significantly lower than in the healthy group (p=0.001 for Hb 
and p<0.001 for eGFR) but significantly higher than in the CKD group (p=0.026 for Hb and 
p<0.001 for eGFR). 
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3.3 The Severity of Fatigue in AAV 
The severity of subjective fatigue symptoms were assessed using the Multi-Dimensional 
Fatigue Inventory (MFI-20). Responses from the three groups are illustrated in Figure 3.1, 
with median scores and interquartile ranges shown for the five different dimensions of 
fatigue. Scores across all dimensions of fatigue were significantly higher in both of the 
disease groups compared with healthy controls (p<0.001 for all comparisons, except p=0.011 
for CKD vs healthy in Mental Fatigue), indicating that both disease groups experience much 
more subjective general, physical and mental fatigue, as well as greater reductions in self-
reported activity and motivation. There is no ‘overall’ or ‘total’ score for fatigue in the MFI-
20, and it has been previously suggested that the General Fatigue score should be used when 
a single score is desired to compare groups (113, 118); the General Fatigue scores of the 
AAV group (median=15, IQR=12-17) were significantly greater than those of the CKD group 
(median=13, IQR=10-16, p=0.013), although differences between the scores of the two 
disease groups were not significant for the other four dimensions of fatigue. 
There is no cut-off for the presence or absence of fatigue in the MFI-20, so in order to assess 
the prevalence of severe fatigue in the AAV and CKD groups patients were dichotomised 
into ‘fatigued’ and non-fatigued’ according to their General Fatigue score, using the 95th 
centile of the healthy control group as the threshold of excessive or severe fatigue. Using the 
resultant threshold score of ≥16, the prevalence of severe fatigue was 42.8% in the AAV 
group and just 29.9% in the CKD group, although this difference was not statistically 
significant (p=0.073). 
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Figure 3.1: Median values and IQR for the 5 dimensions of fatigue on the MFI-20. 
Bars indicate median, boxes indicate the interquartile range, whiskers indicate the range, and dots represent outliers (values greater than 1.5 interquartile ranges away from 
the 25th or 75th percentiles). 
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3.3.1 Were Patients With MPA More Fatigued Than Patients with GPA? 
As described previously, those patients with AAV in the study who had a phenotypic 
diagnosis of GPA had significantly higher Hb and eGFR than those with a diagnosis of MPA, 
and they were also younger. In view of these differences, it seemed possible that the MPA 
subgroup might be much more fatigued than the GPA subgroup, but as the results in Table 
3.5 show, the only difference between the groups was that patients with MPA reported 
slightly worse motivation. Because there is so little difference in fatigue or self-reported 
activity levels (see Table 3.4) between the two groups, the patients with AAV were analysed 
as a single group in the remainder of this thesis. 
 
GPA MPA Significance 
General Fatigue 15 (12-18) 14 (12-17) 0.581 
Physical Fatigue 14 (10-17) 14.5 (10-17) 0.427 
Mental Fatigue 10 (5-14) 10 (6-13) 0.859 
Reduced Activity 11.5 (8-14) 12 (8.5-15.5) 0.283 
Reduced Motivation 10 (7-12) 12 (8-14) 0.020 
Table 3.5: Differences in fatigue between  patients with GPA and MPA.  
Median values and IQR are shown for the 5 dimensions of fatigue on the MFI-20. Comparisons are shown 
between patients with with GPA and those with MPA, with significant differences highlighted in bold. 
 
3.4 The Qualitative Nature of Fatigue in AAV 
Because the MFI-20 splits fatigue symptoms into five different dimensions, it may also be 
used to inform about the quality or nature of the fatigue experienced by respondents. Sample 
statements taken from the questionnaire which help to illustrate the differences between the 
five dimensions are: “I feel tired” (General Fatigue), “Physically I feel only able to do a 
little” (Physical Fatigue), “It takes a lot of effort to concentrate on things” (Mental Fatigue), 
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“I think I do very little in a day” (Reduced Activity) and “I dread having to do things” 
(Reduced Motivation). As shown in Figure 3.1, symptoms of Physical Fatigue were much 
more severe for both the AAV and the CKD groups than were symptoms of mental fatigue, 
and the self-reported impact of fatigue on activity was greater than the impact on motivation; 
this suggests that the fatigue experienced in both AAV and CKD has a very physical quality. 
Becoming fatigued on occasion is a normal part of life for healthy people, and the 
multidimensionality of the MFI-20 allows the nature of this fatigue to be examined. In 
comparison to the AAV and CKD groups, the healthy control group reported Mental Fatigue 
symptoms that were slightly more severe than their physical fatigue symptoms, and a 
marginally greater impact of fatigue on motivation than on activity, which suggests that there 
might be something different about the fatigue experienced in AAV and CKD compared with 
that experienced by healthy people in every-day life. This is in keeping with previous 
research in RA (102, 379) where patients have described the fatigue related to their disease as 
being fundamentally different from the fatigue they experienced in health before the onset of 
their disease. However although in that research patients described sudden episodes of 
physical ‘wipeout’, the authors highlighted differences in the predictability and chronicity of 
fatigue in RA rather than a more physical nature to the symptoms per se. 
3.5 Health-Related Quality Of Life (HRQOL) 
Table 3.6 shows the median scores for the 8 sub-scales and two summary scores of the MOS 
SF-36 for each of the three groups. It should be remembered that, in contrast to all of the 
other symptom scales used in this study, higher scores on the SF-36 indicate better condition 
– for example, a higher score on the PF subscale indicates better physical functioning. 
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 AAV CKD 
AAV vs 
CKD 
Healthy 
AAV vs 
Healthy 
Physical 
functioning (PF) 
55 (32.5-80) 60 (40-90) 0.401 95 (85-100) <0.001 
Role Physical 
(RP) 
25 (0-75) 62.5 (0-100) 0.030 
100 (100-
100) 
<0.001 
Bodily Pain (BP) 62 (41-84) 62 (41-74) 0.350 84 (72-100) <0.001 
General Health 
(GH) 
42 (21-62) 45 (25-67) 0.379 82 (72-92) <0.001 
Vitality (VT) 45 (30-55) 50 (30-65) 0.357 80 (62.5-85) <0.001 
Social 
Functioning (SF) 
75 (50-100) 
87.5 
(62.5-100) 
0.454 
100 (100-
100) 
<0.001 
Role Emotional 
(RE) 
100 (0-100) 100 (0-100) 0.278 
100 (100-
100) 
<0.001 
Mental Health 
(MH) 
68 (52-84) 74 (62-88) 0.077 84 (76-92) <0.001 
Physical 
Component Score 
(PCS) 
38.7 
(26.9-48.4) 
39.0 
(30.3-50.9) 
0.280 
54.7 
(49.8-56.7) 
<0.001 
Mental 
Component Score 
(MCS) 
50.2 
(39.4-56.9) 
52.5 
(40.4-58.7) 
0.538 
56.2 
(52.7-58.4) 
<0.001 
Table 3.6: Health-related Quality of Life by SF-36 domains. 
Median values and IQR are shown for the 8 domains and the two summary scores of the SF-36. Comparisons 
are shown between the AAV group and the other two groups, with significant differences highlighted in bold. 
 
Across all eight domains of the SF-36 and both of the summary scores (PCS and MCS), both 
of the disease groups reported much poorer HRQOL than the healthy group (p<0.001 for all 
comparisons). Comparing the two disease groups, the only significant difference was that the 
AAV group reported greater role limitations due to physical health (RP) (p=0.03) (see also 
section 3.6). 
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3.5.1 Did Fatigue Significantly Influence Health-Related Quality Of Life? 
Table 3.7 shows the correlations found between the five domains of the MFI-20 and the 8 
primary domains and two summary scores of the SF-36 when participants from all groups 
were included in the analysis; all of the correlations shown were significant at the level of 
p<0.001 and, as indicated, the majority were very strong correlations of rs>0.5. When 
considering the patients with AAV only, analysis showed that all correlations remained 
significant at the level of <0.001 except for those between Mental Fatigue and PF (rs=-0.173, 
p=0.051), Mental Fatigue and RP (rs=-0.231, p=0.007), Mental Fatigue and PCS (rs=-0.143, 
p=0.122), and Reduced Activity and MCS (rs=-0.264, p=0.004). It is unsurprising that Mental 
Fatigue correlated less strongly with Physical Functioning and the Physical Component Score 
of the SF-36 than with the mental aspects of HRQOL, and as a whole these results suggest 
that fatigue is a major cause of reduced HRQOL in AAV, supporting reports in the existing 
literature (324). Importantly, they also show a very strong association between fatigue and 
both pain (measured by the Bodily Pain domain of the SF-36) and psychological health 
(measured by the Mental Health domain) in our patients with AAV. This may indicate that 
bodily pain is one of the causes of increased fatigue in AAV, although it could also be argued 
that severe fatigue might itself increase the perception of pain. The relationship between 
fatigue and mental health will be explored further in Section 3.9.1. 
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SF-36 MFI-20 
 
General 
Fatigue 
Physical 
Fatigue 
Mental 
Fatigue 
Reduced 
Activity 
Reduced 
Motivation 
Physical functioning 
(PF) 
-0.672 -0.791 -0.314 -0.695 -0.582 
Role Physical (RP) -0.644 -0.686 -0.376 -0.639 -0.543 
Bodily Pain (BP) -0.495 -0.568 -0.305 -0.468 -0.407 
General Health 
(GH) 
-0.753 -0.835 -0.418 -0.664 -0.624 
Vitality (VT) -0.857 -0.777 -0.489 -0.696 -0.655 
Social Functioning 
(SF) 
-0.643 -0.650 -0.496 -0.587 -0.594 
Role Emotional (RE) -0.510 -0.463 -0.479 -0.463 -0.457 
Mental Health (MH) -0.554 -0.452 -0.585 -0.398 -0.476 
Physical Component 
Score (PCS) 
-0.681 -0.804 -0.315 -0.696 -0.547 
Mental Component 
Score (MCS) 
-0.568 -0.415 -0.574 -0.382 -0.493 
Table 3.7: Correlations between fatigue (MFI-20) and health-related quality of life (SF36). 
Correlations (rs) are shown between the five domains of the MFI-20 and the 8 primary domains and two 
summary scores of the SF-36. Correlations of >0.5 are considered particularly significant and are highlighted in 
bold. All correlations were significant at the level of <0.001. 
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3.6 Fatigue and Role Impairment 
The SF-36 results (section 3.5) revealed that both of the disease groups experienced 
significant role impairments due to their physical health (SF-36 RP), and also that these role 
impairments correlated strongly with severity of fatigue across all domains of the MFI-20. 
However the questions in the SF-36 questionnaire do not allow investigators to separate 
whether these role impairments are due to fatigue or other physical problems or symptoms. 
The direct effect of fatigue on life roles was therefore explored further in a modified version 
of the Piper Fatigue Scale, the results of which are shown in Table 3.8. Both disease groups 
experienced severe role impairments as a direct result of chronic fatigue across all aspects of 
their working, family and social life which were highly significant when compared to the 
healthy group. Although the AAV group reported more severe impairment of all roles than 
did the CKD group, none of the comparisons were statistically significant. 
 
 AAV CKD 
AAV vs 
CKD 
Healthy 
AAV vs 
Healthy 
Work or School 4 (1.5-7) 2 (1-6) 0.241 1 (1-2) <0.001 
Socialising with 
Friends or 
Family 
3 (1-7) 2 (1-5) 0.345 1 (1-1) <0.001 
Sex Life 5 (1-9) 4 (1-8) 0.259 1 (1-2) <0.001 
Enjoyable 
Activities 
6 (2-8) 3 (1-8) 0.081 1 (1-2) <0.001 
Activities of Daily 
Living (ADLs) 
4 (2-7) 2 (1-6) 0.051 1 (1-2) <0.001 
Table 3.8: Impact of fatigue on professional, family and social life. 
Results shown are for the modified Piper Fatigue scale, where scores range from 0 (‘No impact’) to 10 
(‘Greatest possible impact’). Median scores (with IQR) are shown, and statistically significant results are 
highlighted in bold. 
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3.7 Which Participant Characteristics Influenced Fatigue? 
 
General 
Fatigue 
Physical 
Fatigue 
Mental 
Fatigue 
Reduced 
Activity 
Reduced 
Motivation 
rs p rs p rs p rs p rs p 
Age (yrs) -0.003 0.959 0.197 0.001 -0.162 0.007 0.277 
<0.00
1 
0.172 0.004 
Female 
Gender 
0.193 0.001 0.096 0.113 0.029 0.634 0.017 0.778 0.005 0.933 
Ethnicity 0.074 0.216 0.020 0.745 0.042 0.486 0.029 0.634 0.006 0.918 
No Living 
Partner 
0.161 0.007 0.164 0.006 0.121 0.044 0.136 0.024 0.191 0.001 
Age Left 
Education  
-0.200 0.001 -0.292 
<0.00
1 
-0.48 0.423 -0.284 
<0.00
1 
-0.259 
<0.00
1 
Obtained 
University 
Degree 
-0.207 0.001 -0.235 
<0.00
1 
-0.055 0.365 -0.194 0.001 -0.185 0.002 
Unemploy
-ed 
0.181 0.003 0.304 
<0.00
1 
0.028 0.638 0.350 
<0.00
1 
0.195 0.001 
Current 
Smoker 
0.091 0.129 0.146 0.015 0.063 0.296 0.143 0.018 0.162 0.007 
Caffeine 
Intake  
-0.041 0.499 -0.33 0.588 -0.094 0.120 -0.041 0.498 -0.071 0.241 
Alcohol 
Intake  
-0.247 
<0.00
1 
-0.291 
<0.00
1 
-0.089 0.141 -0.278 
<0.00
1 
-0.240 
<0.00
1 
Exercise 
or Sport 
-0.255 
<0.00
1 
-0.361 
<0.00
1 
-0.045 0.494 -0.345 
<0.00
1 
-0.210 0.001 
Hb (g/l) -0.291 
<0.00
1 
-0.264 
<0.00
1 
-0.078 0.211 -0.253 
<0.00
1 
-0.161 0.010 
eGFR  -0.240 
<0.00
1 
-0.355 
<0.00
1 
-0.038 0.556 -0.428 
<0.00
1 
-0.244 
<0.00
1 
Disease 
duration  
-0.004 0.964 0.044 0.618 -0.084 0.338 -0.004 0.965 -0.020 0.820 
VDI 0.141 0.162 0.362 
<0.00
1 
0.035 0.732 0.258 0.010 0.180 0.073 
Table 3.9: Correlations between participant characteristics and MFI-20 scores. 
Study participants from all three groups are included in these correlations. Significant correlations (p<0.05) are 
highlighted in bold. 
 
Table 3.9 shows the univariate correlations that were found between the five dimensions of 
fatigue on the MFI-20 and each of the participant characteristics when the participants from 
all three study groups were analysed together. Since the healthy group had much lower levels 
of fatigue in all five dimensions than the two disease groups, there was a concern that 
differences in the characteristics between the healthy group and the disease group could lead 
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to misleading results, so univariate correlations were also performed using only the 
participants in the AAV group, as detailed in each subsection below. 
3.7.1 Participant Demographics 
When participants from all three groups were analysed together, positive correlations were 
found between participant age and Physical Fatigue, Reduced Activity and Reduced 
Motivation, in keeping with existing literature (451) but a negative correlation was found 
between age and Mental Fatigue, and the results were very similar whenever only AAV 
participants were included in the analysis (rs=0.163, p=0.05 for Physical Fatigue; rs=0.252, 
p=0.002 for Reduced Activity; rs=0.161, p=0.052 for Reduced Motivation; rs=-0.273, 
p=0.001 for Mental Fatigue). The positive correlation with Physical Fatigue and Reduced 
Motivation might be explained by the natural reduction in physical reserve (particularly 
cardiovascular) seen with increasing age, and one explanation for the negative correlation 
with mental fatigue might be that younger participants were more aware of their mental 
fatigue because they were more likely to be in employment or education (correlation between 
age and unemployment for the patients with AAV was rs=0.563, p<0.001), although the lack of 
any correlation between unemployment and mental fatigue (see section 3.7.3) perhaps makes 
this explanation less likely. 
In this study female gender was associated with greater General Fatigue, and when patients 
with AAV were analysed separately not only was this still the case but there was also a 
positive correlation between female gender and Physical Fatigue (rs=0.174, p=0.036); 
however no correlations existed between gender and the other dimensions of fatigue. Studies 
exploring gender differences in fatigue severity have previously given conflicting results 
(451, 460) and it is not yet clear how important an influence gender is on fatigue levels. No 
correlation was seen between ethnicity and fatigue, although it was unlikely such a 
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correlation would be found in view of the very low percentage of participants who were not 
Caucasian in this study. 
3.7.2 Marital Status 
Not having a living spouse or partner correlated positively with higher scores across all 
dimensions of fatigue, which is unsurprising since for most people their partner is their main 
source of psychological support. Since there was no significant difference in marital status 
between the groups, it was surprising that this association was not seen when the AAV group 
was analysed in isolation. This might be explained by the smaller number of participants in 
the analysis, or perhaps other predictors of fatigue were so strong for these patients that 
marital status became less important. 
3.7.3 Education and Employment 
Increasing educational attainment was associated with a lower severity of fatigue, in keeping 
with previous literature (451); this was not simply a result of the better educational attainment 
in the healthy group (discussed in Chapter 3.2.1) because age at the time of leaving education 
was also negatively correlated with MFI-20 scores within the AAV group (rs=-0.225, 
p=0.007 for Physical Fatigue; rs=-0.188, p=0.025 for Reduced Motivation). Unemployment 
was associated with higher scores in all dimensions of fatigue except for Mental Fatigue as 
shown, and this was also true in sub-analysis of the AAV group: rs=0.160, p=0.056 for 
General Fatigue; rs=0.329, p<0.001 for Physical Fatigue; rs=0.369, p<0.001 for Reduced 
Activity; rs=0.234, p=0.005 for Reduced Motivation. This finding was in keeping with 
previous studies which have found that chronic fatigue is strongly associated with 
occupational disability and unemployment (461). 
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3.7.4 Lifestyle 
When all groups were analysed together, being a current smoker correlated positively with 
higher levels of Physical Fatigue, Reduced Activity, and Reduced Motivation. This finding is 
in keeping with previous literature (454-456), but despite there being no difference in 
smoking prevalence between the groups these correlations were not found in sub-analysis of 
only the AAV group. The proposed link between smoking and fatigue is that CO reduces 
oxygen delivery to peripheral muscles, so this finding might suggest that muscular fatigue is 
not an important contributor to the overall experience of fatigue in AAV. An alternative 
explanation might be that smoking does increase fatigue in AAV, but that other influences 
are so much stronger as to render the effect of smoking insignificant in a relatively small 
sample of patients. 
No association was found in this study between caffeine intake and fatigue severity when all 
participants were analysed together, but when the AAV group was analysed separately there 
was a negative correlation between mental fatigue and caffeine intake (rs=-0.169, p=0.042), 
perhaps suggesting that for some patients with AAV, caffeine was a helpful way of reducing 
mental fatigue.  There was a negative correlation between alcohol intake and fatigue (other 
than mental fatigue), and this was not simply a result of the much lower alcohol intake 
reported by patients with AAV in this study because the negative correlation was even 
stronger when the AAV group was analysed separately (rs=-0.257, p=0.002 for General 
Fatigue; rs=-0.302, p<0.001 for Physical Fatigue; rs=-0.289, p<0.001 for Reduced Activity; 
rs=-0.270, p=0.001 for Reduced Motivation). As mentioned previously the most likely 
explanation for these fairly strong correlations might be that more fatigued patients were 
inclined to avoid the further sedative effects of alcohol. 
As would be expected, there were strong negative correlations (as shown in Table 3.9) 
between involvement in sport or exercise and greater severity in all of the dimensions of 
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fatigue other than mental fatigue. When the AAV group were analysed separately, strong 
negative correlations were still found between involvement in sport and both Physical Fatigue 
(rs=-0.339, p<0.001) and Reduced Activity (rs=-0.226, p=0.011). This part of the 
questionnaire was problematic for two reasons: the level of completion was relatively low, 
with 17% of participants not completing the section and, as discussed previously, the 
selection of possible answers anticipated a much higher level of participation in exercise than 
was found in the participants. In view of these problems, the results should be interpreted 
with some caution.  
3.7.5 Biological Factors 
Lower levels of haemoglobin (Hb) and poorer renal function, both recognised independent 
causes of fatigue, were associated with higher levels of fatigue in this cohort as shown. Sub-
analysis of the AAV group showed similarly strong negative correlations between Hb and 
General Fatigue (rs=-0.286, p=0.002), Physical Fatigue (rs=-0.216, p=0.012), Reduced 
Activity (rs=-0.268, p=0.002) and Reduced Motivation (rs=-0.178, p=0.039); the association 
with eGFR was weak in this group, with only Reduced Activity reaching significance (rs=-
0.270, p=0.002). It seems improbable that reduced renal function would not cause fatigue in 
AAV, and it is probable that we only found no correlation because of the relatively well 
preserved renal function in the patients with AAV in this study. Disease duration did not 
significantly correlate with fatigue in our patients with AAV, although it should be noted that 
all patients in this study had been in remission for at least six months. The degree of 
accumulated disease-related damage (as assessed by the VDI) was strongly associated with 
greater physical fatigue and reduced activity. 
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3.8 Did Recruitment of Healthy Controls From the University and 
Hospital Affect The Results? 
Out of the seventy-one healthy controls, thirteen (18%) were recruited from among the staff 
of UoB and UHBNFT. A sensitivity analysis is therefore important to assess whether the 
recruitment of these particular healthy controls had any important effect on the results. 
 AAV CKD Healthy Significance 
n 152 68 58 - 
Age (yrs) 
63.1 (49.8-
71.5) 
64.4 (47.8-75.2) 62.6 (51.6-68.7) 0.568 
Male Gender 73 (48.0%) 39 (57.4%) 30 (51.7%) 0.439 
White Ethnicity 141 (92.8%) 61 (89.7%) 57 (98.3%) 0.149 
Living Partner 102 (67.5%) 48 (70.6%) 47 (81.0%) 0.156 
Age Left 
Education (yrs) 
16 (15-18) 16 (15-18) 18 (15-21) 0.001 
Obtained a 
University Degree 
18 (12.1%) 8 (11.8%) 20 (35.1%) <0.001 
Currently 
Working/Studying 
51 (34.2%) 27 (39.7%) 23 (40.4%) 0.613 
Current Smoker 14 (9.3%) 10 (14.7%) 2 (3.5%) 0.102 
Caffeine Intake 
(g/Wk) 
1.8 (0.9-2.5) 1.6 (0.9-2.4) 1.8 (1.0-2.3) 0.666 
Alcohol Intake 
(Units/Wk) 
1.5 (0-9.0) 1.8 (0-9.8) 4.0 (0-16.5) 0.081* 
Involved in 
Exercise or Sport 
62 (48.1%) 21 (38.2%) 31 (66.0%) 0.018 
Hb (g/l) 132 (125-140) 127.5 (117-138) 140 (130-151) <0.001 
eGFR 
(ml/min/1.73m2) 
61.0 (37.0-
75.5) 
38.8 (27.0-56.0) 77.0 (70.0-90.0) <0.001 
Table 3.10: Characteristics of the study participants by group, excluding UoB/UHBNFT employees.  
‘Male Gender’, ‘White Ethnicity’, ‘Living Partner’, ‘Obtained a University Degree’, ‘Currently 
Working/Studying’, ‘Current Smoker’ and ‘Involved in Exercise or Sport’ are expressed as number of 
participants and as percentage of valid responses; other results expressed as median with IQR. eGFR = 
estimated GFR, calculated using Modification of Diet in Renal Disease (MDRD) formula; VDI = Vasculitis 
Damage Index. Significant differences across the three groups are highlighted in bold. 
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As shown in Table 3.10, excluding the employees of UoB and UHB from the analysis makes 
reassuringly little difference to the group characteristics. For example, although it results in 
the healthy control group having a slightly lower level of educational attainment and a lower 
level of participation in sport and exercise, these differences are much less than might be 
anticipated, and do not at all change the statistical significance of the differences between the 
groups. The only exception to this is with regards to alcohol intake: the healthy group have a 
lower level of alcohol intake in this new analysis, and the change is enough to mean that the 
difference in alcohol intake between the groups is no longer statistically significant. The 
reason that the recruitment of UoB and UHBNFT employees seems to have made little 
difference to the group characteristics is probably because care was taken to keep the group 
as representative as possible: all sections of the work-force were approached, so although 
doctors and professors were recruited, so were nurses, secretaries etc. Also, it is important to 
note that they comprised less than 20% of the total healthy control group. 
Although the recruitment strategy did not greatly alter the participant characteristics of the 
healthy control group, it is still important to examine whether it changed the level of 
subjective fatigue reported. Table 3.11 shows a direct comparison between the median fatigue 
levels reported by the healthy control group when the hospital and university employees are 
included or excluded. The inclusion of the employees does not seem to have made any 
meaningful difference to the fatigue levels in any domain of the MFI-20, and since their 
inclusion has altered neither the characteristics nor the fatigue levels of the group, it seems 
entirely appropriate to include them in the remainder of the analysis. 
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General 
Fatigue 
Physical 
Fatigue 
Mental 
Fatigue 
Reduced 
Activity 
Reduced 
Motivation 
UoB/UHBNFT 
Employees 
Included 
6 (5-10) 6 (5-8) 7 (5-9) 5 (4-8) 6 (4-8) 
UoB/UHBNFT 
Employees 
Excluded 
6 (5-9) 6 (5-8) 6 (5-8.5) 5 (4-8) 6 (4-8.5) 
Significance 0.740 0.802 0.860 0.948 0.907 
Table 3.11: Comparison of the subjective fatigue reported by the healthy control group depending on 
whether the data of university and hospital employees are included or excluded. 
Results shown are for the five dimensions of the MFI-20; median scores (with IQR) are shown. 
 
3.9 Mental Health 
As discussed in Section 3.5, the participants’ responses to the SF-36 suggested that both the 
AAV and the CKD disease groups were suffering from much poorer mental health than the 
healthy control group, and that their mental health correlated strongly with the severity of 
their fatigue. These findings were further explored with analysis of the participants’ 
responses to the Hospital Anxiety and Depression Scale (HADS), which has three important 
advantages over the Mental Health domain of the SF-36: it was specifically designed for use 
with patients, and as such does not ask about symptoms which might be due to physical 
rather than psychological illness (426, 427); it separates psychological symptoms into those 
attributable to depression and those attributable to anxiety, and scores in the ‘abnormal’ range  
have been shown to be predictive of psychiatric disease (427); it has been previously 
validated in AAV (354). 
As shown in Figure 3.2, the AAV group reported significantly more severe anxiety and 
depression than did the healthy group (p<0.001 for both comparisons), but there were no 
significant differences compared with the CKD group (p=0.342 for anxiety and p=0.694 for 
depression). Figure 3.3 illustrates the median total anxiety and depression scores for each of 
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the study groups categorised into ‘Normal’ (scores of 0-7), ‘Borderline’ (8-10) and 
‘Abnormal’ (11-21, highly predictive of psychiatric disease). Significantly more patients with 
AAV than healthy controls had ‘Abnormal’ scores for anxiety (p=0.001) and depression 
(p=0.003); although more patients with AAV than patients with CKD had ‘Abnormal’ scores 
for anxiety and more patients with CKD had ‘Abnormal’ scores for depression, these 
differences did not reach statistical significance. In both of the disease groups, more than 
25% of participants reported HADS scores predictive of clinical anxiety, depression, or both. 
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Figure 3.2: Anxiety and depression scores from the Hospital Anxiety and Depression Scale (HADS). 
Figure a) illustrates total anxiety score, and figure b) illustrates total depression score. Bars indicate median, 
boxes indicate the interquartile range and whiskers indicate the range. 
a) 
b) 
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Figure 3.3: Percentage of participants with HADS scores suggestive of psychiatric morbidity. 
Figure a) illustrates the percentage of subjects in each group who reported anxiety scores on the HADS which 
were predictive of clinical anxiety, and figure b) illustrates the percentage with depression scores predictive of 
clinical depression. 
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3.9.1 The Relationship Between Fatigue and Mental Health 
Table 3.12 shows the correlations which were found between fatigue and mental health for all 
participants as well as for AAV only. All correlations were highly significant as shown in the 
table, with depression in particular showing very strong positive correlations with all five 
dimensions of fatigue on the MFI-20. 
 All Participants Patients with AAV 
 Anxiety Depression Anxiety Depression 
General Fatigue 0.559 0.701 0.458 0.560 
Physical Fatigue 0.435 0.703 0.390 0.642 
Mental Fatigue 0.576 0.586 0.556 0.511 
Reduced Activity 0.298 0.689 
0.192 
(p=0.022) 
0.550 
Reduced Motivation 0.427 0.718 0.398 0.638 
Table 3.12: Correlations between fatigue and mental health. 
Correlations (rs) are shown between the five domains of the MFI-20 and total anxiety and depression scores of 
the HADS. Correlations of >0.5 were considered particularly significant and are highlighted in bold. All 
correlations were significant at the level of <0.001, except for where indicated. 
 
 
These very strong correlations between psychological morbidity and all aspects of fatigue 
suggest that central mechanisms are likely to be making a large contribution to the overall 
fatigue in AAV, although it is impossible in this cross-sectional study to prove whether 
depression and anxiety were contributing to the participants’ fatigue or vice-versa, or indeed 
whether a third variable was causing both symptoms.  
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3.10 Sleep Quality 
Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), with results 
shown in Table 3.13.  The AAV group reported sleep that was significantly worse than the 
healthy controls across all domains except for sleep duration, i.e. the quality of sleep was 
found to be reduced rather than the duration. Patients took longer to get to sleep, experienced 
more frequent disturbances, used medications to help them sleep more often, and reported 
more daytime dysfunction as a result of poor sleep. None of the differences between the AAV 
and CKD groups reached statistical significance. 
 AAV CKD 
AAV vs 
CKD 
Healthy 
AAV vs 
Healthy 
Subjective Sleep 
Quality 
1 (1-2) 1 (1-2) 0.338 1 (0-1) <0.001 
Sleep Latency 1 (0-2) 1 (0-2) 0.677 0 (0-1) <0.001 
Sleep Duration 0 (0-1) 0 (0-1) 0.493 0 (0-1) 0.067 
Sleep Efficiency 1 (0-2) 1 (0-2) 0.198 0 (0-1) <0.001 
Sleep 
Disturbances 
1 (1-2) 1 (1-2) 0.286 1 (1-1) <0.001 
Sleep Medication 0 (0-0) 0 (0-0) 0.413 0 (0-0) 0.008 
Daytime 
Dysfunction 
1 (1-1) 1 (1-1) 0.843 0 (0-1) <0.001 
Global PSQI 
Score 
7 (4-11) 7 (3-9) 0.272 3 (2-5) <0.001 
Table 3.13: Sleep quality as assessed by the Pittsburgh Sleep Quality Index. 
Median values and IQR are shown for the 7 domains and the Global PSQI Score. Comparisons are shown 
between the AAV group and the other two groups, with significant differences highlighted in bold. 
 
The correlations between Global PSQI score (i.e. overall sleep quality) and fatigue, 
psychological morbidity and pain are shown in Table 3.14. As shown, poor sleep quality 
correlated with all dimensions of fatigue as well as anxiety, depression and pain at a 
significance level of <0.001, regardless of whether all participants were analysed together or 
the patients with AAV were analysed separately. Whilst it is impossible to attribute definite 
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cause on the basis of the data from this study, there is clearly a close and complex 
relationship between these symptoms which warrants further investigation. 
 
Global PSQI Score 
All Participants 
Global PSQI Score 
Patients with AAV Only 
General Fatigue 0.602 0.493 
Physical Fatigue 0.470 0.370 
Mental Fatigue 0.429 0.396 
Reduced Activity 0.397 0.308 
Reduced Motivation 0.432 0.367 
Anxiety 0.579 0.539 
Depression 0.488 0.451 
Bodily Pain -0.444 -0.395 
Table 3.14: Correlations between sleep quality and fatigue, anxiety and depression. 
Correlations (rs) are shown between Global PSQI score and the five domains of the MFI-20, total anxiety and 
depression scores of the HADS, and the Bodily Pain domain of the SF-36. Correlations of >0.5 were considered 
particularly significant and are highlighted in bold. All correlations were significant at the level of <0.001. 
  
121 
3.11 Coping Strategies 
Coping strategies were assessed using the Brief COPE questionnaire. As shown in Table 
3.15, the use of most coping strategies was the same across the groups, although the AAV 
group reported: 
 More use of ‘Active Coping’ (defined as “taking action, exerting efforts, to remove or 
circumvent the stressor”) and less ‘Substance Use’ than the CKD group; 
 More use of ‘Denial’ (“attempting to reject the reality of the stressor”) and 
‘Behavioural Disengagement’ (“giving up, or withdrawing effort from, the attempt to 
attain the goal with which the stressor is interfering”), but less use of ‘Active Coping’ 
than the healthy group. 
In other words, the AAV group reported slightly less use of strategies which might be 
regarded as maladaptive compared to the CKD group, but more use than the healthy control 
group. 
The correlations between coping strategies and General Fatigue, Physical Fatigue and 
Reduced Activity for the patients with AAV were very weak, and the only coping strategy 
which  correlated with severity of fatigue across all dimensions was Behavioural 
Disengagement, the use of which was associated with increased severity of all dimensions of 
fatigue (rs=0.225, p=0.007 for General Fatigue; rs=0.365, p<0.001 for Physical Fatigue; 
rs=0.299, p<0.001 for Mental Fatigue; rs=0.302, p<0.001 for Reduced Activity; rs=0.462, 
p<0.001 for Reduced Motivation). Coping strategies were more predictive of Mental Fatigue 
and Reduced Motivation, as shown in Table 3.16, suggesting that teaching adaptive coping 
strategies might help reduce at least these aspects of fatigue.  
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 AAV CKD 
AAV vs 
CKD 
Healthy 
AAV vs 
Healthy 
Active Coping 5 (4-7) 5 (3-7) 0.040 6 (5-8) 0.036 
Planning 6 (4-7) 5 (3-7) 0.232 6 (4-8) 0.081 
Positive 
Reframing 
5 (4-7) 4 (3-6) 0.240 5 (4-7) 0.142 
Acceptance 6 (5-8) 6 (4-8) 0.880 6 (5-8) 0.623 
Humour 4 (3-6) 4 (3-6) 0.808 4 (2.5-6) 0.690 
Religion 2 (2-4) 2 (2-3.5) 0.316 2 (2-4) 0.079 
Using Emotional 
Support 
4 (3-6) 4 (2-5) 0.103 4 (3-5) 0.605 
Using 
Instrumental 
Support 
4 (3-5) 4 (2-6) 0.858 4 (3-6) 0.946 
Self-Distraction 5 (3.5-6) 4 (3-5.5) 0.173 4 (3-6) 0.259 
Denial 2 (2-3) 2 (2-3) 0.553 2 (2-2) 0.001 
Venting 3 (2-5) 3 (2-5) 0.103 4 (2.5-4) 0.832 
Substance Use 2 (2-2) 2 (2-4) 0.020 2 (2-3) 0.234 
Behavioural 
Disengagement 
2 (2-4) 2 (2-3) 0.202 2 (2-2) 0.009 
Self-Blame 4 (2-5) 3 (2-5) 0.875 4 (3-5) 0.073 
Table 3.15: Use of different coping strategies as assessed by the Brief COPE. 
Median values and IQR are shown for the 14 domains. Comparisons are shown between the AAV group and the 
other two groups, with significant differences highlighted in bold.  
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 Mental Fatigue Reduced Motivation 
 rs p rs p 
Active Coping -0.099 0.242 -0.208 0.013 
Planning -0.005 0.955 -0.205 0.013 
Positive Reframing -0.025 0.767 -0.233 0.005 
Acceptance 0.006 0.945 -0.055 0.508 
Humour 0.026 0.757 0.012 0.888 
Religion -0.113 0.175 0.039 0.639 
Using Emotional 
Support 
0.141 0.092 0.069 0.411 
Using Instrumental 
Support 
0.049 0.563 0.052 0.534 
Self-Distraction 0.213 0.010 0.027 0.746 
Denial 0.235 0.005 0.143 0.089 
Venting 0.235 0.005 0.189 0.023 
Substance Use 0.140 0.093 0.047 0.571 
Behavioural 
Disengagement 
0.299 <0.001 0.462 <0.001 
Self-Blame 0.328 <0.001 0.187 0.024 
Table 3.16: Use of coping strategies and severity of fatigue for patients with AAV. 
Correlations (rs) are shown between the fourteen coping strategies and Mental Fatigue and Reduced Motivation 
scores for the AAV group. Statistically significant results (p<0.05) are highlighted in bold. 
 
124 
3.12 Which Factors are Independent Predictors of Fatigue? 
To identify which of the variables that were identified as most strongly associated with 
fatigue in univariate analysis were important independent predictors of each of the 
dimensions of fatigue, these variables (age, gender, age leaving education, employment 
status, haemoglobin, anxiety, depression, sleep disturbance, pain) were then submitted to 
logistic regression models using a backward stepwise selection technique. In these models 
only the patients with AAV were included, and it was confirmed that the standardised 
residuals from these regressions were normally distributed. Results were as follows: 
 For General Fatigue, Depression Score (standardised beta coefficient=0.429, 
p<0.001), Global PSQI Score (standardised beta coefficient=0.275, p=0.001) and 
haemoglobin (standardised beta coefficient=-0.200, p=0.007) were the significant 
independent predictors; the R2 for the model was 0.438, and the adjusted R2 was 
0.423. 
 For Physical Fatigue, Depression Score (standardised beta coefficient=0.512, 
p<0.001), Bodily Pain (standardised beta coefficient=-0.183, p=0.023) and 
employment status (standardised beta coefficient=0.150, p=0.042) were the 
significant independent predictors; the R2 for the model was 0.496, and the adjusted 
R2 was 0.477. 
 For Mental Fatigue, Anxiety Score (standardised beta coefficient=0.350, p<0.001), 
age (standardised beta coefficient=-0.322, p<0.001), and Depression Score 
(standardised beta coefficient=0.285, p=0.002) were the significant independent 
predictors; the R2 for the model was 0.447, and the adjusted R2 was 0.432. 
 For Reduced Activity, Depression Score (standardised beta coefficient=0.568, 
p<0.001), employment status (standardised beta coefficient=0.203, p=0.008) and 
Global PSQI Score (standardised beta coefficient=-0.178, p=0.044) were the 
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significant independent predictors; the R2 for the model was 0.416, and the adjusted 
R2 was 0.395. 
 For Reduced Motivation, Depression Score (standardised beta coefficient=0.565, 
p<0.001) and Bodily Pain (standardised beta coefficient=-0.190, p=0.013) were the 
significant independent predictors; the R2 for the model was 0.456, and the adjusted 
R2 was 0.448. 
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3.13 Summary of Findings 
One hundred and fifty two patients with AAV, sixty eight patients with CKD and seventy one 
healthy controls participated in the questionnaire study. The study confirmed that patients 
with AAV suffer from severe fatigue, with MFI-20 General Fatigue scores that were 
significantly higher than those found in both the CKD and the healthy control groups, and 
results also suggested that the nature of fatigue experienced by patients with either AAV or 
CKD might be quite different from that experienced day-to-day by healthy people. A number 
of patient characteristics, biological factors and other symptoms correlated with fatigue in 
univariate analysis, and stepwise linear regression suggested that the most important 
independent predictors of fatigue symptoms in AAV were depression, sleep quality, 
haemoglobin, pain, and employment status. 
The severity and nature of fatigue were assessed using the MFI-20. Results confirmed that 
patients with AAV were suffering from severe fatigue, with General Fatigue scores that were 
significantly worse than the scores of the CKD and healthy groups in this study, and were 
comparable to those reported elsewhere in cancer, RA, and other chronic illnesses in which 
fatigue is a prominent feature (116, 119, 122, 128, 132, 136, 462). Qualitative analysis of the 
pattern of symptoms across the five dimensions of fatigue suggested that in AAV and CKD 
physical symptoms, such as physically only being able to do a little, were much more severe 
than mental symptoms.  This contrasts with the healthy group in whom fatigue was a less 
physical experience. This is in keeping with research in RA, which also suggested that fatigue 
in disease states is fundamentally different from the fatigue of healthy people (102, 379). 
These findings might suggest that the overall experience of fatigue in chronic disease states 
such as AAV and CKD is more driven by muscular or cardiovascular fatigue than it is in 
health.  On the other hand the perception or reporting of physical fatigue does not necessarily 
mean that there are physiological deficits in the cardiovascular or muscular systems.  The 
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mechanisms underlying this severe physical fatigue will be examined in detail in the 
mechanistic study (see Chapters 4 and 5). 
Health-related quality of life as measured by the SF-36 was significantly worse in the AAV 
and CKD groups than in the healthy control group, and all domains of HRQOL correlated 
very strongly with fatigue, supporting the existing evidence that fatigue is a major cause of 
reduced  HRQOL in AAV. Although the SF-36 does not ask directly whether problems are 
caused by fatigue, a modified version of the Piper fatigue scale showed in this study that 
fatigue was a direct cause of severe role impairments in all aspects of professional, family 
and social life. 
In univariate analysis, a number of patient characteristics were shown to be associated with 
fatigue in AAV including age, which was positively correlated with physical fatigue but 
negatively correlated with mental fatigue.  The positive correlation between age and Physical 
Fatigue is to be expected, because as people age their physical reserve generally declines due 
to a number of physiological factors including a lower maximum heart rate (451). The 
negative correlation between age and Mental Fatigue is more difficult to explain, but since in 
this study age was negatively correlated with being employed or in education, perhaps older 
participants were less likely to be carrying out the sorts of tasks which would exacerbate 
mental fatigue. Female gender was also positively correlated with General Fatigue and 
Physical Fatigue in patients with AAV, although reasons for this are not apparent and the 
existing literature on the impact of gender on fatigue is conflicting (451, 460). Educational 
attainment was negatively correlated with fatigue, in keeping with existing literature (451); 
potential reasons for this might be that education enables people to have a better 
understanding of their disease and symptoms, giving them a better sense of control, or 
perhaps this finding relates instead to subsequent employment, with university graduates less 
likely to find employment which requires manual labour that might exacerbate symptoms of 
128 
physical fatigue. Fatigue was positively correlated with unemployment; there is evidence in 
the literature to suggest that severe chronic fatigue causes people to have to give up their jobs 
(461), and whilst this is perhaps the likeliest explanation for the findings of this study, it 
could also be argued that unemployment might itself lead to inactivity, depression and 
fatigue. 
In this study both the AAV and CKD groups reported symptoms in keeping with much higher 
levels of anxiety and depression than the healthy control group as measured by the HADS, 
with over 25% of patients reporting symptoms that suggested clinically significant anxiety, 
depression, or both. The disease groups also reported significantly worse sleep quality as 
assessed by the PSQI, and higher levels of bodily pain as assessed by the SF-36 BP domain 
than did the healthy control group. These symptoms were shown to correlate strongly with 
fatigue and with each other, suggesting that there was a complex relationship between 
fatigue, pain, sleep quality and psychiatric disease. It could be argued that pain, poor sleep 
quality and psychological symptoms might all have been contributing towards the severe 
fatigue experienced by patients with AAV, but in a cross-sectional observational study such 
as this cause and effect can never be substantiated; indeed fatigue, psychological symptoms 
or poor quality sleep might lower an individual’s pain threshold (463, 464), and severe 
depression is a well-established cause of poor quality sleep (465). Data in this study from the 
Brief COPE questionnaire showed that patients with AAV were also more likely to use 
maladaptive coping strategies than the healthy group were, particularly the methods of 
behavioural disengagement and denial. 
To try to unravel which characteristics and symptoms were most predictive of fatigue, linear 
regression analysis was carried out. This suggested that depression was by far the strongest 
predictor of fatigue in our patients with AAV, although the best predictors varied with the 
dimension of fatigue tested for, with pain, employment status, anxiety and poor sleep quality 
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also shown to be important independent predictors of fatigue in this study. These findings 
suggest a number of symptoms for which targeted interventions might also bring about 
improvements in fatigue for patients with AAV. These potential interventions will be 
discussed further in Chapter Six. 
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4 RESULTS CHAPTER 2: HOW DO BODY COMPOSITION, 
MUSCLE FUNCTION, INFLAMMATION AND 
ENDOGENOUS HORMONE SUPPRESSION RELATE TO 
FATIGUE IN AAV? 
4.1 Introduction 
Forty eight of the patients with AAV and 41 of the healthy controls who had participated in 
the questionnaire study also participated in a mechanistic study, undergoing a series of 
physiological and laboratory tests as described in Chapter 2. This chapter will explore the 
results of the body composition and muscle function tests, as well as how these results relate 
to the symptoms reported in the questionnaire, and with measurements of inflammation and 
endogenous hormones previously implicated in fatigue. 
4.2 Participant Characteristics and Self-Reported Symptoms 
As can be seen in Table 4.1, both groups in the mechanistic study were highly representative 
of the larger populations from which they were recruited. The median age of both groups was 
slightly lower in the mechanistic study (58.4 years [IQR=47.2-65.0] vs 63.1 years 
[IQR=49.8-71.5] for the larger AAV group, 58.2 years [IQR=49.0-62.5] vs 61.9 years 
[IQR=49.8-67.0] for the larger healthy group); although there was no maximum age for entry 
to the mechanistic study per se, this was undoubtedly a consequence of the stricter exclusion 
criteria and the nature of the tests involved, but the difference was small. The two study 
groups in this part of the study remained well matched. In virtually all indices measured the 
same differences existed between the groups in this study as were observed in the 
131 
questionnaire study described in the previous chapter, but there was a noticeable difference 
with regards to involvement in sport and exercise; not only was this activity much more 
prevalent for both groups in the mechanistic study (70% vs 48.1% for the larger AAV group, 
83.3% vs 70.2% for the larger healthy group), but there was no longer a significant difference 
between the disease and control groups. This was almost certainly another consequence of the 
nature of the recruitment of subjects for the tests involved, with those patients with AAV who 
reported no involvement in sport and exercise in their questionnaire being either less able or 
less inclined to participate in the mechanistic study. 
There was also a clear difference in educational level for both groups between studies, 
perhaps because those with an academic background were more inclined to volunteer for 
more time- and effort-intensive research: for the AAV group the proportion who had a 
university degree was only 12.1% in the larger questionnaire study but 21.3% in the 
mechanistic study, and for the healthy group these proportions were 39.7% and 50% 
respectively. 
The severity and nature of the fatigue experienced by both groups was virtually identical to 
that reported by the larger groups in the questionnaire study, as illustrated by their MFI-20 
scores (see Figure 4.1). Scores across the other symptom-rating scales were also very similar 
to those seen in the questionnaire study, with Table 4.2 showing a comparison of the 
summary scores for the SF-36, HADS and PSQI, as well as those domains of the Brief COPE 
where significant differences between health and illness were found in the questionnaire 
study. The only SF-36 domain in which scores varied appreciably from those seen in the 
questionnaire study was Physical Functioning, where the AAV group in the mechanistic 
study scored 75 compared with 55 for the larger questionnaire study cohort, consistent with 
the variance in reported involvement in sport and exercise.  
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 AAV Healthy Significance 
n 48 41 - 
Age (yrs) 58.4 (47.2-65.0) 58.2 (49.0-62.5) 0.610 
Male Gender 26 (54.2%) 23 (56.1%) 1.0 
White Ethnicity 48 (100%) 40 (98%) 0.513 
Living Partner 32 (66.7%) 32 (78.0%) 0.170 
Age Left Education (yrs) 16 (15-18) 20 (16-23) <0.001 
Obtained a University Degree 10 (21.3%) 19 (50%) 0.005 
Currently Working/Studying 25 (53.2%) 22 (57.9%) 0.416 
Current Smoker 2 (4.2%) 1 (2.4%) 0.560 
Caffeine Intake (g/Wk) 1.8 (0.9-2.5) 1.8 (1.2-2.1) 0.922 
Alcohol Intake (Units/Wk) 4.3 (0.0-11.0) 9.5 (2.5-17.5) 0.016 
Involved in Exercise or Sport 28 (70%) 30 (83.3%) 0.137 
Hb (g/l) 135 (124-146) 140 (131-148) 0.195 
eGFR (ml/min/1.73m2) 65.5 (50.0-78.0) 81.5 (74.0-90.0) <0.001 
Disease duration (months) 64 (22-98) - - 
VDI 4 (2-5) - - 
Table 4.1: Characteristics of the study participants by group. 
Gender, ethnicity, ‘Living Partner’, ‘Obtained a University Degree’, ‘Currently Working/Studying’, smoking 
status and ‘Involved in Exercise or Sport’ are expressed as number of participants and as percentage of the total 
number of respondents who provided the required information; other results are expressed as median with IQR. 
VDI=Vasculitis Damage Index; eGFR=Estimated GFR, calculated using Modification of Diet in Renal Disease 
(MDRD) formula. 
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Figure 4.1: Self-reported fatigue using the Multi–Dimensional Fatigue Inventory (MFI-20). 
Bars indicate median, boxes indicate the interquartile range and whiskers indicate the range. 
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Questionnaire Study Mechanistic Study 
AAV Healthy p AAV Healthy p 
Physical 
Component 
Score (PCS) 
38.7 
(26.9-48.4) 
54.7 
(49.8-56.7) 
<0.001 
42.5 
(32.4-50.3) 
55.3 
(53.0-57.5) 
<0.001 
Mental 
Component 
Score (MCS) 
50.2 
(39.4-56.9) 
56.2 
(52.7-58.4) 
<0.001 
48.4 
(39.2-55.0) 
56.3 
(54.4-58.4) 
<0.001 
Anxiety 7 (3-10) 4 (2-6) <0.001 6.5 (3-9) 3 (1-6) 0.005 
Depression 6 (3-8) 1 (0-3) <0.001 5 (2-8) 1 (0-2) <0.001 
Global PSQI 
Score 
7 (4-11) 3 (2-5) <0.001 6.5 (4-9.5) 4 (2-5) <0.001 
Active Coping 5 (4-7) 6 (5-8) 0.036 6 (4-7) 6 (5-8) 0.267 
Denial 2 (2-3) 2 (2-2) 0.001 2 (2-3) 2 (2-2) 0.035 
Behavioural 
Disengagement 
2 (2-4) 2 (2-2) 0.009 2 (2-3) 2 (2-2) 0.284 
Table 4.2: HRQOL, psychological symptoms, sleep quality and coping mechanisms. 
HRQOL measured by the physical and mental summary scores of the SF-36, anxiety and depression measured 
by the HADS, sleep quality measured by the PSQI global score, and three of the component scores from the 
Brief COPE, comparing scores from those in the questionnaire study to the sub-populations in the mechanistic 
study. Scores are expressed as median with IQR. 
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4.3 Obesity and Fatigue 
In this study, two assessments of obesity were made: body mass index (BMI) was calculated 
from direct measurement of height and weight (BMI=weight (kg)/height2 (m2)), and patients 
underwent DEXA scanning which supplied detailed body composition data (Table 4.3). 
 
 
AAV Healthy p 
Body Mass Index 
(kg/m2) 
28.1 (24.8-32.0) 24.8 (23.6-27.9) 0.019 
Percentage Body 
Fat 
32.5 (25.6-40.5) 26.5 (20.6-32.6) 0.007 
Table 4.3: BMI and percentage body fat in patients and healthy controls. 
BMI calculated as weight/height2, percentage body fat measured by DEXA. All results expressed as median 
with IQR. 
 
Obesity, assessed by BMI, was found to be positively correlated with the General Fatigue, 
Physical Fatigue, and Reduced Activity domains of the MFI-20 in patients with AAV, as 
shown in Table 4.4, but not with mental fatigue or motivation. Stronger correlations were 
seen with the direct measurement of percentage body fat on DEXA, which may be due to the 
influence on BMI of other factors such as muscle mass. There was no significant correlation 
between obesity and fatigue in the healthy controls, perhaps as a result of the generally low 
levels of fatigue experienced by this group. In keeping with the association between obesity 
and physical but not mental fatigue, it was also found to be associated with the physical 
component score of HRQOL on the SF-36, but not the mental component score. Interestingly, 
despite the strong correlation between both physical and mental fatigue and psychological 
symptoms, no correlation was seen between obesity and either anxiety or depression on the 
HADS. Obesity correlated strongly with poor sleep quality on the PSQI, in keeping with 
existing literature (466-468). 
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Correlation 
with BMI 
p 
Correlation 
with % Body 
Fat  
p 
General 
Fatigue 
0.333 0.026 0.405 0.006 
Physical 
Fatigue 
0.318 0.038 0.390 0.010 
Mental Fatigue 0.032 0.835 0.177 0.250 
Reduced 
Activity 
0.252 0.099 0.398 0.007 
Reduced 
Motivation 
0.188 0.216 0.264 0.079 
PCS -0.200 0.210 -0.328 0.036 
MCS -0.104 0.518 -0.104 0.519 
Anxiety 0.040 0.796 0.207 0.178 
Depression 0.191 0.214 0.270 0.076 
Global PSQI 
Score 
0.337 0.029 0.371 0.016 
Table 4.4: Correlation between obesity and fatigue for patients with AAV. 
Spearman's rank correlations shown, with statistically significant correlations (p<0.05) highlighted in bold. 
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4.4 Muscle Mass 
Lean body mass, measured by DEXA, was used as an approximation of muscle mass. Table 
4.5 presents the lean body mass data split by group for the whole body and for the 
participants’ dominant lower limb (i.e. the limb subsequently used for muscle function 
testing). No differences were found between the groups, and neither measurement correlated 
with any domain of fatigue in the AAV group, and there was therefore no evidence to suggest 
that fatigue in AAV is due in any part to muscle atrophy. 
 
 AAV (N=48) Healthy (N=41) Significance 
Total Lean Body Mass 
(kg) 
52.4 (42.2-61.9) 51.4 (45.0-59.8) p=0.979 
Dominant Lower Limb 
Muscle Mass (kg) 
8.3 (6.7-9.9) 8.8 (7.1-9.8) p=0.483 
Table 4.5: Muscle mass in patients and healthy controls. 
Lean body and leg mass determined by DEXA, expressed as median and IQR.   
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4.5 Muscle Strength and Voluntary Activation 
Muscle function was next assessed with a series of isometric maximal voluntary contractions 
(MVC) of the dominant side quadriceps muscle, with twitch interpolation to assess the extent 
of voluntary activation and theoretical maximal strength. This is a widely used and well 
validated technique in sports science, but to ensure investigator technique was satisfactory 
and that the equipment was functioning correctly, validation work was performed on two test 
subjects. 
4.5.1 Results for Test Subjects 
Two healthy volunteers each underwent testing on two separate occasions within a two week 
period. For reference, Figure 4.2 shows an example tracing and demonstrates how ‘Voluntary 
Activation’ (VA) and ‘Theoretical Maximal Contraction’ (TMC) were derived from the 
measured data. Note that since the protocol was to administer the super-imposed stimulation 
three seconds after the start of the contraction, TMC was calculated using VA and the 
voluntary contraction strength immediately prior to that superimposed stimulation (F1), 
which was not necessarily the same as the MVC. 
Table 4.6 shows the mean data obtained for the two test subjects. It should be noted that the 
test subjects used were not typical of the study subjects (both were post-graduate students in 
their 30’s), and it was a very small sample. Nonetheless, there were no problems with 
equipment, and it was considered to provide sufficient evidence of reliable equipment and 
adequate investigator technique. 
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Figure 4.2: A typical MVC with twitch interpolation. 
Ti = response from a resting electrical stimulation; Ts = response from electrical stimulation super-imposed on a 
MVC; MVC = maximal voluntary contraction force; F1 = voluntary power just prior to superimposed 
stimulation. 
 
 
 
  
Voluntary 
Activation 
(VA) 
MVC (N) TMC (N) 
Test Subject A 
Test 1 93% 509.5 534.7 
Test 2 90% 517.5 547.2 
Test Subject B 
Test 1 91% 393.3 413.6 
Test 2 95% 390.9 402.3 
Table 4.6: Muscle function results of test subjects. 
Results given are the mean values obtained from 3-5 MVCs, as described in Chapter 2. 
 
 
 
MVC 
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4.5.2 Results for AAV and Healthy Control Groups 
No adverse events occurred, and all participants were able to complete the test satisfactorily. 
Table 4.7 shows the data obtained for both groups during the study. 
 AAV (N=48) Healthy (N=41) Significance 
Maximal Voluntary 
Contraction (MVC) (N) 
275.2 (210.7-336.6) 322.4 (240.2-385.4) p=0.050 
Voluntary Muscle 
Activation (%) 
68.5 (58.2-81.1) 76.2 (67.5-86.5) p=.074 
Theoretical Maximal 
Contraction (TMC) (N) 
347.4 (277.1-441.3) 395.3 (314.6-479.8) p=0.315 
Table 4.7: Muscle strength and activation in patients and controls. 
Results expressed as medians with IQR. 
 
There was a significant difference in median MVC between the two groups, suggesting an 
apparent deficiency in muscle strength in the AAV group despite there being no difference in 
muscle mass. However there was also a trend towards the patients with AAV failing to 
voluntarily activate their muscles to the same extent as the healthy controls, and because of 
this there was no difference found in the TMC between groups, i.e. there was no difference in 
actual strength once the difference in voluntary activation was accounted for. 
It is notable that in this study voluntary muscle activation in the healthy control group was 
lower than would have been anticipated, and very much lower than for the two test subjects 
used in the pilot experiments. This is difficult to explain, as there was considerable verbal 
encouragement given to all participants, and they appeared to be well motivated during the 
experiments. It could possibly be that the participants were reluctant to contract fully because 
they knew that electrical stimulations were going to follow, however this was not apparent 
during the experiments. Moreover when a participant is purposely ‘holding back’ when 
performing an MVC, the shape of the resulting response trace usually takes on a bizarre 
shape (for example it might show a steep drop-off in force after the very first moments of the 
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contraction as the stimulation approaches) but this also was not the case very often. In fact, 
all of the tracings were screened as the results were calculated, and any obviously unusual or 
suspicious tracings were excluded from analysis. It also seems unlikely to be a problem with 
either the equipment or the operator technique, since the test subjects and some of the 
subjects in the main study showed excellent voluntary contraction using the same equipment, 
set-up and operator. Perhaps it was a function of the difference in age between the two test 
subjects and the healthy controls in the study, since the test subjects were both around thirty 
years younger than the median age of the healthy controls. Reports in the literature are 
conflicting, and although some studies have shown no difference in voluntary muscle 
activation across different age groups (469), others have shown that muscle activation is 
either reduced or much more variable in older age (470, 471). Amongst the healthy controls 
in this study, there was actually a weak positive correlation between age and VMA (rs=0.157, 
p=0.326). 
4.5.2.1 Were There Any Differences Between Males and Females For Muscle Strength? 
Because there is usually a difference in muscle strength between males and females it is 
important to look at whether splitting the groups by sex changes the results. As can be seen in 
Table 4.8, there were slight differences seen when the sexes were analysed separately: the 
difference in MCV between groups was more marked for males, and the difference in VMA 
was greater in females. However, none of these differences reached statistical significance, 
and it can only be speculated whether with greater numbers of participants these differences 
might have reached significance or might in fact have evened out. Most importantly perhaps, 
there was no difference in TMC between groups for either males or females, confirming 
again that there was no difference in actual muscle strength between patients with AAV and 
healthy controls. 
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A) AAV (N=26) Healthy (N=23) Significance 
Maximal Voluntary 
Contraction (MVC) (N) 
322.6 (255.8-382.9) 369.8 (328.6-405.6) 0.061 
Voluntary Muscle 
Activation (%) 
71.0 (55.4-81.1) 74.2 (67.2-84.7) 0.459 
Theoretical Maximal 
Contraction (TMC) (N) 
421.3 (343.9-620) 460.9 (420.0-543.1) 0.459 
    
B) AAV (N=22) Healthy (N=18) Significance 
Maximal Voluntary 
Contraction (MVC) (N) 
215.4 (188.5-277.4) 238.9 (200.4-309.3) 0.338 
Voluntary Muscle 
Activation (%) 
65.7 (60.8-80.7) 81.0 (70.5-89.9) 0.075 
Theoretical Maximal 
Contraction (TMC) (N) 
288.2 (251.4-346.3) 306.4 (261.2-341.8) 0.476 
Table 4.8: Muscle strength and activation in patients and controls, divided by sex into A) Males and B) 
Females. 
Results expressed as medians with IQR. 
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4.5.2.2 Did Muscle Strength or Voluntary Activation Correlate With Fatigue? 
When only the patients with AAV were analysed, there was no correlation between muscle 
strength or voluntary activation and any of the dimensions of fatigue (Table 4.9), further 
suggesting that muscle strength is not an important contributor to fatigue in AAV.  
 
 
Correlation 
with MVC 
p 
Correlation 
with VA  
p 
Correlation 
with TMC 
p 
General 
Fatigue 
-0.123 0.411 -0.253 0.086 -0.006 0.965 
Physical 
Fatigue 
-0.208 0.169 -0.142 0.352 -0.144 0.344 
Mental 
Fatigue 
-0.098 0.515 -0.182 0.227 -0.072 0.635 
Reduced 
Activity 
-0.287 0.054 -0.160 0.288 -0.215 0.152 
Reduced 
Motivation 
-0.009 0.952 -0.035 0.813 0.019 0.901 
PCS 0.118 0.450 -0.087 0.587 0.175 0.262 
MCS -0.010 0.950 0.147 0.346 -0.001 0.997 
Anxiety -0.086 0.571 -0.096 0.525 -0.121 0.424 
Depression -0.090 0.551 0.034 0.821 -0.153 0.310 
Global PSQI 
Score 
0.005 0.972 0.025 0.871 -0.059 0.705 
Table 4.9: Correlations between muscle function and symptoms for patients with AAV. 
No correlations were statistically significant. 
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4.6 Muscle Fatigability 
Having examined muscle strength and central motor drive in short bursts of maximal 
voluntary contraction over only a few seconds, muscular fatigability was tested next, by 
asking participants to maintain an isometric quadriceps muscle contraction for as long as 
possible at a force equal to 50% of their own MVC (as measured in the previous test). As 
described in Chapter 2, superimposed electrical stimulation was applied to the quadriceps 
muscle at 10-second intervals throughout the test. The results are shown in Table 4.10. 
 
 
AAV (N=48) Healthy (N=41) Significance 
Endurance Time (S) 70.0 (50.2-89.5) 91.2 (71.2-122.4) p=0.006 
Muscular Reserve at 
Point of Fatigue (%) 
31.6 (21.0-42.1) 25.0 (17.1-32.3) p=0.038 
Table 4.10: Muscle fatigability for patients with AAV and healthy controls. 
Median and IQR shown for time to volitional fatigue when maintaining a 50% MVC, and the muscular reserve 
at the point of that volitional fatigue for patients and controls. 
 
Although there was some overlap between the groups, on average the patients with AAV 
were only able to maintain a 50% MVC for around 75% of the time achieved by the healthy 
controls. This crude measurement is evidence of reduced endurance in the patients with 
AAV, but to distinguish whether task failure was due to peripheral muscular fatigue or to a 
failure of voluntary motor activation (i.e. central fatigue), the response to superimposed 
electrical stimulation must be examined.  
Figure 4.3 illustrates the response to electrical stimulation for both groups at the beginning of 
the test and at the point of volitional fatigue. Since the task was to maintain a contraction at 
50% of MVC, at the beginning of the test there should be 50% muscular reserve, and this was 
approximately the case for both groups. As a participant’s muscle becomes increasingly 
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fatigued during a sustained contraction, there should be a compensatory increase in voluntary 
muscle activation as the nervous system attempts to maintain a constant force. In theory this 
might result in there being no measurable response at all to a superimposed electrical 
stimulus at the point of volitional fatigue, since at that point there should already be maximal 
intrinsic stimulation of the muscle. In fact, as shown in Figure 4.3, both groups in this study 
still had a considerable response to electrical stimulus at the point where they felt unable to 
continue with the test – evidence of failure of voluntary muscle activation. The difference 
between the ‘muscular reserve’ of the two groups at this point was significant however, 
demonstrating evidence of increased central fatigue in the AAV group. 
 
 
Figure 4.3: Muscular reserve at the beginning and end of the fatigue test for patients and controls. 
‘Muscular Reserve’ is the response to superimposed electrical twitch at that time-point as a percentage of the 
response to a resting twitch. Bars indicate median, boxes indicate the interquartile range, whiskers indicate the 
range, and the dot indicates an outlier. 
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When analysing all study participants together, strong correlations were seen between 
endurance time and General Fatigue (r=-0.385, p<0.001), Physical Fatigue (r=-0.310, 
p=0.004), Reduced Activity (r=-0.303, p=0.005) and Reduced Motivation (r=-0.338, 
p=0.002), and also between muscular reserve at point of volitional fatigue and General 
Fatigue (r=0.241, p=0.026). However, when the patients with AAV were analysed alone 
these correlations were lost, suggesting that either the study was underpowered to find such 
correlations, or that the apparent correlations were simply a reflection of the differences 
between the two groups.  
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4.7 Inflammation 
4.7.1 hsCRP 
In this cohort of patients with AAV the serum concentration of hsCRP was within the normal 
range, but was still significantly higher than in the healthy controls, suggesting ongoing 
subclinical inflammation (Table 4.11). Although hsCRP concentration did correlate with 
General Fatigue, Physical Fatigue and Reduced Activity across all of the participants in the 
mechanistic study, correlations with these indices did not reach statistical significance when 
the patients with AAV were analysed separately (Table 4.12). Correlations for hsCRP with 
indices of quality of life, anxiety and depression, and sleep quality also failed to reach 
statistical significance when the patient group was analysed separately.  
 
Patients with AAV Healthy Controls p 
hsCRP (mg/ml) 1.9 (1.15-3.65) 0.92 (0.49-2.14) 0.011 
IL-1b (ng/ml) 3.5 (1.5-5.3) 1.5 (1.1-2.7) 0.007 
IL-1RA (ng/ml) 187.9 (80.5-266.6) 70.0 (48.1-146.9) 0.004 
IL-6 (ng/ml) 13.6 (6.3-20.0) 5.3 (4.2-8.9) <0.001 
IL-8 (ng/ml) 27.7 (9.9-39.2) 8.5 (6.2-19.1) <0.001 
IL-10 (ng/ml) 11.4 (7.4-14.6) 6.9 (4.5-10.2) 0.002 
TNFα (ng/ml) 61.0 (33.4-74.1) 31.9 (25.8-45.7) 0.001 
Table 4.11: Comparison between groups for hsCRP and a panel of cytokines. 
Median results shown, with interquartile range. Correlation between serum concentrations and MFI-20 general 
scores are also shown. 
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hsCRP – All 
Participants 
p 
hsCRP – 
Patients with 
AAV Only  
p 
General 
Fatigue 
0.234 0.031 0.169 0.257 
Physical 
Fatigue 
0.287 0.008 0.264 0.080 
Reduced 
Activity 
0.229 0.036 0.264 0.077 
PCS -0.358 0.001 -0.113 0.469 
MCS -0.190 0.100 -0.114 0.466 
Anxiety 0.103 0.351 -0.048 0.751 
Depression 0.194 0.077 0.162 0.281 
Global PSQI 
Score 
0.234 0.036 0.269 0.078 
Table 4.12: Correlation of hsCRP with fatigue, HRQOL, anxiety, depression and sleep quality. 
General Fatigue, Physical Fatigue and Reduced Activity from MFI-20; PCS and MCS summary scores from SF-
36; Anxiety and Depression subscores from HADS. Median results shown with IQR. 
 
4.7.2 Cytokines 
The measured cytokine concentrations (Table 4.11) were lower than might be anticipated in 
patients with AAV, but this is less surprising when it is considered that the patients in this 
study had all been immunosuppressed for a prolonged period of time, and that the majority of 
the patients were still taking prednisolone regularly at the time they were tested. Indeed, all 
patients with AAV who participated in the study had been in sustained disease remission for 
a minimum of six months.  
Although none of the patients had any clinical evidence of disease activity, all of the serum 
cytokines were present in significantly higher concentrations in patients’ serum than in the 
healthy controls’ serum, again suggesting ongoing sub-clinical inflammation (Table 4.11). 
Despite the significant differences in serum cytokine concentrations between groups 
however, none of those cytokine concentrations correlated significantly with subjective 
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fatigue, quality of life, psychological symptoms, or sleep quality when the AAV group was 
analysed separately (data not shown). 
As discussed in Chapter 4.3, patients were found to be more obese than healthy controls, and 
measures of adiposity were significantly correlated with fatigue. Obesity has previously been 
linked with inflammation, and in this cohort of patients with AAV, hsCRP correlated with 
BMI (r=0.368, p=0.012), but not with percentage body fat as measured by DEXA. There was 
no correlation between serum cytokine levels and adiposity. 
Neither hsCRP nor any of the cytokines correlated with measures of central motor drive 
(voluntary muscle activation during MVC, or muscular reserve at end of 50% MVC).  
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4.8 Endogenous Hormones  
Serum DHEA and DHEAS concentrations at 9am were significantly reduced in patients with 
AAV compared with healthy controls, which was expected given that most patients were 
receiving low dose prednisolone (median dose 5mg, IQR 0-5mg). The suppression of cortisol 
levels in patients with AAV did not reach statistical significance. Current prednisolone dose 
correlated very strongly with hormone levels as shown (Table 4.13).  
 
Patients with 
AAV 
Healthy 
Controls 
p 
Prednisolone 
Dose 
Correlation 
p 
DHEA 
(nmol/L) 
2.4 (1.7-5.2) 6.9 (4.2-13.5) <0.001 -0.544 <0.001 
DHEAS 
(mmol/L) 
1 (0.3-2.2) 4.7 (2.7-5.8) <0.001 -0.552 <0.001 
Cortisol 
(mmol/l) 
161.3 (101.0-
228.0) 
184.0 (142.8-
256.1) 
0.058 -0.487 0.001 
Table 4.13: DHEA, DHEAS and cortisol levels, and correlation with prednisolone dose. 
Median results are shown, with interquartile range. 
 
Within the AAV group, there was a correlation between DHEAS and Physical Fatigue (r=-
0.294, p=0.05), but not with the other dimensions of fatigue on the MFI-20, and there were 
no significant correlations between DHEA or cortisol and subjective fatigue. None of the 
measured hormones correlated significantly with anxiety or depression scores on the HADS, 
or with sleep quality (Global PSQI Score). Likewise, serum hormone levels did not correlate 
with either voluntary muscle activation or with muscular reserve (the measures of central 
motor drive) when only patients with AAV were analysed. Current prednisolone dose did not 
correlate with any of the symptoms measured in the questionnaire, and nor did it correlate 
with the measures of central motor drive. 
Despite hormone levels correlating quite poorly with the above indices, for the patients with 
AAV there were significant correlations between DHEA/DHEAS levels and HRQOL 
measured by the SF-36, as shown in Table 4.14. This suggests that DHEA/DHEAS 
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suppression causes problems which have a deleterious effect on HRQOL but are not well 
measured by the tools used in this study. 
 
 
Correlation with 
DHEA 
p 
Correlation with 
DHEAS  
p 
Physical 
functioning (PF) 
0.379 0.011 0.569 <0.001 
Role Physical (RP) 0.210 0.166 0.111 0.465 
Bodily Pain (BP) 0.344 0.018 0.341 0.019 
General Health 
(GH) 
0.157 0.291 0.374 0.010 
Vitality (VT) 0.137 0.357 0.209 0.159 
Social Functioning 
(SF) 
0.195 0.189 0.268 0.068 
Role Emotional 
(RE) 
0.193 0.200 0.100 0.510 
Mental Health 
(MH) 
-0.027 0.856 -0.310 0.835 
Physical Component 
Score (PCS) 
0.339 0.026 0.464 0.002 
Mental Component 
Score (MCS) 
0.068 0.667 0.095 0.545 
Table 4.14: Correlations between DHEA/DHEAS and HRQOL for patients with AAV. 
Statistically significant correlations are highlighted in bold. 
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4.9 Summary of Results 
In the last chapter it was shown that fatigue in AAV was severe, and that patients experienced 
greater physical symptoms than mental symptoms of fatigue. It was found that fatigue had 
important associations with quality of life and role impairments in patients, and that it was 
predicted by psychological symptoms, pain, and quality of sleep. This chapter attempted to 
explore some of the possible mechanisms underpinning physical fatigue in AAV, and found 
evidence of links with body adiposity and central motor drive, but no evidence linking fatigue 
with muscle mass or strength. 
Patients in this study had significantly higher body adiposity than healthy controls, whether 
measured directly by DEXA or indirectly by BMI. In the patient group, body adiposity was 
significantly correlated with General Fatigue, Physical Fatigue and Reduced Activity on the 
MFI-20, and with the Physical Component Score of the SF-36. A link between obesity and 
fatigue is well reported in the literature (439, 472-474), and although this study did not find 
any correlation in the healthy control group, this may be a result of the relatively small 
sample size and the low levels of fatigue reported by those participants. 
There are a number of plausible mechanisms linking adiposity and fatigue in patients with 
AAV, and in this study there is evidence supporting at least three. Fatigue would be expected 
to result in a more sedentary lifestyle and over time lead to increased body adiposity, and this 
is somewhat supported by the lower levels of exercise reported by the larger group in our 
questionnaire study. Obesity is strongly linked to poor sleep quality through mechanisms 
including obstructive sleep apnoea, which in turn is linked to fatigue in the literature, and in 
patients with AAV in this study it was found that Global PSQI score, measures of body 
adiposity, and the physical dimensions of fatigue in the MFI-20 all correlated with each other. 
Finally, obesity is also linked to inflammation as part of the metabolic syndrome, and this 
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study found a correlation in patients with AAV between BMI and hsCRP, although it did not 
find any statistically significant correlation between serum inflammatory markers and fatigue. 
Prolonged steroid use is often associated with muscle atrophy, and muscle contractility could 
also be reduced in patients with AAV through mechanisms including endothelial damage to 
the epineurial blood vessels (475-477) and reduction of the resting membrane potential of 
muscle and nerve by pro-inflammatory cytokines (478, 479). However this study did not find 
any evidence of reduced muscle mass in patients with AAV compared to healthy controls 
with DEXA, and during maximal voluntary contractions there was also no difference found 
in muscle strength, once reduced voluntary muscle activation was accounted for. However, 
despite having no muscle mass or strength deficit, patients with AAV were less able than 
controls to sustain an isometric contraction at 50% of their MVC, and superimposed electrical 
stimulation demonstrated that at the point of volitional fatigue patients with AAV had a 
significantly greater reserve of muscle force. This suggests a reduction in central motor drive 
in patients with AAV, as does the trend towards reduced voluntary muscle activation that was 
observed during MVC testing (although this did not reach statistical significance). 
Although inflammation, using hsCRP as a surrogate marker, was associated with fatigue 
across all participants in this study, no association was demonstrated between hsCRP and 
fatigue or measures of central motor drive in the patients with AAV. Likewise, there was no 
correlation found with the concentrations of inflammatory serum cytokines measured in this 
study. However it is important to note that all patients in this study were in sustained 
remission, with BVAS scores of 0 and hsCRP concentrations within the normal range, and it 
may be that inflammation at the onset of disease or during flares is a more important 
contributor to fatigue. Inflammation during such phases of the disease may cause central 
changes which result in fatigue, as has been suggested in RA (194), and it may be that for 
unknown reasons these central changes persist following disease remission when the level of 
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inflammation reduces. It has however also been shown in some studies that serum and CNS 
concentrations of cytokines do not correlate, so perhaps the correct fluid compartment was 
not sampled to demonstrate the true effects of inflammation on fatigue. 
Both inflammation and prednisolone use have been associated with suppressed levels of 
DHEA and DHEAS, which have themselves been associated with fatigue, although with 
contradictory findings (232, 238, 480, 481). Low levels of DHEAS have been associated with 
fatigue in patients with MS (482) where there is also evidence of failure of central motor 
drive such as we propose in our patients (483). Suppression of DHEA and DHEAS in this 
study correlated significantly with current prednisolone dose, but did not associate with 
fatigue or central motor drive in patients. It did however correlate strongly with some 
measures of HRQOL, and it seems that DHEA and DHEAS suppression are important in 
ways which are not well captured by the tools used in this study. 
The isometric muscle contractions considered in this Chapter are valuable objective measures 
of muscle function but prolonged isometric contractions are a relatively rare activity in daily 
life and may not, therefore, provide a true reflection of the problems facing patients.  Neither 
do isometric contractions test the respiratory nor cardiovascular systems deficits which can 
severely restrict aerobic exercise capability.  The following Chapter addresses this issue. 
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5 RESULTS CHAPTER 3: HOW DO CARDIO-
RESPIRATORY FITNESS, PERCEPTION OF EXERTION, 
AND MENTAL FUNCTION RELATE TO FATIGUE IN 
AAV? 
5.1 Introduction 
The work described in the last chapter explored the relationship between fatigue and body 
composition, isometric muscle function, and central motor drive in patients with AAV. It was 
found that patients with AAV had higher body fat than healthy controls, and that adiposity 
correlated positively with the General and Physical dimensions of fatigue, as well as reduced 
activity. No difference was found in peripheral muscle mass or contractile strength between 
patients and healthy controls, but patients showed evidence of a failure of central motor drive, 
a central mechanism of fatigue. Although patients had significantly higher peripheral blood 
markers of inflammation and lower levels of the hormones DHEA and DHEAS than the 
healthy control group, no correlation was found between those levels and either subjective 
fatigue or markers of central motor drive. 
The data presented in this chapter are of the submaximal exercise test, which examined both 
cardio-respiratory fitness and perception of exertion, and the Paced Auditory Serial Addition 
Test (PASAT), which was used as a measure of global cognitive function. As previously 
described, the mechanistic study included forty eight of the patients with AAV and 41 of the 
healthy controls who had participated in the questionnaire study; further details of the 
inclusion and exclusion criteria as well as the test methods can be found in Chapter 2. 
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5.2 Pilot Work – What Is The Optimum Method of Assessing Cardio-
Respiratory Fitness In Patients with AAV? 
In sports science literature, the most common measure of cardio-respiratory fitness is 
‘V̇O2max’, which is defined as an individual’s maximum possible rate of oxygen 
consumption during exercise. It is measured by finding the point during an incremental 
exercise test where oxygen consumption reaches a steady state or ‘plateau’, after which any 
further increases in workload are no longer accompanied by an increase in V̇O2. It is 
important to note that if a participant stops exercising before that point is reached then the 
final measurement is simply a ‘peak V̇O2’, although such measurements are sometimes 
misrepresented as V̇O2max. Not only would it be unsafe to push patients with AAV to such 
physical limits, but if there were any element of central fatigue then patients would be 
expected to stop before their true V̇O2max was reached anyway. For the mechanistic study it 
was therefore planned instead to make an estimate of the participants’ V̇O2max using the data 
obtained from a submaximal exercise protocol. 
The relationship between oxygen consumption and heart rate is linear during incremental 
exercise (445), so it was theorised that extrapolating the relationship between heart rate and 
V̇O2 observed during any individual’s submaximal exercise test out to that same individual’s 
predicted maximum heart rate would provide an acceptable estimate of V̇O2max (see Figure 
5.1). Pilot tests were carried out to examine the acceptability of this technique by asking two 
healthy volunteers to each undergo exercise testing on two separate occasions a few weeks 
apart. On the first occasion the participants undertook exactly the same submaximal exercise 
protocol that would subsequently be used in the mechanistic study; on the second occasion 
the same protocol was used initially, but after completion of the final 75W stage the workload 
was then further increased in 25W and then 10W increments every three minutes until the 
true V̇O2max was observed. 
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Figure 5.1: Technique for estimation of V̇O2max. 
The steps in the estimation of V̇O2max were as follows: 1) Data for heart rate and V̇O2 observed during the last 
30 seconds of each stage in the sub-maximal exercise test were plotted; 2) A ‘line of best fit’ for the observed 
data was extrapolated out to the estimated maximum heart rate; 3) The corresponding V̇O2 was then taken as the 
estimated V̇O2max.  
 
The estimated and measured V̇O2max values from the pilot tests are illustrated in Table 5.1. 
Any difference of less than 10% between estimated and measured V̇O2max was considered 
tolerable but, as shown, one of the estimated values for subject A was 15% greater than the 
measured value. A large part of the discrepancy between that individual’s estimated and 
measured V̇O2max was due to the reliance on equations for predicting maximum heart rate, 
even the best of which are known to be unreliable (484). For Subject A the predicted 
maximum HR was 161bpm but the actual measured maximum HR was only 148bpm in the 
max test, whereas for Subject B the predicted and measured maximum HR were close at 
176bpm and 174bpm respectively. If the vectors for HR/V̇O2 derived from the Subject A’s 
two submaximal exercise tests had been extrapolated out to their true maximum heart rate 
rather than the inaccurate predicted value, the two V̇O2max estimates would have differed 
from the true V̇O2max by just 2.3% and 4.9%. 
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 Test Subject A Test Subject B 
First estimated V̇O2max 34.5 (115%) 32.5 (92%) 
Second Estimated V̇O2max 31.9 (106%) 32.7 (92%) 
Measured V̇O2max 30.0 35.5 
Table 5.1: Results of the pilot submaximal exercise tests. 
Results are shown in ml/min/kg, and ‘estimated VO2max’ results are also expressed as a percentage of that 
participant’s measured V̇O2max in brackets. 
 
 
It was decided that estimated V̇O2max should be retained in the study as a measurement of 
cardio-respiratory fitness because V̇O2max is the value most often quoted in the literature. 
However, because this method of estimation was shown in the pilot work to be somewhat 
unreliable, ‘O2 pulse’ was added as a second measure of cardiorespiratory fitness which did 
not rely on estimated maximum HR. O2 pulse, which is the volume of oxygen consumed 
during exercise per heart beat, is widely regarded to be a good reflection of cardio-
respiratory efficiency (485) and can be simply determined as the slope of the linear regression 
of V̇O2 against heart rate (444). 
5.2.1 Correcting for Total Body Weight versus Lean Body Mass 
In health, cardiac output varies in a linear fashion with lean body mass (LBM) (486). 
Generally in the literature, cardio-respiratory variables such as V̇O2max and O2 pulse are 
corrected for total body weight rather than LBM, mainly because total body weight is easier 
to measure. It makes more physiological sense, however, to correct instead for lean body 
mass (LBM), since the quantity of body fat is highly variable and does not consume 
significant amounts of oxygen during exercise. As described in the previous chapter the AAV 
group had a significantly greater percentage body fat than the healthy group, so in this study 
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it was decided to express measures of cardio-respiratory fitness relative both to total body 
weight and LBM. 
5.3 Incremental Submaximal Exercise Test 
As described in Chapter 2, all participants in the mechanistic study undertook a 10 minute 
submaximal exercise test on a cycle ergometer, with a one minute warm-up at a workload of 
10W followed by three sequential three-minute periods at 25W, 50W and 75W. Heart rate 
and oxygen consumption (V̇O2) were recorded continuously to assess cardiorespiratory 
fitness, and perception of exertion was assessed with the Borg 6-20 RPE Scale at the end of 
each exercise period. 
There were no adverse events during testing, and the majority of the participants completed 
all three stages of the test. Eight female patients, one male patient, and one female healthy 
control stopped the exercise before completing the final stage, citing a combination of 
dyspnoea and leg pain as their reasons for stopping the test early. The data from four patients 
with AAV was excluded from the analysis of cardio-respiratory fitness – two of the four 
because they only managed to complete the first stage of the exercise protocol, and the other 
two because they were not able to maintain a sufficient cadence during the test to cause a 
meaningful rise in heart rate. 
5.3.1 Cardio-respiratory Fitness 
5.3.1.1 Were Patients Less Fit Than Healthy Controls? 
Comparing the two groups, there was no significant difference between the resting heart rates 
or the heart rates at each of the three workloads during the exercise test (Figure 5.2). This 
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might suggest similar levels of fitness, but is a very crude measurement compared with 
estimated V̇O2max or O2 pulse. 
 
 
Figure 5.2: Comparison of heart rates at rest and during exercise for patients and controls. 
There were no significant differences at rest or at the end of any of the workloads. Bars indicate median, boxes 
indicate the interquartile range, whiskers indicate the range and dot indicates an outlier.. 
 
As shown in Figure 5.3, patients had lower estimated V̇O2max than healthy controls: the 
median estimated V̇O2max per kg of total body weight of the patient group was 24.8 
(IQR=21.6-31.9) compared to 30.5 (IQR=24.5-35.3) for the healthy controls, and the median 
estimated V̇O2max per kg of LBM was 37.9 in the AAV group (IQR=34.1-49.5) compared to 
43.4 (IQR=38.2-50.5) for the healthy controls. The difference between groups was not 
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statistically significant, although it was closer to significance (p=0.056) when adjustment was 
made for total body weight than when LBM was adjusted for (p=0.103). As previously 
discussed fat is not metabolically active during exercise, therefore it is more valid to 
normalise these results to LBM and to conclude that there was no difference between groups 
for estimated V̇O2max. 
The median O2 pulse adjusted for total body weight was 0.196 (IQR=0.155-0.280) in the 
AAV group and 0.259 (0.212-0.331) in the healthy control group, and in contrast to the 
difference between groups for estimated V̇O2max this difference was highly significant 
(p=0.007). When O2 pulse was instead adjusted for LBM, the difference between groups was 
still significant, but less so: median O2 pulse for the AAV group was 0.310 (IQR=0.258-
0.419) compared with 0.371 (IQR=0.323-0.456) for the healthy group (p=0.029). Therefore, 
even using the more valid method of normalising the results to LBM, the patients with AAV 
still had lower O2 pulse than the healthy controls. 
Due to the previously described inaccuracies inherent in predicting participants’ maximum 
heart rate, estimated V̇O2max is a less reliable measurement of cardio-respiratory fitness than 
O2 pulse. For this reason it is reasonable to assert that there was indeed a significant 
difference between the groups, and O2 pulse will be used in the rest of this chapter when 
discussing cardio-respiratory fitness. 
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Figure 5.3: Estimated V̇O2max of patients with AAV and healthy controls. 
Figure A shows the V̇O2max adjusted for total body weight, and Figure B shows the V̇O2max adjusted for lean 
body mass for patients with AAV and healthy controls during exercise testing. Bars indicate median, boxes 
indicate the interquartile range and whiskers represent the highest and lowest values within 1.5 times the 
interquartile range 
 
A) 
B) 
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5.3.1.2 Was Reduced Cardio-respiratory Fitness a Cause of fatigue in AAV? 
As shown in Table 5.2, when O2 pulse was adjusted for total body weight it correlated with 
the General Fatigue, Physical Fatigue and Reduced Activity MFI-20 scores of all participants, 
suggesting that subjective fatigue was related to cardio-respiratory fitness in this study. 
However, when O2 pulse was instead more correctly adjusted for LBM it did not correlate 
with any the MFI-20 dimensions of fatigue. General Fatigue, Physical Fatigue and Reduced 
Activity scores were shown in the last chapter to correlate strongly with percentage body fat, 
and it seems likely that this relationship is responsible for the apparent correlation when 
adjusting O2 pulse for total rather than lean body weight. Furthermore, when only the patients 
with AAV are analysed the association between fatigue symptoms and O2 pulse falls short of 
statistical significance even when adjusted for total body weight  (p=0.077 for general 
fatigue). In summary, although there was a significant difference in cardio-respiratory fitness 
between groups it does not appear that it was an important cause of subjective fatigue. 
 
 
 
O2 Pulse Adjusted For Total 
Body Weight 
O2 Pulse Adjusted For LBM 
 Correlation (rs) p Correlation (rs) p 
General Fatigue -0.268 0.016 -0.154 0.176 
Physical Fatigue -0.239 0.034 0.110 0.341 
Mental Fatigue -0.193 0.087 -0.120 0.297 
Reduced Activity -0.220 0.048 -0.110 0.337 
Reduced 
Motivation 
-0.170 0.128 -0.096 0.402 
Table 5.2: Cardio-respiratory fitness and participants’ symptoms. 
Non-parametric correlations between cardiorespiratory fitness and: the five dimensions of fatigue on the MFI-
20; the physical and mental component scores on the SF-36; anxiety and depression scores on the HADS; and 
overall sleep quality score on the PSQI. Analysis includes patients with AAV and healthy controls. 
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5.3.2 Perception of Exertion 
The perception of exertion for any given workload increases with increasing age, most likely 
because the maximum heart rate decreases with age, resulting in that workload being carried 
out at an ever increasing fraction of the maximum aerobic capacity.  Similar arguments apply 
to differences in body size but because the patient and healthy control groups were well 
matched for age (as well as for gender and ethnicity) it is reasonable to look for differences 
between groups using the raw RPE in the last 30 seconds before cessation of the exercise test. 
The perception of exertion was significantly heightened in the patients compared to the 
control subjects: median final Borg Score was 14 (IQR=13-15.5) for patients with AAV 
compared with 12 (IQR=11-13) for healthy controls (p=0.006), even though patients and 
control subjects finished the exercise at very similar relative work rates, as judged by their 
heart rates as a percentage of their age predicted maxima (Figure 5.4). 
 
 
Figure 5.4: Perceived exertion as a function of work rate. 
The Borg scale ratings (RPE) at the end of exercise are shown compared to exercise intensity, expressed as 
actual heart rate as a percentage of estimated maximum heart rate. Closed symbol, patients; open symbol, 
controls. Data is given as median and IQR. 
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5.3.2.1 Was Perception Of Exertion An Important Cause Of Subjective Fatigue? 
Whilst there were clear differences between the median final RPE scores of the two groups, 
the most important question is whether there is a correlation between perception of exertion 
during exercise and the subjective symptoms of fatigue.  Since there was a wide range of ages 
and body sizes within both the patients and healthy control groups, it was necessary to allow 
for this using the RPEindex.  The median RPEindex was 0.88 (IQR=0.72-1.12) for patients with 
AAV compared with 0.78 (IQR=0.71-0.85) for healthy controls (p=0.031). 
As shown in Table 5.3, perception of exertion correlated strongly with fatigue across all 
participants, and it also correlated with HRQOL, bodily pain, psychological morbidity and 
sleep quality. When only the patients with AAV were included in the analysis there were still 
strong, statistically significant correlations with Physical Fatigue and Reduced Motivation on 
the MFI-20. There were also reasonably strong correlations with General Fatigue on the MFI-
20, Depression and Anxiety scores on the HADS, and Global PSQI score, and although these 
correlations were not statistically significant this may have been a function of the relatively 
small participant numbers. Univariate analysis therefore suggests that altered perception of 
exertion is an important central mechanism of fatigue in AAV, and that it may be related in 
some way to pain, psychological morbidity and reduced sleep quality.  
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 RPEIndex All Participants 
RPEIndex Patients with AAV 
Only 
 rs p rs p 
General Fatigue 0.391 <0.001 0.287 0.051 
Physical Fatigue 0.431 <0.001 0.337 0.023 
Mental Fatigue 0.236 0.031 0.156 0.302 
Reduced Activity 0.319 0.003 0.187 0.213 
Reduced Motivation 0.451 <0.001 0.387 0.007 
Bodily Pain -0.256 0.020 -0.163 0.274 
PCS -0.358 0.002 -0.235 0.130 
MCS -0.267 0.020 -0.163 0.296 
Anxiety Score 0.292 0.007 0.250 0.094 
Depression Score 0.404 <0.001 0.275 0.064 
Global PSQI Score 0.280 0.011 0.260 0.089 
Table 5.3: Relationship between perception of exertion and participants’ symptoms. 
Non-parametric correlations between perception of exertion and: the five dimensions of fatigue on the MFI-20; 
the physical and mental component scores on the SF-36; anxiety and depression scores on the HADS; and 
overall sleep quality score on the PSQI. Analysis is shown for all participants and also for patients with AAV 
only. 
 
167 
5.4 Multivariate Analysis – Which Mechanisms Predicted Fatigue in This 
Study? 
As described over the last two chapters, univariate analysis in this study suggested that 
fatigue in patients with AAV was unrelated to skeletal muscle bulk or strength, or to cardio-
respiratory fitness, but was instead predicted, in the statistical sense, by reduced central motor 
drive and altered perception of exertion. A logistic regression model was constructed using a 
backward stepwise selection technique to further explore which of these mechanisms were 
predictive of fatigue in the AAV patient group. The variables entered into the analysis were: 
muscle mass, voluntary muscle activation (during MVC), theoretical maximal contraction, 
muscular reserve (at the end of the sustained 50% MVC), O2 pulse (adjusted for LBM), and 
RPEIndex. Results for the AAV group were as follows: 
 For General Fatigue, only RPEIndex independently predicted fatigue (standardised beta 
coefficient=0.396, p=0.010), in a final model which also included voluntary muscle 
activation (standardised beta coefficient=-0.272, p=0.068). The overall R2 for the 
model was 0.208, and the adjusted R2 was 0.166. 
 For Physical Fatigue, only RPEIndex independently predicted fatigue (standardised beta 
coefficient=0.433, p=0.006), in a final model which also included voluntary muscle 
activation (standardised beta coefficient=-0.418, p=0.070) and muscular reserve 
(standardised beta coefficient=-0.394, p=0.087). The overall R2 for the model was 
0.246, and the adjusted R2 was 0.181. 
 For Reduced Motivation, only RPEIndex independently predicted fatigue (standardised 
beta coefficient=0.517, p=0.001), in a final model which also included theoretical 
maximal contraction (standardised beta coefficient=0.247, p=0.092) and O2 pulse 
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(standardised beta coefficient=-0.253, p=0.086). The overall R2 for the model was 
0.318, and the adjusted R2 was 0.263. 
 None of the mechanisms studied appeared to significantly predict Mental Fatigue or 
Reduced Activity in these models. 
This multivariate analysis appears to confirm the findings of univariate analysis - that altered 
perception of exertion is the most important mechanism underlying fatigue in patients with 
AAV. 
5.5 Was Altered Perception of Exertion Related to Suppression of 
Endogenous Hormones or to Inflammation? 
It was shown in the previous chapter that DHEA and DHEAS levels were suppressed in the 
AAV group, and that this correlated with Physical Fatigue. However, as shown in Table 5.4, 
although perception of exertion correlated with DHEAS when all participants were analysed 
together, the correlation was not present when only the patients with AAV were analysed. 
This apparent correlation in fact was probably due to the large difference in serum 
concentrations between study groups, and there was no evidence to support a link between 
hormone suppression and altered perception of exertion. 
 
 
RPEIndex All Participants RPEIndex Patients with AAV Only 
 
rs p rs p 
DHEA -0.110 0.308 -0.075 0.613 
DHEAS -0.255 0.019 -0.155 0.294 
Table 5.4: Perception of exertion and endogenous hormone suppression. 
Correlations between DHEA/DHEAS and RPEIndex when all participants are analysed together and also when 
patients with AAV are analysed separately. Statistically significant correlations are highlighted in bold. 
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Inflammation was assessed in all participants by measurement of hs-CRP and a panel of pro-
inflammatory cytokines. Although all of these markers were significantly raised in the 
patients with AAV compared to the healthy controls (as described in the previous chapter), 
baseline inflammation did not correlate with RPEIndex regardless of whether patients with 
AAV were analysed alone or together with healthy controls. 
Because some studies have shown an association between fatigue and the change in serum 
inflammatory marker concentrations after exercise, the same inflammatory markers that were 
measured at baseline were also measured after the sub-maximal exercise at three time-points: 
immediately after cessation of exercise, one hour afterwards, and two hours afterwards. The 
changes in serum concentration from baseline for each group are shown in Table 5.5. The 
only change in serum concentration from baseline that was significantly different between 
groups was that of Il-1RA from baseline to one hour post-exercise; in isolation this would 
seem to be of highly doubtful clinical significance, and indeed there was no correlation 
between the change in concentration and any of the dimensions of subjective fatigue or 
objective measures of central fatigue. In summary, no evidence was found to link 
inflammation to fatigue either at baseline or post-exercise. 
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 Change Post-Exercise Change At 1 Hour Change At 2 Hours 
 AAV Healthy p AAV Healthy p AAV Healthy p 
hs-CRP 
(mg/ml) 
0.08 
(0.00-0.21) 
0.03 
(-0.00-0.10) 
0.212 
-0.05 
(-0.18-0.01) 
-0.01 
(-0.10-0.02) 
0.224 
-0.06 
(-0.17-0.02) 
-0.01 
(-0.09-0.02) 
0.154 
Il-1b 
(ng/ml) 
0.15 
(-0.58-0.70) 
0.24 
(0.00-0.52) 
0.477 
0.22 
(-0.23-0.84) 
0.04 
(-0.33-0.28) 
0.099 
-0.17 
(-1.45-0.63) 
0.08 
(0.20-0.66) 
0.197 
Il-1RA 
(ng/ml) 
7.97 
(-8.98-45.67) 
16.58 
(-7.14-33.95) 
0.626 
14.9 
(-8.95-42.76) 
-0.69 
(-21.85-
13.51) 
0.005 
1.51 
(-32.99-
30.78) 
0.00 
(-22.93-
19.72) 
0.728 
Il-6 
(ng/ml) 
0.71 
(-0.86-2.49) 
0.89 
(0.27-1.83) 
0.781 
0.11 
(-1.47-3.05) 
0.43 
(-0.87-1.74) 
0.645 
-0.04 
(-2.11-2.75) 
0.89 
(-0.64-2.03) 
0.692 
Il-8 
(ng/ml) 
1.21 
(-3.26-7.16) 
1.66 
(0.13-2.96) 
0.781 
1.46 
(-2.24-9.08) 
0.47 
(-1.48-1.88) 
0.189 
-0.66 
(-5.38-2.63) 
0.36 
(-1.58-2.56) 
0.626 
Il-10 
(ng/ml) 
1.74 
(0.00-3.87) 
1.09 
(-0.26-1.97) 
0.189 
1.05 
(-0.70-2.52) 
-0.43 
(-1.80-1.08) 
0.052 
-0.28 
(-1.81-2.00) 
0.03 
(-1.45-0.75) 
0.951 
TNF-α 
(ng/ml) 
2.48 
(-5.12-8.84) 
3.67 
(0.00-10.46) 
0.869 
5.63 
(-3.58-14.21) 
-0.22 
(-5.72-6.64) 
0.101 
1.22 
(-11.37-9.82) 
0.23 
(-5.47-7.65) 
0.905 
Table 5.5: Change from baseline of inflammatory marker concentrations. 
Changes in concentration are shown from baseline to immediately post-exercise, one hour post-exercise, and two hours post-exercise. Median values are shown, with IQR in 
brackets. 
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5.6 Multivariate Analysis – Which Factors Best Predicted Altered 
Perception Of Exertion in Patients with AAV? 
Chapter 3 showed that a number of biological and psychosocial factors appeared to predict 
fatigue in AAV, including: Depression Score and Anxiety Score on the HADS, Global PSQI 
Score, Bodily Pain on the SF-36, employment status, and haemoglobin. Multiple regression 
analysis was carried out, again using a backwards stepwise selection technique, to identify 
whether any of these factors were predictors of altered perception of exertion in AAV. In this 
model the only independent predictor of altered perception of exertion in AAV was global 
PSQI score (standardised beta coefficient=0.372, p=0.017). The overall R2 for the model was 
0.138, and the adjusted R2 was 0.116. 
5.7 Paced Auditory Serial Addition Test (PASAT) 
Although patients with AAV in this study reported much more severe physical fatigue than 
mental fatigue, it is anecdotally very common for patients with AAV to complain of 
difficulty concentrating. In order to investigate this, the mechanistic study also included the 
PASAT, which is a test of global cognitive function (see Chapter 2 for details). 
As shown in Table 5.6, patients with AAV achieved much lower scores in all four sections of 
the PASAT, indicating that patients with AAV displayed significant cognitive impairment 
compared to the healthy controls in this study. As described in Chapter 2, four different inter-
digit intervals were used in case either all participants did well at slow speeds because they 
were too easy, or all did badly at fast speeds because they were too hard, but in this study 
significant differences were found between the groups across all four speeds. 
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 Patients with AAV Healthy Controls p 
Section 1 (60 
calculations; 2.4s 
inter-digit interval) 
39 (31-46.5) 46 (38-53) 0.003 
Section 2 (60 
calculations; 2.0s n 
inter-digit interval) 
32.5 (27.5-40.5) 39 (31-47) 0.001 
Section 3 (60 
calculations; 1.6s 
inter-digit interval) 
29 (22.5-36.5) 37 (29-43) 0.004 
Section 4 (240 
calculations, 1.2s 
inter-digit interval) 
18.5 (14-24) 29 (19-33) 0.001 
Total 120 (93-137.5) 151 (121-177) 0.001 
Table 5.6: PASAT results for patients with AAV and healthy controls. 
The median number of correct answers given (out of a possible 60) for each of the four different sections of the 
PASAT, and median total scores (out of a possible 240) for each of the groups. IQR in brackets. Differences 
between groups which reached statistical significance are highlighted in bold. 
 
As expected, cognitive function did correlate with fatigue in both groups of participants, but 
perhaps unexpectedly, cognition correlated most strongly with Physical Fatigue and Reduced 
Activity rather than Mental Fatigue (Table 5.7). As shown above, symptoms of Physical 
Fatigue also correlated with central mechanisms of fatigue such as RPE Index, so one possible 
explanation might be that whatever had caused the reduced cognition had also affected the 
centres in the brain responsible for central fatigue, although in this study there was no direct 
correlation between PASAT scores and voluntary muscle activation, muscular reserve at the 
end of a 50% MVC, or RPEIndex. There is a well-established link between physical activity 
and cognition (487, 488), so another explanation might be that physical fatigue had led to 
reduced activity, and this in turn had led to reduced cognition over time - although there was 
no correlation between disease duration and cognition in the AAV group (rs=0.172, p=0.259). 
Where the link between cognitive function and fatigue on the MFI-20 has been reported 
previously, investigators have not stated which dimension of fatigue correlated best (489). 
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 All Participants Patients with AAV 
 rs p rs p 
General Fatigue -0.333 0.002 -0.211 0.154 
Physical Fatigue -0.370 0.001 -0.358 0.016 
Mental Fatigue -0.191 0.082 -0.206 0.169 
Reduced Activity -0.364 0.001 -0.396 0.006 
Reduced Motivation -0.276 0.011 -0.212 0.153 
Table 5.7: Cognition and fatigue. 
Non-parametric correlations are shown between fatigue and total score on the PASAT for all participants and 
also for patients with AAV separately. Statistically significant correlations are highlighted in bold. 
 
Cognition in this study correlated strongly with educational attainment, whether assessed by 
age of leaving education (rs=0.412, p<0.001 for analysis of both groups together) or 
attainment of a university degree (rs=0.494, p<0.001 for both groups together), and this is 
particularly important since the level of educational attainment for participants in this study 
was much greater in the healthy control group than in the AAV group. To further examine 
whether or not AAV was independently predictive of reduced cognition, multiple regression 
analysis was carried out, again using a backwards stepwise selection technique. Both groups 
were included, and the variables entered into the analysis were ‘patient group’ (AAV or 
healthy), age of school-leaving, attainment or not of a university degree, and the five 
subscales of the MFI-20. In this model the only independent predictors of cognitive level 
were ‘University degree’ (standardised beta coefficient=0.461, p<0.001) and Reduced 
Activity (standardised beta coefficient=-0.384, p<0.001); the overall R2 for the model was 
0.369, and the adjusted R2 was 0.353. This suggests that in fact educational attainment and 
activity levels might explain the difference between the two groups in this study, and that the 
presence or absence of AAV was of little consequence. However, since patients anecdotally 
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complain of reduced cognition, the factors associated with cognitive level within the AAV 
group were further examined.  
5.7.1 Interaction of Biological Factors with Cognition 
When only patients with AAV were included in analysis, cognition did not correlate with 
haemoglobin, renal function, DHEA, DHEAS or CRP. However there were significant 
correlations with IL-1RA (rs=-0.411, p=0.004), IL-6 (rs=-0.457, p<0.001), IL-8 (rs=-0.306, 
p=0.034), IL-10 (rs=-0.363, p=0.011), and TNF-α (rs=-0.363, p=0.012). The correlation 
between the PASAT scores of patients with AAV and all of these cytokine concentrations 
might suggest the possibility of a causal relationship between chronic inflammation and 
reduced cognitive function; however, in a cross-sectional study such as this it is impossible to 
prove cause and effect, and in any case it must be remembered that IL-1RA and IL-10 are 
anti-inflammatory. Vasculitic involvement of the peripheral nerves (as recorded in the 
patients’ records) strongly correlated with reduced cognition (rs=0.423, p=0.006), but this is 
difficult to explain and none of the participants in the study had evidence of cerebral 
vasculitis. 
5.7.2 Cognition and Psychosocial Factors 
Surprisingly, objective cognition in patients with AAV did not correlate with quality of sleep 
as measured by the Global PSQI Score (rs=-0.2, p=0.194). There were strong correlations 
with Anxiety Score (rr=-0.501, p<0.001) and Depression Score (rs=-0.419, p=0.004) on the 
HADS; although this might suggest that whatever is leading to reduced cognition is also 
causing psychological symptoms, the relationship might in fact be artifactual, since anxiety 
could be expected to lead to panic and impaired performance during the PASAT. Bodily Pain 
(SF-36) correlated strongly with cognition (rs=0.373, p=0.01), but this might be most easily 
explained by speculating that reduced cognition could be a predictor of reduced pain 
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threshold. In view of the relationships observed between cognition and fatigue, anxiety, 
depression and pain, it is unsurprising that it also correlated with the Social Functioning 
(rs=0.405, p=0.005), Role Emotion (rr=0.326, p=0.027), Mental Health (rs=0.350, p=0.016) 
and Mental Component Score (rs=0.343, p=0.024) measures of HRQOL on the MOS SF-36. 
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5.8 Summary of Results 
In the last chapter evidence was presented that fatigue in patients with AAV was related to 
reduced central motor drive and also to adiposity, but that it was not related to peripheral 
muscle mass or strength. In this chapter results showed that fatigue in patients with AAV was 
related to a heightened perception of exertion, but was not related to cardio-respiratory 
fitness. Taking these findings together, the evidence suggests that fatigue in AAV is due to 
central and not peripheral mechanisms. Evidence was also shown of impaired cognition in 
patients with AAV, which correlated with cytokine concentrations, vasculitis of the 
peripheral nerves, fatigue, psychological morbidity, pain and HRQOL. 
The measure of cardio-respiratory fitness which is most commonly quoted in the literature is 
V̇O2max, but because it is not safe to measure this directly in patients with AAV, the original 
study design included a method of estimating V̇O2max using predicted maximum heart rate. 
However, pilot work shown in this chapter confirmed that the available equations to predict 
HR are unreliable, and that the method used in this study to estimate V̇O2max was therefore 
unacceptably inaccurate. It was therefore decided to use ‘O2 pulse’ as an additional 
measurement of cardio-respiratory fitness even though it is less commonly used than 
V̇O2max, since it may be measured directly in a submaximal exercise test. 
Submaximal exercise testing confirmed that patients with AAV were less fit than age-
matched healthy controls, and when the results were corrected for total body weight and both 
groups were analysed together cardiorespiratory fitness appeared to correlate with fatigue. 
However, since adipose tissue makes a negligible contribution to oxygen consumption during 
exercise, it makes more physiological sense to correct O2 pulse for LBM, and when this was 
done there was no correlation with any of the dimensions of fatigue. It was shown in Chapter 
4 that fatigue correlated with adiposity in patients with AAV, and this probably skewed the 
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results when O2 pulse was corrected using total body weight. In fact, it appears that although 
cardio-respiratory fitness was reduced in patients with AAV, it was not an important 
mechanism underpinning their subjective symptoms of fatigue. This is unsurprising when it is 
considered that patients, unlike healthy people, report that their fatigue is unpredictable and 
often unrelated to physical exertion. 
Perception of exertion was measured using the Borg RPE scale at the end of the three stages 
of the submaximal exercise test. It was shown that the AAV group had a heightened 
perception of exertion compared with the healthy group – in other words at the same 
workload and for the same physiological response, the patients with AAV felt like they were 
working harder. In univariate analysis of the AAV group, perception of exertion correlated 
strongly with symptoms of fatigue on the MFI-20, reaching statistical significance for 
symptoms of Physical Fatigue and Reduced Motivation, and in a multivariate analysis of the 
AAV group RPEIndex was the only independent predictor of General Fatigue, Physical Fatigue 
and Reduced Motivation. These results suggested that perception of exertion was the most 
important mechanism of fatigue in the patients with AAV in this study. Previous chapters 
have shown that psychosocial factors including quality of life, anxiety, depression, sleep 
disturbance and pain were all associated with fatigue, and in this chapter it was shown that 
these same factors were also associated with perception of exertion. Although the correlations 
did not reach statistical significance when only the AAV group were analysed this may have 
been due to the relatively small study size, and the results suggest that these psychosocial 
factors may result in fatigue through altered perception of exertion in patients with AAV. The 
link between increased perceived exertion in patients with anxiety and depression has been 
suggested previously (490), and it may be that patients with psychological symptoms are 
more likely to catastrophize feelings during physical activity (491). There was no evidence to 
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support a link between perception of exertion and either hormone suppression or 
inflammation in patients with AAV. 
Anecdotally, patients with AAV often complain to physicians that they are unable to 
concentrate when performing mental tasks. To investigate this, participants underwent testing 
with the Paced Auditory Serial Addition Test (PASAT) at four different test speeds. It was 
demonstrated that patients with AAV in this study had significantly impaired global cognitive 
function compared to the healthy controls. Cognitive function correlated most strongly with 
the Physical Fatigue and Reduced Activity dimensions of fatigue on the MFI-20, and perhaps 
counter-intuitively did not correlate with Mental Fatigue. Perhaps the most likely explanation 
is that that fatigue had led to reduced physical exertion in these patients, and thereby to 
reduced cognition over time in keeping with the established literature (487, 488). Indeed, 
regression analysis showed that the presence of AAV was not independently associated with 
reduced cognition in this study, and that the only independent predictors of reduced cognition 
were lower educational attainment and higher scores in the Reduced Activity subscale of the 
MFI-20. Within the AAV group, correlations were seen between cognition and the 
concentrations of both pro-inflammatory and anti-inflammatory cytokines. One explanation 
might be that chronic low level inflammation reduces cognitive level in patients with AAV, 
but this can only be speculated in a cross-sectional study, particularly when so much of the 
reduced cognition appears to be explained by education and activity. Anxiety and Depression 
Scores on the HADS correlated very strongly with PASAT scores in the AAV group, but this 
is difficult to interpret since anxiety might actually impair a participants’ technique in this 
particular test due to the time pressures involved. Correlations with scores on the MOS SF-36 
suggested that reduced cognition was leading to reduced HRQOL in patients with AAV, 
chiefly through reduced social functioning and role impairment. 
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6 DISCUSSION 
This study has demonstrated that fatigue in AAV is severe, and that it is a principle cause of 
impaired quality of life in patients with AAV, in keeping with the existing literature (324). 
This is the first study to demonstrate central mechanisms of fatigue in patients with AAV in 
stable remission and to show that fatigue in AAV is not due to problems with peripheral 
muscles or to reduced cardio-respiratory fitness. It has been shown that perception of effort is 
independently associated with fatigue, and that there is also evidence of reduced central 
motor drive in patients with AAV. Importantly, the study also showed that previously 
identified psychosocial factors including quality of life, anxiety and depression and sleep 
disturbance were all associated with perception of effort and fatigue, suggesting that these 
psychosocial factors may result in fatigue through heightened perception of exertion and 
reduced central activation in patients with AAV. DHEAS and inflammation did not 
independently contribute to fatigue. This is one of the largest studies to date to examine 
peripheral and central elements associated with fatigue in inflammatory rheumatologic 
disease in a systematic manner. 
6.1 Fatigue in AAV is Severe and Causes Reduced HRQOL 
The existing literature suggests that patients with AAV believe fatigue to be their most severe 
symptom, and that it is the symptom which has the biggest impact in their daily life (324), 
and that suggestion was supported by the questionnaire data in this study. Patients in the 
AAV group reported levels of fatigue on the MFI-20 which were greater than that reported by 
the CKD control group, and comparable to fatigue in other diseases characterised by fatigue, 
including RA, Sjogren’s syndrome and cancer (116, 119, 122, 128, 132, 136, 462). Analysis 
of the results suggested that patients in both the AAV and CKD groups experienced fatigue 
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as a very physical phenomenon, and that it was qualitatively different from the fatigue 
experienced as part of normal every-day life by the healthy control group. This is in keeping 
with previous research in patients with RA (102, 106, 379), who described the fatigue of RA 
as ‘akin to carrying a weight around with you’, and stated that it was fundamentally different 
from the fatigue they had experienced in every-day life before they developed RA. 
In this study, there were very strong correlations for patients with AAV between fatigue 
measured by the MFI-20 and HRQOL as measured by the MOS SF-36, suggesting that 
fatigue was indeed a very important cause of the reduced quality of life experienced by 
patients with AAV. This was further supported by the results of the modified Piper Fatigue 
Scale, which showed that fatigue was directly responsible for multiple role impairments in 
working, social and family life, demonstrating the need for a better understanding of the 
determinants and mechanisms of fatigue in AAV. 
6.2 The Mechanisms of Fatigue in AAV Are Central 
The very physical nature of fatigue in AAV would suggest that it might be a result of 
peripheral problems such as skeletal muscle weakness or reduced cardio-respiratory fitness, 
but the perception of exertion is influenced by emotional and psychological as well as 
physical factors (446). Physical fatigue can be caused by central mechanisms such as ‘central 
activation failure’ (167, 168), and so both peripheral and central mechanisms were examined 
in the mechanistic part of this study. 
There are many reasons why patients with AAV might have significant muscle atrophy or 
loss of contractility: steroids and cyclophosphamide are mainstays of the treatment of AAV, 
and can cause muscle atrophy and toxicity (335, 336, 338, 339); pro-inflammatory cytokines 
can reduce the resting membrane potential of muscle and nerve (475), and have been 
 181 
implicated in reduced muscle endurance (334); and either the disease itself or complications 
of the treatment might cause damage to or dysfunction of the epineural endothelium (475-
477). However, in this study there was no significant difference between the muscle mass of 
the AAV group and the healthy control group on DEXA, and there was no correlation 
between muscle mass and subjective fatigue on the MFI-20. Prednisolone dose was not 
associated with fatigue, but all of the patients in this study had been taking a dose of ≤7.5mg 
for longer than 6 months (data not shown), unlike those in the previous study (354). 
Muscle strength was tested by a series of brief isometric maximal voluntary contractions 
(MVCs) of the quadriceps muscle, and the MVCs of the AAV group were significantly 
weaker than those of the healthy control group. However, the twitch interpolation technique 
showed that there was evidence of central activation failure in the AAV group, who did not 
activate their muscles to the same extent as the matched healthy controls, and when this was 
accounted for there was no difference in muscle strength between the groups.  Further 
evidence was found of central activation failure in the AAV group when participants were 
asked to maintain a 50% isometric contraction: the endurance time of patients with AAV was 
around 25% less than the healthy controls, and superimposed electrical stimulation 
demonstrated that at the point of volitional fatigue patients with AAV had a significantly 
greater reserve of muscle force.  
It may be that interoception is more sensitive in patients with AAV, with afferent signals 
from the muscles and joints causing the brain to ‘shut down’ exercise prematurely at a point 
where the participant would be perfectly able to continue exercise from the perspective of 
physiological reserve. The findings in this study are similar to those in other diseases 
associated with increased fatigue, including fibromyalgia and multiple sclerosis (MS), where 
there is also evidence of central fatigue (140, 437, 492). Patients with fibromyalgia also reach 
the point of volitional muscle contraction failure more rapidly than healthy controls. 
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Fibromyalgia is associated with hypersensitisation to many stimuli (493) and it has been 
suggested that these patients may fail to activate endogenous pain inhibitory mechanisms 
during muscle contraction (494) resulting in central fatigue. Interestingly, patients with AAV 
exhibit increased pain scores that correlate with fatigue (90) and have increased rates of 
fibromyalgia compared with the general population (353). The relationship between 
neuromuscular central activation failure and fatigue in patients with AAV requires further 
investigation. 
Although they are valuable methods of testing muscle function, repeated or prolonged 
isometric contractions are not common activities in daily life, and it could therefore be argued 
that they do not replicate the sorts of activities which lead to fatigue in the lives of patients 
with AAV. The aerobic exercise capacity of the participants was therefore also assessed using 
a submaximal exercise test, but although the patients with AAV did have poorer cardio-
respiratory fitness than the healthy control group, fitness levels did not correlate with fatigue 
on the MFI-20. This is perhaps unsurprising since, in contrast to healthy people, patients with 
AAV and other chronic diseases often complain that their fatigue is unpredictable and 
frequently occurs without the precipitant of exercise (102). 
The perception of exertion during aerobic exercise was significantly heightened in the AAV 
group compared to the healthy controls, meaning that for the same workload and a similar 
physiological response the patients with AAV felt as if they were working much harder. More 
importantly, perception of exertion was found to correlate strongly with Physical Fatigue and 
Reduced Motivation in univariate analysis of the AAV group, and regression analysis showed 
that perception of fatigue independently predicted fatigue in patients with AAV. This study 
therefore showed that fatigue in AAV appears to be due to central mechanisms including 
heightened perception of exertion and central activation failure, and not due to peripheral 
mechanisms involving skeletal muscle or cardio-respiratory fitness. 
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6.3 Inflammation and Endogenous Steroid Suppression 
Pro-inflammatory cytokines probably have an important role in inducing sickness behaviour 
(181-183), and injection of pro-inflammatory cytokines into humans has been shown to 
induce fatigue (185, 186). Animal studies have suggested an important role for cytokines 
affecting introception centres within the brain (495), which could perhaps explain central 
activation failure if the same were true in patients with AAV. However, observational studies 
in autoimmune disease have generally failed to show any association between inflammation 
and fatigue (133, 284, 285). Likewise, although in this study the baseline concentrations of 
hsCRP and a panel of pro-inflammatory cytokines were all significantly higher in the AAV 
group than in the healthy controls, this did not correlate with fatigue, central activation failure 
or perception of exertion in patients with AAV. 
It is possible that the much higher levels of inflammation present when patients have active 
disease are a more important contributor to fatigue. All patients in the current study were in 
sustained remission, and although hsCRP was significantly raised compared with the healthy 
control group, the median concentration remained within the normal range. It may be that 
inflammation during the initial active stage of the disease causes central changes within the 
brain leading to fatigue, as has been suggested in rheumatoid arthritis (194), and that these 
changes then persist following disease remission when the level of inflammation reduces. 
Perhaps the patients who experience the most severe fatigue during remission are those who 
had the highest levels of inflammation during that initial stage of disease activity. It could be 
argued that the very strong correlation found in this study between accumulated disease 
damage (VDI) and Physical Fatigue supports this theory, since that accumulated damage is 
the result of active inflammation which has since settled, but this needs further investigation, 
and a better understanding of the effects of inflammation on the brain in human disease is 
required. Another possible explanation for the lack of association between inflammation and 
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fatigue might be that in this study the wrong fluid compartment was sampled, since there is 
evidence to suggest that cytokine concentrations in the brain do not correlate with those in the 
blood (194). 
Both inflammation and prednisolone use have been associated with suppressed levels of 
DHEAS which has, itself, been associated with fatigue, although with contradictory results 
(232, 238). Low levels of DHEAS have been associated with fatigue in patients with MS 
(240) where there is central activation failure (140). In this study, DHEA and DHEAS were 
both significantly suppressed in patients with AAV, and the levels correlated strongly with 
the current prednisolone dose. DHEAS correlated significantly with physical fatigue in the 
AAV group in univariate analysis, but other correlations between the dimensions of fatigue 
on the MFI-20 and either DHEA or DHEAS were weak, and in multivariate analysis DHEA 
and DHEAS did not independently associate with fatigue. 
6.4 Anaemia and Renal Function 
Previous studies have suggested that anaemia and severity of chronic kidney disease may be 
related to fatigue, and in the questionnaire study anaemia did correlate quite strongly with 
fatigue for patients with AAV. eGFR did not correlate with fatigue except in the Reduced 
Activity dimension on the MFI-20, however it must be noted that the median eGFR in that 
group was 61 ml/min, a level which would not be expected to cause fatigue. 
6.5 Psycho-Social Factors Are of Great Importance 
High levels of anxiety and depression have been reported previously in patients with AAV 
(353), and in this study more than 25% of patients in both the AAV group and the CKD 
group reported symptoms of anxiety, depression, or both that were predictive of psychiatric 
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disease. Psychological symptoms, particularly those of depression, correlated very strongly 
with all dimensions of fatigue in patients with AAV in univariate analysis. Patients in both 
disease groups also described very poor sleep quality and high levels of chronic pain. 
Depression, anxiety, pain, poor sleep quality and fatigue all correlated strongly with each 
other in univariate analysis of the patients with AAV, and it was impossible in this 
observational study to ascribe any causal relationship between the different variables. In 
multivariate analysis, depression, anxiety, sleep quality, pain, and employment status were all 
independent predictors of fatigue in the AAV group. There is clearly a complex interplay 
between all of these psycho-social factors which warrants further study. 
In this study, depression, anxiety, pain and sleep quality all correlated strongly with 
perception of exertion across all participants. In analysis of only the patients with AAV, 
correlations with depression, anxiety and sleep quality remained fairly strong, and perhaps 
were only non-significant because of the modest sample size. The link between increased 
perception of exertion in patients with anxiety and depression has been suggested previously 
(496), perhaps because these patients are more likely to catastrophize feelings during physical 
activity (491). It is interesting that in this study patients with AAV also reported increased 
use of maladaptive coping strategies (‘denial’ and ‘behavioural disengagement’) than did the 
healthy control group, and that in patients with AAV, there was a strong positive correlation 
between the use of behavioural disengagement and both Mental Fatigue and Reduced 
Motivation. 
6.6 Which Interventions Might Improve Fatigue in AAV? 
This study has identified a number of factors which correlated with fatigue, and whilst it is 
impossible to identify cause and effect in a cross-sectional study such as this, it seems likely 
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that interventions which treat those associated factors might also lead to improvements in 
fatigue. 
Patient factors such as poor sleep, anxiety and depression, increased perception of effort, and 
reduced central activation may be amenable to treatment with psychological therapies such as 
cognitive behavioural therapy. Although in this study reduced cardio-pulmonary fitness did 
not correlate with fatigue, patients with AAV were nonetheless significantly less fit than 
healthy controls, and it remains reasonable to think that improved fitness levels might bring 
about some improvement in fatigue. Indeed, even if that were not the case, there would 
undoubtedly be other benefits such as reduced cardiovascular morbidity and mortality. A 
similar combination of factors is present in chronic fatigue syndrome, and a recent large 
study suggests there may be improvements in these patients with cognitive behavioural 
therapy or exercise (359) or perhaps a combination of both. 
In patients with AAV, depression and anxiety were the symptoms which correlated most 
strongly of all with fatigue in both univariate and multivariate analysis, and these symptoms 
should be actively sought out and treated, particularly in those patients who complain of 
severe fatigue. In addition to CBT, pharmacological treatment with antidepressants might be 
expected to help, and this approach has achieved some success in fibromyalgia (355). 
Pain also correlated strongly with fatigue in this study, and pharmacological treatments might 
again have an important role to play in treating this. An important caveat, however, is that 
opioids and many other analgesics may actually cause fatigue in some patients, so the risk 
and benefit of pharmacological treatment should be balanced on an individual basis, and 
patients observed closely for worsening of fatigue. Depending on the nature of the pain, non-
pharmacological treatments such as TENS (transcutaneous electrical nerve stimulation) might 
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be more appropriate. Indeed a recent randomised controlled study in fibromyalgia suggested 
that TENS might have benefits for pain, fatigue and hyperalgesia (497). 
‘Sleep hygiene’ is the term used for a number of behaviours and practices which may help 
people with poor sleep quality, including: avoidance of daytime napping; avoidance of 
stimulants such as caffeine close to bedtime; vigorous exercise in the morning, or relaxing 
exercise such as yoga before bed; adequate exposure to natural light during the day. Sleep 
hygiene has been associated with improvements in pain, fatigue and sleep quality in 
fibromyalgia (498). Treatment of biological factors is important too. This study showed an 
association between anaemia and fatigue in patients with AAV, and anaemia should be 
investigated and treated as appropriate. 
6.7 Strengths and Weaknesses of the Study 
This is the first study to systematically examine both peripheral and central mechanisms of 
fatigue in AAV, and is one of the largest to do so in any rheumatological disease. It achieved 
good recruitment of patients with AAV, and the groups were well matched for age, gender 
and ethnicity for both the questionnaire and the mechanistic studies. The AAV group was a 
good representation of patients with AAV as a whole, particularly in the questionnaire study, 
and it therefore seems reasonable to extrapolate the findings to the larger population of 
patients with AAV.  In combining the questionnaire and mechanistic elements, it enabled the 
complex aetiology of fatigue to be examined more completely than in any other study to date. 
The experiments in the mechanistic study were well designed, and no patients withdrew from 
the study or suffered any adverse events as a result of the study. 
Recruitment to the questionnaire study was good for the AAV group but disappointing for the 
CKD and Healthy Control groups, and this led to the study being underpowered; this must be 
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considered when interpreting the results. Recruitment to the healthy control group was also 
problematic in the mechanistic study. The ‘buddy system’ of recruitment was less effective 
than anticipated, and this led to a disproportionate number of professionals in this group, 
recruited from the university or hospital. For future clinical studies conducted locally, it 
would be useful to keep a list of well-matched healthy controls that are happy to participate in 
clinical research. 
Whilst very comprehensive, the questionnaire was long, and this probably impacted on 
completion rates. The ‘demographics’ section of the questionnaire was written specifically 
for this study, and with hind-sight a number of improvements could have been made if it had 
been piloted prior to use in the main study. In particular: 
 The section which asked about habitual exercise was not well designed for this age-
group, and was not sensitive enough to distinguish between the low levels of activity 
reported by the participants, since the ‘least active’ option which could be selected for 
each activity was ‘1-4 hours per week’. 
 The sections which asked about alcohol and caffeine intake were left blank in a 
number of cases, and this might have been avoided if ‘tick-box’ options had been 
provided rather than space left for written answers. 
 The questionnaire included some sections which proved to be of no benefit; for 
example the EQ-5D-3L provided no additional information over the MOS SF-36. 
A more robust method of assessing habitual exercise might have been to distribute 
pedometers instead of administering that particular questionnaire section, or to have given 
pedometers to a random sample of the participants in order to test the reliability of the 
information provided in the questionnaire. Pedometers are not expensive, so their use would 
be recommended in similar studies in the future. 
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The mechanistic study was comprehensively designed, and the experiments as a whole 
worked very well. Some of the results were unexpected however – in particular the voluntary 
activation of skeletal muscle by the healthy group was much lower than expected in the 
muscle strength experiment, a finding which cannot be easily explained. The pain of the 
superimposed electrical stimulus might have affected some participants’ performance, and 
perhaps their voluntary muscle activation was therefore not as complete as it would be in a 
‘real-life’ situation. Pain due to electrical stimulation might also have affected the results of 
the muscle fatigue/endurance test, as some participants might have stopped the test early 
because they were not keen to endure further electrical stimuli rather than because of true 
central fatigue. However, although some study participants undoubtedly found the electrical 
stimulation painful, without using the ‘interpolated twitch’ technique it would have been 
difficult to detect central mechanisms of fatigue in these tests.  
6.8 Summary 
Although of limited size, this study is the largest to date to have investigated the complex 
aetiology of fatigue in autoimmune rheumatologic disease. The results showed that central 
mechanisms including ‘central activation failure’ and ‘heightened perception of exertion’ 
may be the most important mechanisms underpinning fatigue in AAV, but that muscle mass, 
muscle strength and cardio-pulmonary fitness did not predict fatigue in this group. Increased 
perception of effort is likely to make any physical exertion feel more demanding, thus 
reducing motivation and constituting a barrier to adhering to exercise advice and undertaking 
physical activity (324, 499). A number of psychosocial factors including depression, anxiety, 
and reduced sleep quality might lead to fatigue through these central mechanisms, and 
interventions such as CBT and sleep hygiene might therefore be expected to improve fatigue 
in patients with this disease. This study adds to our understanding of the complexity of 
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fatigue in patients with AAV and is similar to findings in chronic diseases where fatigue is 
common. The role of DHEA and its sulphate ester remains unclear, but inflammation appears 
not to be important in the aetiology of fatigue in AAV. 
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7 APPENDIX 1: SAMPLE QUESTIONNAIRE WITH 
CODING 
 
 
 
Participant Number: 
 
_________________
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This booklet contains a questionnaire which will tell us how fatigue and illness is affecting 
your life. This questionnaire will take between 30 and 45 minutes to complete. You may 
notice that some of the questions sound a bit similar; just try to answer each question 
independently. There are no right or wrong answers; simply indicate what applies best to you. 
 
 
Section 1 
Firstly, we would like to ask you about yourself in general. 
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Section 2 
We would now like to ask you some questions about your general health. 
 197 
198 
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These questions are about how you feel and how things have been with you during 
the past 4 weeks.  (For each question, please indicate the one answer that comes 
closest to the way you have been feeling).  How much time during the past 4 weeks: 
e
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Section 3 
The next section asks about tiredness, fatigue and concentration. 
 
 
 
 201 
Section 4 
 
We would like to get an idea of how you have been feeling over the last few 
days.  If you think any of these statements are entirely true, please tick the box 
for “1” on the extreme left. The more you disagree with the statement, the 
more you can tick the box in the direction of “no, that is not true”. Please do 
not miss out a statement. 
202 
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Section 6 
The next questions are designed to help us know how you feel in further detail. 
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Section 7 
We would now like to ask you about the presence and severity of any ear or 
nose problems you may have experienced in the last 2 weeks.  
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Section 8 
Some more general questions specific to how you feel today 
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Section 9 
We would now like to ask some questions about sleep. 
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Thank you for taking the time to complete our questionnaire.  
 
This information is very important and will help us to understand chronic fatigue in patients 
with vasculitis or chronic kidney disease.  
 
When you return your questionnaire, we may contact you to ask if you are interested in 
helping with a second part of this study, in which we are investigating the causes of fatigue. 
If you are interested, we will send you an information booklet to help you decide whether or 
not to participate. You will be free to participate or not participate as you wish, with no impact 
on your care.  Also, if you do decide to participate, you will be free to change your mind 
again at any time.   
 
FINALLY, IF YOU HAVE A PARTNER, FAMILY MEMBER OR FRIEND OF ABOUT THE SAME 
AGE, BUT NOT SUFFERING VASCULITIS, CHRONIC KIDNEY DISEASE, OR ANY SERIOUS 
CHRONIC ILLNESS, WE WOULD BE GRATEFUL IF YOU COULD TALK TO THEM ABOUT THIS 
STUDY. PLEASE LET THEM READ THE INFORMATION LEAFLET WE HAVE ENCLOSED.  
IF THEY ARE INTERESTED IN HELPING US WITH THE STUDY, WE WOULD ASK THEM EITHER 
TO JOIN YOU AT YOUR NEXT APPOINTMENT, OR TO CONTACT DR ANDREW MCCLEAN AT 
THE ADDRESS BELOW. (NOTE: ANY INFORMATION PROVIDED BY YOU, YOUR PARTNER, OR 
FAMILY MEMBER WILL BE KEPT STRICTLY CONFIDENTIAL).  
 
Please put the questionnaire back into the stamped addressed envelope provided, and post 
it back to us as soon as is convenient. 
 
 
Dr. Andrew McClean, 
Department of Renal Immunobiology, 
IBR West Extension, 
The Medical School, 
University of Birmingham, 
Edgbaston, 
Birmingham, 
B15 2TT. 
 
 
 217 
8 APPENDIX 2: PARTICIPANT INFORMATION LEAFLET 
FOR QUESTIONNAIRE STUDY (AAV GROUP) 
 
Patient Information Sheet: Investigating Fatigue In People With Vasculitis 
 
We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would 
involve for you. One of our team will go through the information sheet with you 
and answer any questions you have. This should take about five minutes. Ask us 
if there is anything that is not clear. 
 
What Is The Study About? 
Vasculitis is a group of diseases that may damage various parts of the body by 
disturbing the immune system and blood vessels. It commonly results in kidney 
damage known as ‘chronic kidney disease’. Vasculitis causes about 10% of all 
chronic kidney disease. Some research has previously shown that patients with 
vasculitis feel less energetic than other people, get tired more easily, and cannot do 
as much physically or mentally. These symptoms, which we describe as ‘fatigue’ are 
very common, even when the vasculitis has been brought under control by 
medication. 
Even though fatigue is one of the commonest symptoms in vasculitis, and can have 
a major impact upon sufferers’ lives, we know very little about it. We are carrying out 
this study to better understand fatigue in vasculitis. We aim to discover how common 
the symptom is, how it impacts on peoples’ lives, and how all of this compares to 
people with other sorts of chronic kidney disease, and with people who have neither 
disease. We hope that this study will help us to eventually become better at 
preventing or treating fatigue. 
 
Why Have I Been Invited? 
You have been invited because you have vasculitis.  
 
Who Else Is Taking Part? 
We intend to enrol 200 people from the Vasculitis Clinic, 200 people from the 
‘Chronic Kidney Disease Clinic’, and 200 people from the kidney transplant clinic at 
the Queen Elizabeth Hospital. In addition, we will enrol an equal number of people 
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who have no vasculitis or CKD, and with your permission we may ask your family 
and friends whether they would like to help as part of this healthy group. 
 
Do I Have To Take Part? 
It is up to you to decide to join the study. We will describe the study and go through 
this information sheet. If you agree to take part, we will then ask you to sign a 
consent form. You are free to refuse, without giving a reason. This would not affect 
the standard of care you receive. 
 
What Will Happen To Me If I Take Part? 
If you agree to help us with this study and have signed the consent form, we will ask 
you to complete a questionnaire booklet. This booklet should take around half an 
hour to complete. To help us understand the information, we will need your 
permission to look through your medical notes, and to take a record of your illnesses 
and medications. 
In addition, we will take 5ml of your blood, which we will test for inflammation.  
With your permission, we will share your anonymised results with other research 
groups who are carrying out similar research. 
The study will run for around two years in total, during which time we hope to have 
enrolled the full 800 people. However you will only be asked to fill in the 
questionnaire on this one occasion. 
Afterwards we may ask you whether you wish to be involved in another part of the 
study. The aim of the other part of the study is to identify what actually causes 
people with vasculitis to suffer from fatigue. However any involvement in that second 
part of the study is separate and is again entirely optional. 
 
Payments 
There will be no payment made for agreeing to help with this research. 
Please note in particular that it will not be possible to reimburse any additional travel 
or parking expenses. 
 
What Are The Risks And Benefits? 
There are no risks involved in this study. Equally, there will be no immediate benefit 
to you from helping with this study. However, the results will help us to plan further 
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studies, and we hope that eventually they will help us to be much better at 
preventing and treating this significant problem. 
 
Will My Taking Part In The Study Be Kept Confidential? 
Yes. We will follow ethical and legal practice, and all information about you will be 
handled in confidence. With your permission we will inform your General Practitioner 
that you have helped us with this study, but they will have no access to the 
information you give us. 
 
What Will Happen To The Results Of The Research Study? 
It is intended that the results will be published in various scientific journals with an 
interest in vasculitis, chronic kidney disease, or fatigue. We will also seek to increase 
public awareness by speaking to patient groups such as the Stuart Strange Trust for 
Research into Vasculitis, and the West Midlands Vasculitis Group. 
In addition, the results will form the basis for future research investigating how we 
might treat fatigue in vasculitis patients. 
 
Who Is Funding The Research? 
The research is being funded by University Hospitals Birmingham Charities. The 
doctors conducting the research are employees of University Hospital Birmingham 
NHS Foundation Trust. They will receive no direct payment for including you in this 
study, and there are no conflicts of interest. 
 
Who has Reviewed this Study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. 
 
What if I have any Questions? 
If you have any queries or concerns please ring (Queen Elizabeth 
Hospital switchboard) and ask to be put through to extension (Wellcome Trust 
Clinical Research Facility). One of the Research Nurses will be able to answer any of 
your queries and arrange a suitable appointment with Dr Andrew McClean. 
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9 APPENDIX 3: PARTICIPANT INFORMATION LEAFLET 
FOR MECHANISTIC STUDY (AAV GROUP) 
 
 
Participant Information Sheet 2: 
Investigating the Causes of Fatigue In People With Vasculitis 
 
We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would 
involve for you. One of our team will go through the information sheet with you 
and answer any questions you have. This should take about five to ten minutes.  
Part 1 tells you the purpose of the study, and what will happen to you if you take 
part. Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear. 
 
Part 1 
What Is The Study About? 
Vasculitis is a group of diseases that may damage various parts of the body by 
disturbing the immune system and blood vessels. It commonly results in kidney 
damage known as ‘chronic kidney disease’. Vasculitis causes about 10% of all 
chronic kidney disease. Some research has previously shown that patients with 
vasculitis feel less energetic than other people, get tired more easily, and cannot do 
as much physically or mentally. These symptoms, which we describe as ‘fatigue’ are 
very common, even when the vasculitis has been brought under control by 
medication. 
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Even though fatigue is one of the commonest symptoms in vasculitis, and can have 
a major impact upon sufferers’ lives, we still know very little about it. We are carrying 
out this study to better understand what factors contribute to causing fatigue in 
vasculitis, as well as how this compares to people with other sorts of chronic kidney 
disease, and to with people who have neither disease. We hope that this study will 
help us to eventually become better at preventing or treating fatigue. 
 
Why Have I Been Invited? 
You have been invited because you have vasculitis and have already helped us with 
the first part of this study.  
 
Who Else Is Taking Part? 
We intend to enrol 50 people from the vasculitis clinic to this part of the study, 50 
people with ‘Chronic Kidney Disease’, and 50 people with kidney transplants. In 
addition, we will enrol 50 people who have no kidney disease or vasculitis, and with 
your permission we may ask your family and friends whether they would like to help 
as part of this healthy group. 
 
Do I Have To Take Part? 
It is up to you to decide to join the study. We will describe the study and go through 
this information booklet. If you agree to take part, we will then ask you to sign a 
consent form. You are free to withdraw at any time, without giving a reason. This 
would not affect the standard of care you receive. 
 
What Will Happen To Me If I Take Part? 
This part of the study will be conducted over two half day sessions, with different 
investigations occurring on each day. The order in which you undergo these two 
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different sets of investigations may differ, and will depend on finding you a 
convenient appointment for each. 
 
Session 1: (approximately 4 hours) This will take place in the Wellcome Trust 
Clinical Research Facility, at the Queen Elizabeth Hospital. We will ask you not to 
eat or drink from midnight on the night before this appointment. The tests are as 
follows: 
• Before doing anything else we would like to take a fasting blood sample, and 
will ask you to complete a very short questionnaire about how you are feeling, which 
should take no more than around a minute to fill in. Once you have had this blood 
sample taken, we will provide you with some breakfast, and will give you a short 
break before doing the next test. 
• Exercise test: We will ask you to pedal on an exercise bike for nine minutes. 
The workload will start off very low and every three minutes it will be increased by a 
small amount. Each minute during the exercise, we will ask you how difficult the 
exercise feels. During all of this you will have 6 leads similar to ECG leads attached 
to stickers on your chest and back. These leads will measure your heart rate, as well 
as measuring the amount of blood your heart is pumping around your body. You will 
breathe into a rubber mouthpiece similar to a snorkel, which measures the gas in 
your breath, and will wear a nose plug so that all your breath passes in and out of 
the mouthpiece. Afterwards you can sit or lie down while you get your breath back 
and recover. We will take further blood tests immediately after the exercise test and 
then one and two hours later, and on each of these occasions we will also ask you to 
fill in the 1 minute questionnaire about how you are feeling. 
• We would like to measure your body composition - that is, the amount of 
muscle, fat and bone in your body using an x-ray test called DEXA scanning. This 
will expose you to a minimal x-ray radiation. The radiation will be 0.0042 mSv, which 
is less than a chest x-ray or less than 0.2% of the annual dose from natural 
background radiation in the UK. In other words, it is less than a day of naturally 
occurring background radiation in the UK. All risks will be minimised by safe practice, 
and conducted by a trained NHS radiographer. This test will not involve any blood 
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tests or injections, and will not involve enclosed spaces that could induce 
claustrophobia. 
 
Session 2: (approximately 2 hours) This will take place in the Wellcome Research 
Laboratories in the School of Sport and Exercise Sciences, University of 
Birmingham. The tests are as follows: 
• Muscle tests: We will measure the strength of your thigh muscles while you sit 
in a specially designed chair.  First of all we will place two pads onto one of your 
thighs, and will put a strap around the ankle of the same leg. We will use the pads to 
apply a small electrical stimulation to the muscles in your thigh. This only lasts for a 
fraction of a second, and although it can feel a little uncomfortable it is not painful. 
We will start with a very weak current, and will repeat with a slowly increasing current 
until the stimulation causes your muscle to contract well.  
Next, we will do a test that it allows us to measure your muscle strength and assess 
the reasons for any weakness. We will ask you to kick your leg out against the strap 
as strongly as possible for about five seconds, and during your normal muscle 
contraction we will give another electrical stimulation for a fraction of a second. We 
will ask you to do this three times in total. 
After a few minutes rest, we will perform a test that assesses how easily your 
muscles become tired. We will ask you to kick out your leg against the strap again, 
but this time we will ask you to hold the contraction for as long as you are able to. 
Every 10 seconds we will give a small electrical stimulus. 
• Blood Supply: To perform the next test, you will lie on a bed, and we will place 
a device around your forearm which allows us to measure the oxygen levels in your 
muscles. We will inflate a blood pressure cuff around the same arm, and then ask 
you to squeeze a hand grip for 1 minute. This will make your forearm muscles feel 
tired and a little uncomfortable, as if you had done a lot of exercise. As soon as the 
minute has passed we will ask you to stop squeezing the hand grip, and we will 
deflate the blood pressure cuff. This will allow your muscles to recover from the 
exercise, and we will measure the time taken for the oxygen level in the muscles to 
get back to normal. 
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• To test your concentration and memory, we will ask you to do a test called the 
PASAT. This simple test will last for less than half an hour. During it, you will be 
played a CD through computer speakers. You will hear a series of numbers spoken, 
and will be asked to add up each pair of numbers. The process will be fully explained 
to you before we start, and you will also be given some practice before you begin. 
 
Your involvement will end after you have attended each of the half day sessions. 
 
Payments 
There will be no payment made for agreeing to help with this research. 
Please note in particular that it will not be possible to reimburse any additional travel 
or parking expenses. 
 
What Will I have To Do? 
Apart from attending for the two appointments detailed above, we will ask you to do 
three other things: 
1. On the day before your appointment at the Queen Elizabeth Hospital 
(described as ‘session 1’ above) you will have to collect some saliva samples for us. 
We will give you the labelled bottles beforehand, and one of our Research Nurses 
will contact you the day before to remind you about the collections. We will ask you 
to collect five samples through the day: when you waken, and at 10am, noon, 3pm 
and 9pm. You will then bring these samples along to your appointment, when we will 
send them for testing. 
 
2. When you are coming up for ‘session 1’, we will ask you to fast from midnight 
the night before. Once we have taken the first blood test, we will provide you with 
breakfast free of charge. When our nurse contacts you to remind you about the 
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saliva collections, she will also remind you that you will need to fast before the 
appointment. 
 
3. On both test days, please come wearing loose fitting clothes, preferably 
shorts and T-shirt. 
 
What Are The Possible Risks of Taking Part? 
The assessments described in this section may sound a little technical but you 
should not worry about this, these assessments are routinely performed in our labs.  
Our investigators are friendly and experienced and will explain everything to you at 
the time, answer any questions that you may have and will only proceed when you 
are happy to do so.  
The main potential risk is the exercise bike testing, which could put strain on your 
heart if you have heart disease. However we have taken a number of steps to 
minimise any risk to you: 
• We will not allow you to undertake the test at all if we know that you have 
significant heart disease. 
• We will only carry on with the test until the point where you ask to stop. We 
will never attempt to push you beyond your limits. 
• The test will always be supervised by NHS staff who are trained in how to 
help if there are any problems. 
• The test will be performed within the Queen Elizabeth Hospital, with full 
medical facilities onsite for dealing with any possible problems. 
Taking the blood tests may result in a small bruise, but this will resolve over a few 
days. It will be no different from your experience of giving blood samples during your 
normal clinical care. 
The electrical stimulation we will give you during the muscle testing is an unusual 
sensation but most people find it acceptable and you will be given plenty of time to 
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get used to it.  We will always keep the intensity of the stimulation within the limits 
you are happy with.  The measurement of muscle oxygen content is entirely without 
sensation. 
At the end of the fatigue test you can sit or lie down for as long as you like to recover 
but we would expect your muscle to be fully recovered within about 10 minutes and 
you should have no problems or after-effects from the testing. 
 
What Are The Possible Benefits Of Taking Part? 
There will be no immediate benefit to you from helping with this study. However, the 
results will help us to plan further studies, and we hope that eventually they will help 
us to be much better at preventing and treating this significant problem. 
 
What If There Is A Problem? 
Any complaint about the way you have been dealt with during the study, or any 
possible harm will be addressed. The detailed information about this is given in Part 
2. 
 
Will My Taking Part In The Study Be Kept Confidential? 
Yes. We will follow ethical and legal practice, and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making 
any decision. 
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Part 2 
 
What Will Happen If I Don’t Want To Carry On With The Study? 
Remember that if you are unhappy with the way things are going you can withdraw 
from the study at any time without having to give an explanation, even if you have 
signed a consent form.  Whether or not you decide to take part in this research, or if 
you withdraw having started, it will have no effect on the care and treatment you are 
receiving. If you withdraw from the study, we will destroy all your identifiable 
samples, but we will need to use the data collected up to your withdrawal. 
 
What If I Have A Complaint? 
If you have any queries or concerns please ring (Queen Elizabeth 
Hospital switchboard) and ask to be put through to extension Wellcome Trust 
Clinical Research Facility). One of the Research Nurses will be able to answer any of 
your queries and arrange a suitable appointment. If you remain unhappy and wish to 
complain formally, you can do this through the normal NHS complaints procedure. 
Details can be obtained from the Patient Advice Liaison Service at the Queen 
Elizabeth Hospital (Tel: , or email: ). 
 
What If I Suffer Harm? 
In the event that something does go wrong and you are harmed during the research, 
and this is due to someone’s negligence, then you may have grounds for a legal 
action against University Hospital Birmingham NHS Foundation Trust. However, you 
may have to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you (if appropriate). 
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Will My Taking Part In The Study Be Kept Confidential? 
Yes. We will follow standard ethical and legal practice, and all information about you 
will be handled in confidence. All the data collected will be stored securely in locked 
filing cabinets, in rooms with locked doors. The results of your investigations will also 
be kept on computer; the computers will be physically stored behind locked doors, 
and the data on them will be protected by passwords. All data stored will have your 
name and address removed so that you cannot be recognised, and only one 
member of the research team will have the means to link the data to you. The 
anonymous parts of the data will be stored for three years after the study, so that it 
can be used to help in further linked studies. However, any such studies will also 
have to go through detailed assessment by a Research Ethics Committee. Once this 
period is up, the data will be destroyed securely by shredding it physically and 
electronically. 
With your permission we will inform your General Practitioner that you have helped 
us with this study, but they will have no access to the information you give us. 
 
What Will Happen To The Samples I Give? 
Blood and saliva samples will be taken during this study, as previously described. 
The blood samples that we take from you will be used for this study, but they will 
also be stored beyond the end of the study. We may wish to make use of them again 
for future studies, but we will apply to the relevant authorities for approval if we 
intend to do this. 
The samples will be sent securely to the on-site laboratory for processing. During the 
short time that they are to be stored, they will be held securely, protected from theft 
by a locked door. The electronic results of your samples will again have your 
personal details removed before they are added to the research data, and will be 
treated in the same manner as all the rest of the data, as described above. 
Afterwards the samples will be destroyed in accordance with normal NHS standards. 
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What Will Happen To The Results Of The Research Study? 
It is intended that the results will be published in various scientific journals with an 
interest in vasculitis, chronic kidney disease, or fatigue. We will also seek to increase 
public awareness by speaking to patient groups. 
In addition, the results will form the basis for future research investigating how we 
might treat fatigue in patients with CKD. 
 
Who Is Funding The Research? 
The research is being funded by University Hospital Birmingham Charities. The 
doctors conducting the research are employees of University Hospital Birmingham 
NHS Foundation Trust. They will receive no direct payment for including you in this 
study, and there are no conflicts of interest. 
 
Who Has Reviewed This Study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given favourable opinion by Birmingham, East, North and Solihull Research 
Ethics Committee. 
Further Information and Contact Details 
If you have any queries or concerns please ring  (Queen Elizabeth 
Hospital switchboard) and ask to be put through to extension (Wellcome Trust 
Clinical Research Facility). One of the Research Nurses will be able to answer any of 
your queries, or arrange a suitable appointment with Dr Andrew McClean (the doctor 
coordinating the study) if necessary.  
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